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ABBREVIATIONS 
A1C   Primary auditory cortex 
AAL  Automated Anatomical Labeling 
AI   Artificial intelligent 
AMY  Amygdala 
ANOVA  Analysis of variance 
ANCOVA Analysis of covariance 
AUC   Area Under the receiver operating characteristic Curve 
AUT  Autism 
BA  Brodmann area 
BDNF   Brain-derived neurotrophic factor, 
BioMM  Biologically informed machine learning  
BP  Bipolar disorder 
CACNA1C Calcium Voltage-Gated Channel Subunit Alpha1 C 
CACNA1I Calcium Voltage-Gated Channel Subunit Alpha1 I 
CACNB2 Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2 
CBC  Cerebellar cortex 
CNV  Copy number variation 
COMT  Catechol-O-methyltransferase  
CpG  The " 5'—C—phosphate—G—3' " sequence of nucleotides 
CSF  Cerebral spinal fluid 
CTNNA3 Catenin Alpha 3 
DARPP-32 dopamine- and cyclic-AMP-regulated phosphoprotein of molecular weight 32,000 
DARTEL  Diffeomorphic Anatomical Registration Through Exponential Lie algebra 
dbGaP  Database of Genotypes and Phenotypes  
DFC  Dorsal prefrontal cortex 
DISC1  Disrupted-in-Schizophrenia 1  
DLPFC  Dorsolateral prefrontal cortex    
DLPFC-HC Dorsolateral-Prefrontal-Cortex – Hippocampal 
DNA  Deoxyribonucleic acid 
DRD2  Dopamine receptor D2 
DRD4  Dopamine receptor D4 
DSM-IV  Diagnostic and Statistical Manual of Mental Disorders IV edition 
EPI  Echo planar imaging 
eQTL  Expression quantitative trait loci 
ESTs   Expressed sequence tags 
EWAS   Epigenome-Wide Association Study 
FDR  False Discovery Rate 
fMRI  Functional magnetic resonance imaging 
FOV  Field of view 
FWHM   Full width at half maximum 
GAIN   Genetic Association Information Network 
GLM  Generalized linear model 
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GM  Grey matter 
GO  Gene Ontology 
GRCh37 Genome Reference Consortium Human Build 37 
GRM3  Glutamate Metabotropic Receptor 3 
GRIN2A Glutamate Ionotropic Receptor NMDA Type Subunit 2A 
GRIA1  Glutamate Ionotropic Receptor AMPA Type Subunit 1 
GSEA  Gene Set Enrichment Analysis 
GWAS  Genome-wide association study 
HC  Healthy controls 
hESC  Human embryonic stem cell 
hg19  Human genome version 19 
HIP  Hippocampal anlage or hippocampus 
hiPSC  Human-induced pluripotent stem cell  
ICD10  International Classification of Diseases 10  
IPC  posterior inferior parietal cortex 
ITC   Inferior temporal cortex  
LCLs  Lymphoblastoid cell line 
LD  Linkage disequilibrium 
M1C  Primary motor cortex 
MAF  Minor allele frequency 
MD  Mediodorsal nucleus of the thalamus 
MDD  Major depressive disorder 
MFC  Medial prefrontal cortex 
MNI  Montreal Neurological Institute  
MOFA  Multi-omics factor analysis 
MPRAGE magnetization-prepared rapid acquisition with gradient echo 
NF-kappaB The regulation of nuclear factor kappaB 
NHS   National Health Service 
OFC  Orbital prefrontal cortex 
OPCRIT  Operational Criteria Checklist 
PCW  Post-conceptional week 
PGC  Psychiatric Genomics Consortium 
PMI  Post-mortem interval 
PMS   Poly-methylation-signature 
PRS  Polygenic risk score 
QC  Quality control 
RDoC/RDC Research Domain Criteria 
relAUT  First-degree relatives of patients with autism 
relBP  First-degree relatives of patients with bipolar disorder 
relMDD First-degree relatives of patients with major depressive disorder 
RELN  Reelin 
relSCZ  First-degree relatives of patients with schizophrenia 
RGS4  Regulator Of G Protein Signaling 4 
RIN  RNA Integrity Number 
RNA  Ribonucleic acid  
RNA-Seq RNA-sequencing 
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RPKM  Reads per kilobase million mapped reads 
S1C  Primary somatosensory cortex 
SADS-L  Schedule for Affective Disorders and Schizophrenia-Lifetime Version 
SBE  Single base extension 
SCID  Structured Clinical Interview for DSM-IV 
SCZ  Schizophrenia 
SNP  Single nucleotide polymorphism 
STC  Superior temporal cortex 
STR  Striatum 
SubCtl    Subset of healthy controls 
SVM  Support Vector Machine  
V1C  Primary visual cortex 
VFC   Ventral prefrontal cortex 
ZNF804A Zinc finger protein 804A   
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1 INTRODUCTION 
1.1 Background 
Mental health is an essential component of human wellbeing, and has a profound impact on 
individual and civil society. With a prevalence of 22.1%, mental illness is one of the predominant 
global disease burdens (Charlson, van Ommeren et al. 2019). These debilitating conditions often have 
a young age-of-onset and long term impairments that lead to a substantial reduction in life-
expectancy. As a consequence, mental illnesses have an enormous socioeconomic cost that has been 
estimated to exceed 600 billion annually in the European Union alone (OECD and Union 2018). The 
clinical management of most mental illnesses is severely hampered by our lack of understanding the 
underlying biology, clinical tools for objective diagnosis and treatment selection, and personalized 
therapy for individual patients.  
Schizophrenia is a severe, highly heritable, mental health disorder with a  lifetime prevalence of 0.5-
1% (Saha, Chant et al. 2005, American Psychiatric Association 2013). Despite the massive clinical and 
socioeconomic burden, process in tackling this devastating illness has been painfully slow with few 
efficacious treatments and many unanswered questions. Moreover, the pharmaceutical industry has 
broadly withdrawn from the psychiatric field, due to a lack of suitable targets and difficulties in 
stratifying patients to address the low response rate in clinical studies. There is an urgent need to 
move biological research in schizophrenia towards clinical applications that facilitate more accurate 
early diagnostics for identifying at-risk subjects and novel pharmaceutical targets. 
1.1.1 Clinical features of schizophrenia 
Schizophrenia is characterized by a broad spectrum of symptoms that include hallucinations and 
delusions, reduced volition, and disorganized speech and behavior (Andreasen 1995). The typical age 
of onset is in adolescence or young adulthood (Messias, Chen et al. 2007) (Leung and Chue 2000, 
Messias, Chen et al. 2007) with meta analytical studies reporting that a higher prevalence in males 
who often experience earlier onsets and a more severe illness course (odds ratio = 1.4 (Aleman, Kahn 
et al. 2003, McGrath, Saha et al. 2008). The prognosis is moreover highly heterogeneous with many 
patients experiencing a poor outcome despite some recent advances in treatment (Häfner and an 
der Heiden 1997, Hafner 1998, Millan, Goodwin et al. 2015, Millan, Andrieux et al. 2016, Häfner 
2019).  
Currently, the diagnosis of schizophrenia is based on two major diagnostic systems: the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5) (Association 2013) and the International 
Classification of Diseases 10 (ICD-10) (Organization 1992). These systems have heuristic clinical value, 
high inter-rater reliability and are continuously updated. It is noteworthy that these diagnostic 
criteria are remarkably similar to the first classification of mental disorders by Emil Kraeplin in 1898. 
Indeed, the diagnosis of schizophrenia is still purely phenomenological and relies on clinical 
observation and psychological self-reports with limited consideration of biological measures. Given 
the heterogeneous presentation of schizophrenia, whose symptoms overlaps with several other 
mental disorders (Kirkpatrick, Buchanan et al. 2001, Buckley, Miller et al. 2009), there is concern 
about over reliance on categorical systems that do not index patients according to their underlying 
neurobiology.  
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This is particularly pertinent in light of evidence for biological similarities between several 
neuropsychiatric disorders which blur the line between diagnostically separate entities (McDonald, 
Bullmore et al. 2004, International Schizophrenia, Purcell et al. 2009, De Peri, Crescini et al. 2012, 
Consortium 2013, Li, Cai et al. 2016).  
In 2010 the National Institute of Mental Health responded to this unmet need by launching the 
Research Domain Criteria framework (RDoC) (Insel, Cuthbert et al. 2010). RDoC introduced a new 
nosology that uses multidimensional constructs that are guided by neuroscience and behavioral 
science instead of descriptive phenomenology. The RDoC framework is built around 
multidimensional constructs that are better aligned to the underlying neurobiology and can be 
readily assessed on the genetic, behavioral and neural functional level (Morris and Cuthbert 2012). 
However, the RDoC concept has thus far not been translated towards clinical application as further 
effort is needed to characterize the underlying molecular and neurobiological dimensions and turn 
the resulting insights into predictive algorithms for future clinical use.  
1.1.2 Genetic and environmental hypotheses of schizophrenia 
Despite substantial progress in the understanding of the biology underlying schizophrenia, the illness’ 
etiology remains elusive. Gaining a better understanding of complex genetic and environmental risk 
factors is thus considered a top priority (Tsuang 2000, van Os, Rutten et al. 2008). In the next section 
research  strategies for investigating genetic and environmental aspect of schizophrenia are 
discussed. 
 
Genetics 
Over the last few decades deep insights into the genetic basis of schizophrenia have been gained 
through genetic study of schizophrenia patients and their first and second degree relatives. These 
studies have shown schizophrenia is substantially aggregated in families, and that genetic factors 
play a significant role in its development (Aberg, Liu et al. 2013). One meta analyses of twin studies 
produced an estimated heritability of liability of 80% (Sullivan, Kendler et al. 2003). Despite the 
identification of high heritability, such epidemiological approaches, however, provide no direct 
insight into the specific genetic factors contributing to illness risk.  
The completion of the Human Genome Project in 2003 ushered in a new wave of genetic research in 
schizophrenia. This project, sought to map the entire human genetic code, identifying approximately 
22,300 protein-coding genes in the process. This maps of the human genome allowed use of the 
molecular biology technique to establish correlation ‘or linkage’ between proximally located genetic 
markers (which tend to be inherited together during meiosis). Although the linkage approach was 
first used to investigate simple Mendelian traits,  these studies have successfully identified a number 
of genes and chromosomal abnormalities associated with schizophrenia (Kendler and Diehl 1993) 
(Bassett, Chow et al. 2000). However, sample size limitations and the considerable genetic 
heterogeneity of schizophrenia have posed a problem, resulting in comparably low replicability of 
findings (Risch and Merikangas 1996).    
The next generation of research took a markedly different approach: In contrast to linkage analysis, 
which feature an unbiased exploration of potentially relevant genes across the entire genome, 
candidate gene  studies aimed to uncover risk associated genetic variants belonging to genes thought 
to be particularly relevance for the biology of schizophrenia. However, notwithstanding early 
successes, this approach was limited to the a priori selection of plausible genes where some 
information was already known, and did not take into account the complex gene-gene interactions 
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and regulatory elements so important for elucidating underlying causal mechanisms. These 
limitations impacted the biological reproducibility of findings and lead to a shift back towards 
hypothesis free approaches (Gejman, Sanders et al. 2011). However, despite some misgivings, 
candidate gene approaches have been very useful for estimating the plausibility of identified variant-
associations. For instance, the SzGene database resource summarizes findings on over 1,000 genes 
associated with schizophrenia (Allen, Bagade et al. 2008).  
Finally, considerable advances in our understanding of the genetic basis of schizophrenia have been 
gained through genome-wide association study (GWAS). GWAS are facilitated by simultaneous, chip-
based analysis of hundreds of thousands of common genetic variants. These studies have led to 
profound insight into the genetic architecture of schizophrenia. Findings from International consortia 
that have allowed pooling of data resources have been especially bountiful (Visscher, Wray et al. 
2017). These studies have identified more than 100 risk loci congruent with major hypotheses of 
neurobiological basis of schizophrenia, including genes related to dopamine signaling (DRD2), 
glutamatergic neurotransmission (GRM3, GRIN2A, and GRIA1), and voltage-gated calcium signaling 
(CACNA1C, CACNB2, and CACNA1I) (Schizophrenia Working Group of the Psychiatric Genomics 2014).  
Importantly, these large, well powered-studies provide support for the hypothesized polygenic 
nature of schizophrenia (International Schizophrenia, Purcell et al. 2009, Schizophrenia Working 
Group of the Psychiatric Genomics 2014). A summary of the last 10 years’ worth of psychiatric GWAS 
research is given in the ‘GWAS Catalog’ website (https://www.ebi.ac.uk/gwas/) (Horwitz, Lam et al. 
2019). One notable finding from these studies is the observation that many psychiatric disorders 
share common genetic risk loci that are with physical traits or somatic illness. For instance, 
schizophrenia-related GWAS signals have also been identified in studies exploring cholesterol and 
body mass index (Horwitz, Lam et al. 2019), and blood pressure (Andreassen, Djurovic et al. 2013). 
These findings may help to point to the importance of developing personalized medicine approaches 
in schizophrenia interventions.  
 
Environment 
Schizophrenia arises from the complex interplay of genetic predisposition and environmental risk 
factors. These environmental risk factors are categorized into early life, childhood and later life 
stages based on their assumed relevance for the etiology of schizophrenia (Dean and Murray 2005, 
Stilo, Di Forti et al. 2011). The boundary between these stages is, however, blurry and specific factors 
may impact on susceptibility across stages. Studies focusing on environmental risk during early life 
point to the contribution of factors such as obstetric complications, season of birth, maternal 
malnutrition and other stress factors. During childhood, maltreatment, trauma and other adversities 
increase susceptibility to schizophrenia. Relevant environmental risk factors during later life (i.e. 
adolescence and early adulthood) include stress, lifestyle, urbanicity, social adversity, traumatic life 
events, and substance abuse. These environmental risk factors can also be categorized according to 
their specific social, environmental, familial, neurodevelopmental, economic, and other contexts 
(Iyegbe, Campbell et al. 2014).  
 
Gene and environment interplay 
Individual genetic or environmental factors possesses insufficiently large effect sizes to account for a 
major portion of schizophrenia risk. Therefore the study of gene-environment interactions, which  
may explain this so-called ‘missing heritability,’ have therefore received widespread attention 
(Manolio, Collins et al. 2009). By definition, a gene-environment interaction (G x E) is "a different 
effect of environmental exposure on disease risk in persons with different genotypes," or "a different 
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effect of a genotype on disease risk in persons with different environmental exposures." (Ottman 
1996). Indeed, a meta-analysis of 12 twin studies has strengthened the view that nature and nurture 
are both highly relevant in the development of schizophrenia (Sullivan, Kendler et al. 2003). The 
diverse G x E studies have been systematically reviewed by (Duncan and Keller 2011, Modinos, 
Iyegbe et al. 2013, Iyegbe, Campbell et al. 2014). Findings of these studies are, however, rarely been 
replicated in independent samples due to insufficient sample size and methodological heterogeneity. 
Furthermore, most of the conducted studies have focused on  candidate genes. This knowledge gap 
on genome level effects was first addressed by Børglum  et al (Børglum, Demontis et al. 2013),  found 
the CTNNA3 gene may interact with maternal cytomegalovirus infection, reiterating the importance 
of environmental risk factors in genetic studies of schizophrenia. One way of overcoming some of the 
challenges of G x E studies is the use of integrated, large-scale investigations that combine different 
paradigms and considering the illnesses biological architecture (Modinos, Iyegbe et al. 2013, 
European Network of National Networks studying Gene-Environment Interactions in Schizophrenia, 
van Os et al. 2014, Iyegbe, Campbell et al. 2014). In particular, the strategies adopting polygenic risk 
score in conjunction with well documented environmental factors could help to enhance 
personalized genetic risk stratification  and ensure early detection of high-risk profiles. 
 
1.1.3 Current progress on personalized medicine  
The personalized medicine approach describes the tailoring of medical treatment and health care 
towards a given patient depending on their specific clinical and/or biological characteristics (Schork 
2015). Advances in personalized medicine have been made in many other diseases including cancers 
(Kakimi, Karasaki et al. 2017, Krzyszczyk, Acevedo et al. 2018), HIV (Lengauer, Pfeifer et al. 2014, Mu, 
Kodidela et al. 2018), and cardiovascular disease (Dainis and Ashley 2018, Leopold and Loscalzo 
2018). The psychiatric field has been slow to implement personalized medicine, but it is starting to 
become more commonplace (Dalvie, Koen et al. 2016, Gandal, Leppa et al. 2016). Personalized 
medicine approaches in schizophrenia center on diagnostic and predictive biomarkers, including 
genetic variants (Schizophrenia Working Group of the Psychiatric Genomics 2014, Pardiñas, Holmans 
et al. 2018), omics (Schwarz, Guest et al. 2012, Montano, Taub et al. 2016, Gandal, Zhang et al. 2018) 
neuroanatomical factors (van Erp, Hibar et al. 2016, Van Erp, Walton et al. 2018), and drug discovery 
research (Xu and Wang 2015). One representative example is a genetic study that identified 108 risk 
loci using up to 36,989 schizophrenia cases and 113,075 controls. A polygenic risk score calculated for 
each subject can be used to quantify the individual risk, albeit with a limited prediction accuracy. 
Furthermore, statistical and machine learning models for personalized predictions in schizophrenia 
are being continuously developed (as reviewed by (Chen and Schwarz 2017, Bzdok and Meyer-
Lindenberg 2018)). However, despite the development of high-throughput large-scale screening and 
computational methodologies, personalized medicine for schizophrenia is still in its infancy. It has 
been broadly recognized, however, that personalized medicine approaches are rooted in an 
improved understanding of  schizophrenias underlying biology, and are critical for improved clinical 
management of the illness (DeLisi and Fleischhacker 2016, Buckley and Miller 2017, Zhang, Mao et al. 
2018). 
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1.2 Omics 
Increasing interest in systems-wide exploration of schizophrenia is evidenced by a recent wave of 
studies and funding opportunities. The omics field allows researchers to investigate subtle molecular 
changes within cells or tissues in a holistic manner, enabling researchers to study a complex 
molecular system as a whole. Omics technologies have shown substantial utility in uncovering 
biological factors likely involved in the etiology of schizophrenia across multiple levels of biological 
organization. This thesis focuses on the application of three omics approaches: genomics, 
transcriptomics, and epigenomics, as detailed below. 
1.2.1 Genomics 
Genomics is the comprehensive study of a given organism’s genetic sequence. The genome is defined 
as the complete set of DNA inside a given cell, with the human genome containing tens of thousands 
of genes organized into 23 pairs of chromosomes. There are two primary goals of genomics: 1) to 
sequence and analyze the structure and function of the genome with the help of DNA sequencing 
technologies and bioinformatics methods, and 2) to characterize and quantify all genes of a 
particular organism and the interplay of these genes with each other and with the environment. In 
comparison to genetics, which describes the study of heredity, genetic variation, and individual genes 
(Organization 2002), genomics is the study all genes and their interactions. Genomic approaches 
have thus particular utility for the exploration of biologically complex psychiatric disorders such as 
schizophrenia, which are hallmarked by substantial polygenicity and epistasis. 
Genomic research in psychiatry has been mainly driven by a fluffy of GWAS that identified a number 
of reproducible risk loci from millions of genomic variants (Schizophrenia Working Group of the 
Psychiatric Genomics 2014, Wray, Ripke et al. 2018, Stahl, Breen et al. 2019). In contrast to 
Mendelian disorders where the mutational patterns are predictable, the majority of psychiatric 
disorders are polygenic or multi-factorial (O'Donovan 2015). Moreover, the presence of pleiotropic 
effects in psychiatry has been observed for common (O'donovan, Craddock et al. 2008, Purcell, Wray 
et al. 2009, Lee, Ripke et al. 2013) and rare genetic variants (Malhotra and Sebat 2012, Kirov, Rees et 
al. 2014, Schizophrenia Working Group of the Psychiatric Genomics 2014), which suggested the need 
of new approaches for psychiatric diagnostic delineation (Owen 2014, O'Donovan 2015). Moreover, 
the genetic correlation between schizophrenia, bipolar and major depressive disorder has been 
shown to converge upon genes implicated in biological processes involving histone methylation, and 
immune and neuronal pathways (Network, O'Dushlaine et al. 2015). As individual common variants 
mostly have small effect sizes, a fundamental question is whether the aggregation of variants can 
explain a larger portion of the heritable variance. The predominant approach for performing this 
integration is to sum up effect size weighted allele counts across variants, yielding a poly-genic risk 
score (PRS) (International Schizophrenia, Purcell et al. 2009, Schizophrenia Working Group of the 
Psychiatric Genomics 2014). When determined from large-scale GWAS data, PRS have been shown to 
explain up to  18% of schizophrenia-associated variance. It is notable that the comparatively simple 
PRS have also been shown to outperform more complex machine learning algorithms, such as kernel 
support vector machines (Vivian-Griffiths, Baker et al. 2019) and are still considered the best 
aggregate measure of genetic risk for common genetic variants. While the increasing predictive value 
of PRS scores highlights their potential diagnostic utility (Torkamani, Wineinger et al. 2018), larger 
genetic samples and more studies are  required before schizophrenia PRS can be translated into 
clinical application.  
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A major advance made by the psychiatric research community is the increasing public availability of 
data and summary statistics that can be used for calculating PRS for genotyped samples from large-
scale GWAS analyses. For example, the association-analysis results from thousands of phenotypes 
(diseases and traits)  have been produced by UK Biobank’s rapid GWAS program 
(http://www.nealelab.is/uk-biobank/). Remarkably, many identified schizophrenia-linked GWAS 
signals have been found to be located in non-coding regions that encompass regulatory elements 
(Ripke, O'Dushlaine et al. 2013, Schizophrenia Working Group of the Psychiatric Genomics 2014). 
These findings imply a possible role for gene regulation in the pathophysiology of schizophrenia. 
While the functional impact of most schizophrenia risk loci still remains elusive, a number of large-
scale studies (Fromer, Roussos et al. 2016, Gusev, Mancuso et al. 2018, Jaffe, Straub et al. 2018) 
provide evidence that these chromosomal regions are associated with perturbations in gene 
expression and highlighted the utility of gene expression profiling for providing more mechanistic 
interpretations of genetic liability for schizophrenia. 
1.2.2 Transcriptomics   
Transcriptomics describes the study of the complete set of RNA transcripts that are generated in a 
specific cell or a population of cells at a one time. The first human transcriptomics study was 
conducted in 1991 (Adams, Kelley et al. 1991) and facilitated the discovery of new genes, as well as 
the functional tagging of genomic elements. There are two main procedures to quantify whole-
genome RNA transcripts: Microarrays and RNA-Sequencing (RNA-Seq) (Lowe, Shirley et al. 2017). 
Microarrays determine the abundance of pre-selected transcripts through nucleic acid hybridization 
of transcripts to an ordered array of complementary nucleotide probes. Microarrays allow large 
numbers of transcripts to be measured at the same time, facilitating the generation of 
transcriptome-wide gene expression data. In RNA-Seq, individual transcripts or expressed sequence 
tags (ESTs) are sequenced across the genome, and abundance is determined from the number of 
counts of each transcript. RNA-Seq offers an advantage over microarrays due to its ability to detect 
alternatively spliced, non-coding, and novel transcripts. Moreover, RNA-Seq has higher accuracy and 
more reproducibility compared to  than microarray-based gene expression analysis (Wang, Gerstein 
et al. 2009, Martin, Dehler et al. 2016). On the other hand, due to more mature experimental 
protocols and affordable cost, microarrays are still widely used in the psychiatric field. 
Transcriptome profiling has a wide range of applications which include, the identification of 
differentially expressed genes in a given patient cohort (Sanders, Drigalenko et al. 2017, Wu, 
Bendriem et al. 2017), interrogation of co-expressed genes (Pacifico and Davis 2017, van Dam, Vosa 
et al. 2018), and exploration of regulatory processes important for development (Kang, Kawasawa et 
al. 2011, Shi, Zhang et al. 2016, Semick, Collado-Torres et al. 2018). The investigation of differentially 
expressed transcripts in schizophrenia has been the focus of numerous studies. For instance, 
exploration of abnormal gene regulation has been performed in whole blood (de Jong, Boks et al. 
2012), lymphoblastoid cell line (LCLs) (Sanders, Goring et al. 2013, Sanders, Drigalenko et al. 2017, 
Duan, Goring et al. 2018) post-mortem brain tissue (Roussos, Katsel et al. 2012, Fillman, Cloonan et 
al. 2013, Fromer, Roussos et al. 2016, Ramaker, Bowling et al. 2017), and human-induced pluripotent 
stem cell (hiPSC) (Maschietto, Tahira et al. 2015, Roussos, Guennewig et al. 2016, Hoffman, Hartley 
et al. 2017). Despite substantial inconsistencies in findings (particularly in regard to the most 
differentially expressed genes) some replicable themes have emerged. These are immune system-
related dysregulation  (Fillman, Cloonan et al. 2013, Gardiner, Cairns et al. 2013, Mistry, Gillis et al. 
2013, Sanders, Goring et al. 2013, Bergon, Belzeaux et al. 2015, Hess, Tylee et al. 2016, Sanders, 
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Drigalenko et al. 2017, Duan, Goring et al. 2018, Kos, Duan et al. 2018, Leirer, Iyegbe et al. 2019), 
neural or synaptic function (Mistry, Gillis et al. 2013, Sanders, Goring et al. 2013, Fromer, Roussos et 
al. 2016, Ramaker, Bowling et al. 2017, Sanders, Drigalenko et al. 2017, Duan, Goring et al. 2018, 
Gusev, Mancuso et al. 2018, Jaffe, Straub et al. 2018, Kos, Duan et al. 2018, Pergola, Di Carlo et al. 
2019), and oxidative stress and mitochondrial dysfunction (Torkamani, Dean et al. 2010, Maschietto, 
Tahira et al. 2015, Kos, Duan et al. 2018, Leirer, Iyegbe et al. 2019). Consequently, it has been argued 
that schizophrenia may result from alterations across numerous molecular pathways rather than 
from impairment in a single biological process (Horváth and Mirnics 2015), which is also in line with 
GWAS findings (Network, O'Dushlaine et al. 2015). Lastly, sex-specific gene expression profiling  has 
suggested the possibility of distinct molecular mechanism in males and females (Qin, Liu et al. 2016, 
Tiihonen, Koskuvi et al. 2019). 
Microarray-based expression profiling initially focused on the analysis of postmortem brain tissue, 
and later peripheral samples. Despite the relevance of brain tissue for the investigation of psychiatric 
illness, its analysis is limited by sample size constraints, sample preparation issues and the impact of 
postmortem effects on downstream analysis. In contrast, peripheral samples are more readily 
available and the data is thought to be less heterogeneous as it captures only effects which have a 
systemic manifestation in schizophrenia.  
1.2.3 Epigenomics   
Epigenomics describes an the use of omics profiling to study all possible biochemical modifications of 
DNA inside a cell or a population of cells. Epigenetic changes contribute significantly to the regulation 
of gene expression and activity (Jaenisch and Bird 2003, Gibney and Nolan 2010). Epigenetic 
modifications can be inherited through mitosis and meiosis without involving the alteration of the 
genomic sequence. There are three major types of epigenetic modifications: DNA methylation, 
histone modification, and non-coding RNA interference. In contrast to genetic effects, a notable 
property of epigenetic modifications is their reversibility (Ramchandani, Bhattacharya et al. 1999, Jia, 
Fu et al. 2013, Wu and Zhang 2014) meaning that epigenetic alterations have a significant role in 
regulating  genome function during development through non-mutagenic mechanisms. Of note, it 
allows the engineering of targeted molecular changes and provides the potential for therapeutic 
development (Kelly, De Carvalho et al. 2010).  
DNA methylation describes the addition of a methyl group to DNA with the aid of a family of 
enzymes termed DNA methyltransferases. DNA methylation is one of the best-characterized 
epigenetic mechanisms. The methylome refers to the complete set of DNA methylation events in the 
genome as determined by whole-genome DNA methylation analysis. The first high-resolution DNA 
methylome was reported for the flowering plant Arabidopsis (Zhang, Yazaki et al. 2006) and the first 
human methylome studies were carried out in human embryonic stem cell (hESC) (Lister, Pelizzola et 
al. 2009, Laurent, Wong et al. 2010).    
While the epigenetic landscape of schizophrenia has only been studied only in recent years, 
numerous DNA methylation differences have already been identified (Nishioka, Bundo et al. 2012, 
Pries, Gülöksüz et al. 2017). Analogous to GWAS, unbiased, hypothesis-free DNA methylome profiling 
(also termed Epigenome-Wide Association Study (EWAS)) has been employed to investigate aberrant 
DNA methylation in schizophrenia in blood (Aberg, McClay et al. 2012, Nishioka, Bundo et al. 2013, 
Aberg, McClay et al. 2014, Hannon, Dempster et al. 2016, Montano, Taub et al. 2016), brain (Pidsley, 
Viana et al. 2014, Jaffe, Gao et al. 2016) and saliva (Lin, Chen et al. 2018, Braun, Han et al. 2019). The 
resulting epigenetic signals were compared in terms of CpGs, genes, differentially methylated 
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regions, and biological pathways. While these studies have identified up to thousands of 
schizophrenia-associated differentially methylated CpGs, reproducibility of the illness-relevant CpGs 
across studies has been poor. This is likely due to tissue specificity, as well as methodological and 
disease-related heterogeneity. Nevertheless, more than ten genes with differentially methylated 
sites have been replicated in at least four independent studies (as reviewed by Pries and colleagues 
(Pries, Gülöksüz et al. 2017)). Some of the genes were consistent with those obtained from candidate 
gene methylation profiling including COMT (Murphy, O'Reilly et al. 2005, Nishioka, Bundo et al. 2013, 
Chen, Zhang et al. 2014, Wockner, Noble et al. 2014), RELN (Grayson, Jia et al. 2005, Aberg, McClay et 
al. 2012, Aberg, McClay et al. 2014, Fikri, Norlelawati et al. 2017) and BDNF (Kordi-Tamandani, 
Sahranavard et al. 2012). Although DNA methylation is cell type-specific (Ziller, Gu et al. 2013, Titus, 
Gallimore et al. 2017), there is a degree of overlap between blood, saliva, and brain tissue (Smith, 
Kilaru et al. 2015, Walton, Hass et al. 2016). This facilitates use of the more readily accessible blood 
or saliva samples for exploration of DNA methylation effects with brain-functional relevance for 
schizophrenia.  
Pathway and gene ontology analyses have also highlight some convergent biological processes 
relevant to schizophrenia. Consistent with findings from genomic and transcriptomic data, these are 
primarily immune-related (Liu, Chen et al. 2013, Aberg, McClay et al. 2014, Hannon, Dempster et al. 
2016), neurodevelopmental, or related to synaptic functioning (Mill, Tang et al. 2008, Dempster, 
Pidsley et al. 2011, Aberg, McClay et al. 2014, Pidsley, Viana et al. 2014, Hannon, Dempster et al. 
2016). Importantly, the hypothesized neurodevelopmental component of schizophrenia can be 
probed by mapping DNA methylation changes across brain development and for schizophrenia-
associated GWAS loci (Hannon, Spiers et al. 2015, Jaffe, Gao et al. 2016). 
A present, there have been few attempts to build machine learning models for classification of 
schizophrenia from genome-wide DNA methylation data. Two of these (Richfield, Alam et al. 2016, 
Alam, Lin et al. 2018) which used kernel based machine learning models in conjunction with blood-
based DNA methylation and fMRI data for approximately 200 genotyped subjects (92 schizophrenia 
patients and 116 controls, and 79 patients and 104 controls, respectively), have produced good 
prediction accuracy. However, the models were built without appropriate confounder adjustment 
making the final outcome challenging to interpret. Another recent study (Moghadam, Etemadikhah 
et al. 2019) analyzed post-mortem bulk frontal cortex tissue from 73 schizophrenia cases and 52 
controls to build a machine learning classifier that identified methylation patterns that differentiated 
cases from controls. The classifier was trained using Monte Carlo feature selection and ROSSETA rule-
based modeling consisting of a set of minimal IF-THEN rules. However, no significant patterns were 
identified with these models. Nevertheless, the authors highlighted strategies for improved 
classification, such as use of single-cell methylation data and whole-genome bisulfite re-sequencing 
technologies. We have also developed a machine learning framework termed BioMM (Chen and 
Schwarz 2019) (see also Figure 3) for schizophrenia case-control status classification using genome-
wide DNA methylation data from two independent cohorts (in total 767 cases and 755 controls). The 
prediction accuracy of our model was shown to outperform five conventional machine learning 
models. However, similar to other peripheral studies, brain-functional insight was not gained due to 
exclusive focus on peripheral DNA methylation differences. The lack of meaningful biological 
interpretation and clinically sufficient accuracy in the existing studies has highlighted the need for 
more explainable machine learning models that integrate large-scale datasets (Roscher, Bohn et al. 
2019). 
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1.3 Systems Biology 
On a biological level,  schizophrenia is hallmarked by small, illness-associated changes that can be 
observed across many different data modalities. Therefore, and a systems-wide, integrative 
approach is essential for characterizing the illnesses biology. A core focus of this thesis is use of 
systems level biological knowledge in combination with data science to identify putative biomarker 
candidates for schizophrenia. This section describes the application of pathway analysis and the 
analysis of developmental specificity for the systems-biological exploration of high-dimensional 
omics resources.  
1.3.1 Pathway analysis   
A biological pathway refers to set of linked molecular events in a cell or a tissue that lead to 
alteration of a particular phenotype. The genes that encode the proteins involved in these events can 
be grouped into different sets and analyzed together to identify important biological aspects of a 
dataset. Pathway approaches can be particularly helpful in casting light on hidden trends in high-
throughput omics data. Over the last two decades a number of pathway resources have been 
developed with the view of increasing the explanatory power of omics studies (Khatri, Sirota et al. 
2012, Garcia-Campos, Espinal-Enriquez et al. 2015). The existing methods are broadly classified into 
three classes: over-representation analysis, (Capper, Jones et al.)(Capper, Jones et al.)(Capper, Jones 
et al.)(Capper, Jones et al.)(Capper, Jones et al.)(Capper, Jones et al.)(Capper, Jones et al.)(Capper, 
Jones et al.)(Capper, Jones et al.)(Capper, Jones et al.)(Capper, Jones et al.)(Capper, Jones et 
al.)functional class scoring, and pathway topological analysis. All these methods aim to identify a list 
of pathways significantly associated with a given outcome or disease state. In addition to commercial 
pathway analysis resources such as Ingenuity Pathways Analysis 
(https://www.qiagenbioinformatics.com/), there are many public repositories are available for the 
research community (Bauer‐Mehren 2009, Garcia-Campos, Espinal-Enriquez et al. 2015). Of 
particular note is the Gene Ontology (GO; http://geneontology.org/), which is  the world largest 
resource concerning the functions of genes (Ashburner, Ball et al. 2000, 
The Gene Ontology Consortium 2018). The GO is organized into a tree like structure with three major 
branches (or ontologies). These ‘biological process’, ‘molecular function’ and ‘cellular component’ 
ontologies recursively categorize a given set of genes based on bimolecular functions and cellular 
location. The GO knowledgebase can be used to investigate gene functions  via an enrichment 
analysis. 
Pathway analysis has been extensively applied to explore various complex diseases (Jin, Zuo et al. 
2014). Convergent pathways have been identified across schizophrenia, depression and bipolar 
disorder using five different pathway enrichment analyses of GWAS data from more than 60,000 
adult subjects (Network and Pathway Analysis Subgroup of Psychiatric Genomics 2015). These 
pathways indicate a shared importance for genes linked to immune, neuronal and histone 
methylation processes in these disorders. This finding suggested that pathway analysis is biologically 
informative when integrating association signals therefore providing value insight into disease-
relevant etiological mechanisms. 
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1.3.2 Developmental specificity 
The influential neurodevelopmental hypothesis of schizophrenia dates back to the 1980s 
(Weinberger 1987) and is supported by mounting evidence (Fatemi and Folsom 2009, Andreasen 
2010, Rapoport, Giedd et al. 2012). The neurodevelopmental hypothesis posits that neurological 
insults which occur many years before an illness onset can lead to developmental trajectories which 
sensitize the brain to certain risk factors. These risk factors may, in turn, affect neurodevelopmental 
processes to the point that the overt symptoms of schizophrenia emergence during adolescence or 
early adulthood. The hypothesis of an early risk-associated developmental processes having a 
delayed influence on later-developing brain functions particularly in cortical regions has been 
supported by various studies employing animal models of the disorder (Saunders, Kolachana et al. 
1998, Lipska and Weinberger 2000, Floresco, Geyer et al. 2005, Fung, Webster et al. 2010, Marco, 
Macri et al. 2011).   
The availability of post-mortem brain tissue-derived transcriptomics data, which covers multiple 
developmental stages and brain regions (Colantuoni, Lipska et al. 2011, Kang, Kawasawa et al. 2011, 
Hawrylycz, Lein et al. 2012, Miller, Ding et al. 2014) has afforded new opportunities to study 
schizophrenia-associated developmental trajectories. Despite the complexity of human brain 
development it has been shown the human brains transcriptome has a highly reproducible 
organization (Oldham, Konopka et al. 2008, Hawrylycz, Lein et al. 2012). The developmental 
characterization of schizophrenia risk has mainly investigated by mapping schizophrenia 
susceptibility genes onto developmental networks. For example, trajectories of gene expression 
profiles enriched for SNPs associated for schizophrenia are associated with schizophrenia-relevant 
developmental stages (Clifton, Hannon et al. 2019). Furthermore, relatively higher gene expression 
during the early mid-fetal period and early infancy are correlated with schizophrenia genetic risk. In 
contrast, the expression during late childhood showed a negative correlation with genetic risk and 
then remained steady during adolescence. In addition, a similar gene expression pattern associated 
with schizophrenia in these two critical periods was more pronounced in the prefrontal cortex than 
in non-prefrontal and subcortical regions at any developmental stage. Another study (Huckins, 
Dobbyn et al. 2019) integrated GWAS data with and postmortem brain eQTL information to identify 
schizophrenia risk genes. These genes were then mapped onto developmental transcriptomic data 
obtained from the BrainSpan database (Miller, Ding et al. 2014). The identified risk genes were 
predominantly co-expressed during the early prenatal and postnatal stages. However, the identified 
brain region with significant co-expression does not have good evidence linking to schizophrenia. In 
addition to studies involving common genetic variants, studies have been conducted that focus on 
the 108 risk-associated loci (Birnbaum, Jaffe et al. 2015, Jaffe, Straub et al. 2018), genes harboring de 
novo mutations in schizophrenia (Xu, Ionita-Laza et al. 2012, Gulsuner, Walsh et al. 2013), and a 
combination of schizophrenia-related genetic variants (Gilman, Chang et al. 2012). These mappings 
on the developmental trajectory are predominantly linked to early fetal life through transcriptomic 
profiling. Lastly, temporal gene expression profiling revealed that schizophrenia risk gene expression 
patterns during prenatal neurodevelopmental period largely did not overlap with those for bipolar 
disorder (Clifton, Hannon et al. 2019). While there is substantial genetic overlap between these 
disorders, this is in line with the lower neurodevelopmental impairment seen in bipolar disorder 
(Owen and O'Donovan 2017). Overall, the analysis of developmental specificity is beneficial process 
that may permit a new, more systematic characterization of illness risk.  
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1.4 Machine learning 
1.4.1 Machine learning models 
Over the last few years massive amounts of molecular data have been made available to the 
biomedical research community. To handle this data, contemporary artificial intelligent (AI) 
techniques have been adopted to assess the probability of being affected by specific diseases. In 
conjunction with medical expert opinion, these techniques have enhanced clinical diagnosis and 
decision-making performance (Yu, Beam et al. 2018). Jiang and colleagues, (Jiang, Jiang et al. 2017) 
who surveyed the current status of AI applications for medical diagnostics reported that a large part 
of the AI literature focuses on diagnostic imaging, genetic testing and electro-diagnosis. The 
attention primarily concentrated on three disease areas: cancer, neurology, and cardiology. Due to 
the increasing availability of large-scale omics data, there has also been substantial adoption of AI 
applications in psychiatry (Bzdok and Meyer-Lindenberg 2018). These application aim to integrate 
frequently small biological alterations into classifiers with high predictive value for diagnostic or 
therapeutic applications. 
Machine learning, a sub-field of AI, aims to teach a model to identify patterns, by employing a 
specific input/output paradigm based on the learned model. Generally speaking machine learning 
models typically fall into one of two classes: supervised and unsupervised learning. Supervised 
learning aims to identify a combination of variables (i.e. predictors) that can optimally predict an 
outcome (e.g. diagnostic status), which needs to be specified in advance. It is then possible to 
quantify how accurately the model can perform this prediction when applied to unseen data not 
used for model training. In contrast, unsupervised learning does not require the prior specification of 
an outcome, instead aiming to learn structural properties of the data from the available variables 
only. The most prominent application of unsupervised learning is clustering, i.e. the identification of 
observations that show more similar patterns of variable values compared to observations that are 
part of a different cluster. In contrast to supervised learning, it is more challenging to evaluate the 
performance of these models due to a lack of ‘ground truth’. Furthermore, clustering approaches 
always yield a certain clustering solution, which may not be biologically meaningful and has resulted 
in clustering approaches being frequently considered ‘hypothesis-generating’. Ideally, clustering 
solutions should be evaluated in regard to their association with independent variables, such as 
clinical course or treatment response. This section describes three frequently used supervised 
machine learning models that are applied in this work. 
 
Generalized Linear model. A general linear model is a simple model that forms a linear combination 
of variables to predict the dependent variable. The generalized linear model (GLM) is an extension to 
non-linear forms. Some examples of well-known GLMs are summarized in Table 1 (Nelder and 
Wedderburn 1972). For GLMs, the probability distribution of the response variable is allowed to be 
non-Gaussian which would not be appropriate in a general linear models. For example, when 
modeling a categorical or multinomial distribution for the dependent variable, a logistic regression 
model can be a good choice (a graphical presentation of logistic regression is shown in Figure 1A).  
The objective of logistic regression is to establish the relationship between a binary (in the case of 
two classes) dependent variable and one or more input variables. 
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Table 1. Popular GLM models  
Model Random Link Systematic 
Linear Regression Normal Identity Continuous 
ANOVA Normal Identity Categorical 
ANCOVA Normal Identity Mixed 
Logistic Regression Binomial Logit Mixed 
Loglinear Poisson Log Categorical 
Poisson Poisson Log Mixed 
Multinomial  Multinomial Generalized Logit Mixed 
 
Support Vector Machines. The Support Vector Machine (SVM) identifies a hyperplane separating 
observations into different classes (Cortes and Vapnik 1995). This is represented by single line for 
two-dimensional data, a plane for three-dimensional data, and a hyperplane for data with more than 
three dimensions. The distance between this hyperplane and its nearest observations is maximized, 
leading to a classification ‘margin’. In the frequent scenario where classes are not linearly separable, 
a cost-parameter is optimized to penalize observations falling on the wrong side of the hyperplane. A 
graphical depiction of SVM is provided in Figure 1B. A comprehensive review of the application of 
SVM in the detection of imaging biomarkers in neurological and psychiatric disorders can be found 
elsewhere (Orru, Pettersson-Yeo et al. 2012). 
 
Figure 1 A.) Logistic regression; B.) Support vector machine. 
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Figure 2. Random forest. 
 
Random Forest. The Random Forest algorithm is an ensemble learning method that combines a set 
of weak learners to reduce the overall variance (Breiman 2001). Here each weak learner is a decision 
tree. A random forest comprises a number of random decision trees with two kinds of built in 
randomness. First each tree is built on a random input sample of the training data. Second, at each 
node of the tree, a subset of features are selected at random to yield the best split (Figure 2). In the 
classification setting, the prediction result is determined by the majority vote cast from a committee 
of trees and the averaged predicted result from bootstrapping predictions is used for regression. A 
particular advantage of the random forest is its intrinsic ranking of important predictors. There are 
two popular types of importance scores provided for each feature: accuracy-based importance and 
Gini-based importance. The accuracy-based measure is determined from the decrease in accuracy 
when a given feature is permuted while the Gini-based importance is accessed by the reduction of 
Gini impurity when the feature is selected for a  split at a given node. 
1.4.2 The curse of dimensionality and dimensionality reduction   
The analysis of high-throughput omics data is challenging due to the problem of ‘large p, small n’, 
meaning that the number of variables greatly exceeds that of the observations. This can often result 
in a phenomenon termed “curse of dimensionality” when machine learning models operate on data 
in high-dimensional spaces. In this situation, the dimensionality rapidly increases with the addition of 
input variables with the volume of the space increasing so quickly that the data becomes sparse. Due 
to this sparsity, it is highly difficult to evaluate statistical significance or find a decision boundary for 
any learning methods. Consequently, machine learning models then tend to capture effects that are 
overly specific for a given dataset, and lack of reliability and generalizability, leading to so-called 
‘overfitting’.  A commonly applied strategy to address this issue is the reduction of data 
dimensionality, which also aids the visualization and interpretation of high-dimensional omics 
datasets. Data dimensionality reduction techniques applied in this thesis fall into two broad 
categories: 1) feature selection and II) feature extraction or engineering.  
Feature selection aims to identify useful features directly from a given dataset, while feature 
extraction describes the process of extracting or generating new features from the dataset via 
feature transformation or mapping to reduce dimensionality. Three commonly used feature selection 
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techniques used in the context of classification are filters, wrappers and embedded or hybrid 
methods, which are comprehensively reviewed elsewhere (Saeys, Inza et al. 2007). In the case of 
feature extraction, there are two general approaches: linear and nonlinear feature extraction. 
Principal Component Analysis is the most well-known linear feature extraction method and works by 
projecting the original data into a lower-dimensional feature space such that the variance of the data 
in this set of features is maximized. Non-linear dimension reduction methods are based on manifold 
learning in which the high dimensionality of the data may relate to redundant information or noise. 
Here, relevant information can be condensed into lower dimension manifolds which can be 
especially useful when the data contains nonlinear dependencies. Some popular methods regarding 
the nonlinear dimensionality reduction were systematically discussed by (Van Der Maaten, Postma et 
al. 2009).  
 
Figure 3. The basic architecture of BioMM. From left to right: the input layer consists of genome-
wide CpGs; The stage-1 layer comprises individual CpGs mapped into their corresponding pathways 
by means of the pathway database; The stage-2 layer contains the pathway level features created 
using machine learning; the output layer contains the predicted outcome, which can be either 
probabilistic or binary. BioMM 1st stage describes the learning process to create stage-2 layer 
features. BioMM 2nd stage integrates information from stage-2 layer features using machine learning 
and yields the final prediction. 
1.4.3 Biologically informed machine learning 
Despite high-performing machine learning models holding the promise of revolutionizing the clinical 
management of schizophrenia, their development is hampered by several unresolved challenges. 
One issue is that machine learning models trained on high-dimensional data are often regarded black 
boxes that do not yield an intuitive explanation of their predictive value, limiting biological insight 
and the possibility for further improvement (Ribeiro, Singh et al. 2016). In terms of the development 
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of more explainable machine learning models three descriptive terms are currently being 
distinguished: transparency, interpretability and explainability (Roscher, Bohn et al. 2019). By and 
large, transparency refers to the machine learning model itself, interpretability refers to the model 
together with data, and explainability refers to the model, the data and human involvement. An 
essential part of explainability is the explicit integration of domain knowledge into the machine 
learning framework, which is called informed machine learning (von Rueden, Mayer et al. 2019). On 
the other hand, scientific consistency or reproducibility is another fundamental element for creating 
explainable machine learning approaches (Reichstein, Camps-Valls et al. 2019, Roscher, Bohn et al. 
2019). To this end, there has been a number of biologically informed machine learning models 
developed for different purposes in the context of omics data (Cun and Fröhlich 2012, Chen and 
Schwarz 2017, Kang, Ding et al. 2017, Zarringhalam, Degras et al. 2018). 
An example of these methods are the so-called ‘synthetic feature random forest’ [SF-RF] (Pan, Hu et 
al. 2014), first developed to detect phenotype-associated pathways by taking the gene-gene and 
pathway-pathway interactions into account. Genotyping data from bladder cancer patients and 
healthy controls consisting of 1,303 preselected SNPs were used in this study. It was hypothesized 
that each disease-associated pathway could be represented as a single synthetic feature, which is 
learned by the random forest classifier. High-level interactions between such features that are 
captured by random forest, as well as statistical epistasis networks may better explain illness-
associated genetic mechanisms. A similar strategy  was developed by Liu and colleagues who created 
a pathway-based machine learning framework that identified a subtle overlap of schizophrenia-
associated pathways between patients of three different ancestries using GWAS data (Liu, Bousman 
et al. 2017).  
Pathway-informed machine learning has also been reported for gene-level associations. A Markov 
Random Field approach that incorporated a pathway’s topological information was used to identify a 
set of disease-related genes using both simulated and real SNP data for Crohn’s disease (Chen, Cho et 
al. 2011). The genetic interactions encoded by the topology of a pathway can be explicitly modeled 
so that disease-associated genes can be identified with increased statistical power. In addition to 
genetic association data, these methods have been applied to the analysis of gene expression data. 
For instance, a two-stage machine learning approach has been developed to identify pathways 
associated with traits of interest using three gene expression datasets (Zhang, Emrich et al. 2010). 
The significance of gene sets was investigated using four different machine learning classifiers, 
combined with four different feature selection methods and compared with results from Gene Set 
Enrichment Analysis (GSEA) (Subramanian, Tamayo et al. 2005). This demonstrated that the two-
stage machine learning approach to integrating pathway information outperformed GSEA by 
detecting larger number of active pathways with more statistical power.  
A recent study incorporating gene ontology into deep learning models has shown the improved 
clustering of single-cell RNA-seq data (Peng, Wang et al. 2019). In this study the authors employed 
both supervised and unsupervised models to reduce the dimensionality for the clustering of 
mammalian cell types from two different RNA-seq datasets, and demonstrated better performance 
over eight other dimension reduction methods. The approaches illustrate the potential application of 
explainable machine learning model in omics analyses of schizophrenia. The present thesis describes 
such an application in the context of biologically-informed multi-stage machine learning (BioMM), 
which was used to identify predictive signatures from epigenetic data. 
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1.5 Imaging genetics 
Imaging genetics is concerned with the study of how genetic variation impacts on brain structural 
and functional phenotypes that are captured using neuroimaging. This rapidly evolving field has 
existed for nearly two decades and aims to better characterize risk mechanisms contributing to brain 
disorders. During this time it has provided a fascinating window into potential neurobiological 
processes underlying brain images (Mufford, Stein et al. 2017). Neuroimaging techniques allows 
characterization of brain structure and function in-vivo and have hugely advanced our knowledge of 
brain disorders (Bandettini 2009) such as schizophrenia (Pfefferbaum and Zipursky 1991, Kotrla, J. et 
al. 1995), by providing a map of candidate structural, functional and network alterations in patients 
and at-risk subjects (Meyer-Lindenberg 2010).  
The exploration of genetic effects on imaging phenotypes has progressed from  investigation of 
variants in candidate genes to GWAS and polygenic scores with more recent multivariate machine 
learning approaches being discussed in the  next section.  
1.5.1 From candidate association to GWAS    
Candidate gene approaches offer a more direct path towards mechanistic interpretation compared 
to genome-wide analyses and have been the primary focus of imaging genetics research. As reviewed 
elsewhere (Meyer-Lindenberg 2010, Meyer-Lindenberg 2010), genetic variation in a number of well-
known candidate genes has shown associations with imaging phenotypes, with genes including 
COMT (Egan, Goldberg et al. 2001), NRG1 (Hall, Whalley et al. 2006), DISC1 (Callicott, Straub et al. 
2005), DARPP-32 (Meyer-Lindenberg, Straub et al. 2007), RGS4 (Buckholtz, Meyer-Lindenberg et al. 
2007), DRD2 (Bertolino, Fazio et al. 2008), and BDNF (Ho, Milev et al. 2006). However, candidate 
gene studies frequently produce inconsistent associations across studies (Nickl-Jockschat, 
Janouschek et al. 2015, Bogdan, Salmeron et al. 2017). Beyond variants harbored by candidate genes, 
several SNPs supported by genome-wide significant illness-association have been explored for neural 
associations in a comparatively more hypothesis-free manner. Representative examples include 
ZNF804A (Esslinger, Walter et al. 2009, Rasetti, Sambataro et al. 2011) and CACNA1C (Paulus, 
Bedenbender et al. 2014).  
The intermediate phenotype or endophenotype concept of Gottesman and Shields (Gottesman and 
Shields 1973) refers to a latent biological feature that lies somewhere between gene effects and the 
overt clinical phenotype. Endophenotypes are thought to be closer to underlying molecular 
processes that contribute to an illnesses development and progression and thus show greater 
genetic penetrance than conventional phenotypes. This is particularly relevant for imaging genetics 
which often focus on analysis of heritable aspects of brain related function or structure (Gottesman 
and Gould 2003, Meyer-Lindenberg and Weinberger 2006, Greenwood, Braff et al. 2007, Rasetti and 
Weinberger 2011, Cao, Dixson et al. 2016, Dixson, Tost et al. 2018). The aforementioned, genome-
wide supported variants in ZNF804A and CACNA1C were associated with one of the most well-
established imaging intermediate phenotypes for schizophrenia. This phenotype quantifies the 
decoupling of the dorsolateral prefrontal cortex and the hippocampus (DLPFC-HC) during a working 
memory paradigm (Meyer-Lindenberg, Olsen et al. 2005, Schneider, Walter et al. 2017), and shows 
how schizophrenia patients possess a significantly different connectivity pattern compared to healthy 
controls and unaffected first degree relatives. Although single variant focus study in imaging genetics 
focusing have substantial utility in characterizing the genetic architecture of neural functioning,  
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these studies are limited to  small effect sizes and further do not capture complex epistastic effects 
that likely contribute to the polygenic architecture of schizophrenia.  
1.5.2 Machine learning models - From PRS to multivariate and machine learning  
Due to the low explanatory power of individual common variants, recent imaging genetics research 
has increasingly focused on the analysis of PRS scores in order to aggregate genetic effects (Dima and 
Breen 2015, Bogdan, Salmeron et al. 2017). For example, the association of a schizophrenia PRS with 
neural activity during working memory performance has been explored in a cohort of 79 
schizophrenia cases and 99 healthy controls (Walton, Turner et al. 2012). This PRS summarizes the 
combined effect of variants harbored by 34 schizophrenia risk genes for schizophrenia which were 
correlated with decreased activation in the left DLPFC during working memory. Several other studies 
have observed similar patterns linking higher PRS scores to lower DLPFC activity during working 
memory (Kauppi, Westlye et al. 2014, Whalley, Hall et al. 2015, Miller, Scult et al. 2017). Moreover, 
PRS for schizophrenia has been associated with reduced hippocampal activity during memory 
encoding (Chen, Ursini et al. 2018), increased global cortical thickness (Neilson, Bois et al. 2017), and 
decrease cortical gyrification (Liu, Zhang et al. 2017). Interestingly, a recent study (Alnæ s, Kaufmann 
et al. 2019) reported that there is substantially increased brain structural heterogeneity in cortical 
thickness, and cortical and hippocampal volumes in schizophrenia. In this study, the PRS was 
associated with mean changes in schizophrenia implicated regions, but could not capture the brain 
heterogeneity warranting longitudinal investigations to disentangle the hidden factors underlying 
inter-individual variability. Taken together these findings further supported the utility of polygenic 
score analysis  for characterizing the genetic architecture of schizophrenia.  
It should be noted that the PRS approach has several limitations which are reviewed in detail 
elsewhere. Limitation include the lack of consideration of potential epistatic effects, the restricted 
biological insight into underlying mechanisms (Bogdan, Salmeron et al. 2017), constrained diversity in 
the populations under study (Bogdan, Salmeron et al. 2017, De La Vega and Bustamante 2018), and 
insufficient generalizability (Torkamani, Wineinger et al. 2018).Multivariate or machine learning 
approaches are an alternative to the PRS approaches that can substantially profit from big data 
collected in large-scale collaborations such as the ENIGMA consortium (Thompson, Stein et al. 2014, 
Thompson, Andreassen et al. 2017). However, these approaches have not yet been widely applied in 
the schizophrenia field, likely due to the scarcity of the multimodal data and the lack of well-
developed methodological frameworks. While there are several studies investigate brain disorders 
using multivariate or machine learning techniques these do not primarily focus on schizophrenia (Liu 
and Calhoun 2014, Bogdan, Salmeron et al. 2017, Mufford, Stein et al. 2017). One of these few 
studies using a semi-blind multivariate approach termed parallel ICA with reference (Chen, Calhoun 
et al. 2013).  This study integrated imaging and SNP data with prior knowledge from 140 patients 
with schizophrenia and 160 healthy controls to identify genomic risk variants involved in 
neurotransmission and neural signaling pathways that were significantly associated with 
schizophrenia-linked  grey matter reduction in prefrontal and temporal regions .  
Multivariate or machine learning frameworks should preferably feature under researched factors 
such as epistatic effects, gene-environment interactions, with transcriptomic, epigenetic, clinical and 
environmental data (Bogdan, Salmeron et al. 2017, Mufford, Stein et al. 2017). However, there is 
currently insufficient data to effectively cover this broad spectrum of modalities. That said, the 
ongoing efforts in international collaborations provide opportunities for increasingly sophisticated 
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data analysis that  integrate small-effect changes across modalities to better characterize the risk 
architecture of schizophrenia and its impact on neural functioning.  
 
In summary, the application of machine learning offers promising approaches to characterize the 
molecular risk mechanisms contributing to the polygenetic nature of schizophrenia. The 
characterized effect of molecular perturbations can then be mapped onto the brain imaging space to 
infer systems-level consequences. It is hoped such a strategy it would allow a more precise and 
comprehensive understanding of risk mechanisms and aid in the personalization of precognitive 
therapy.   
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2 EMPIRICAL STUDIES 
2.1 Study 1 - Identification of a reproducible epigenetic risk profile for schizophrenia 
with brain methylation and function1 
 
2.1.1 Key points   
Question  Can a blood marker of epigenetic risk for schizophrenia be derived that is specific for the 
disease and predicts epigenetic changes in brain and disease-associated brain function? 
Findings  In this case-control study, machine learning was used to identify a reproducible 
schizophrenia blood DNA-methylation signature that was associated with functional dorsolateral 
prefrontal cortex hippocampal connectivity, mapped to methylation differences found in dorsolateral 
prefrontal cortex hippocampal connectivity postmortem samples, and indexed biological pathways 
associated with synaptic function. No interactions with polygenic schizophrenia risk were found. 
Meaning  These findings support the presence of a systemic methylation profile in schizophrenia that 
is associated with established intermediate functional phenotypes as well as with epigenetic 
signatures in brain and should thus be useful to capture the biological effects of gene-environment 
interactions. 
2.1.2  Abstract 
Importance: Schizophrenia is a severe mental disorder in which epigenetic mechanisms may 
contribute to illness risk. Epigenetic profiles can be derived from blood cells, but to our knowledge, it 
is unknown whether these predict established brain alterations associated with schizophrenia. 
Objective: To identify an epigenetic signature (quantified as polymethylation score [PMS]) of 
schizophrenia using machine learning applied to genome-wide blood DNA-methylation data; 
evaluate whether differences in blood-derived PMS are mirrored in data from postmortem brain 
samples; test whether the PMS is associated with alterations of dorsolateral prefrontal cortex 
hippocampal (DLPFC-HC) connectivity during working memory in healthy controls (HC); explore the 
association between interactions between polygenic and epigenetic risk with DLPFC-HC connectivity; 
and test the specificity of the signature compared with other serious psychiatric disorders. 
Design, setting, and participants: In this case-control study conducted from 2008 to 2018 in sites in 
Germany, the United Kingdom, the United States, and Australia, blood DNA-methylation data from 
2230 whole-blood samples from 6 independent cohorts comprising HC (1238 [55.5%]) and 
participants with schizophrenia (803 [36.0%]), bipolar disorder (39 [1.7%]), major depressive disorder 
35 [1.6%]), and autism (27 [1.2%]), and first-degree relatives of all patient groups (88 [3.9%]) were 
analyzed. DNA-methylation data were further explored from 244 postmortem DLPFC samples from 
                                            
1
 Published as: Chen, J., Zang, Z., Braun, U., Schwarz, K., Harneit, A., Kremer, T., ... & Schwarz, E. (2020). 
Association of a Reproducible Epigenetic Risk Profile for Schizophrenia With Brain Methylation and Function. 
JAMA psychiatry.  
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136 HC and 108 patients with schizophrenia. Neuroimaging and genome-wide association data were 
available for 393 HC. The latter data was used to calculate a polygenic risk score (PRS) for 
schizophrenia. The data were analyzed in 2019. 
Main outcomes and measures: The accuracy of schizophrenia control classification based on 
machine learning using epigenetic data; association of schizophrenia PMS scores with DLPFC-HC 
connectivity; and association of the interaction between PRS and PMS with DLPFC-HC connectivity. 
Results: This study included 7488 participants (4395 men [58.7%]), of whom 3158 (2230 men [70.6%]) 
received a diagnosis of schizophrenia. The PMS signature was associated with schizophrenia across 3 
independent data sets (area under the curve [AUC] from 0.69 to 0.78; P value from 0.049 to 1.24 × 
10-7) and data from postmortem DLPFC samples (AUC = 0.63; P = 1.42 × 10-4), but not with major 
depressive disorder (AUC = 0.51; P = .16), autism (AUC = 0.53; P = .66), or bipolar disorder (AUC = 
0.58; P = .21). Pathways contributing most to the classification included synaptic processes. Healthy 
controls with schizophrenia-like PMS showed significantly altered DLPFC-HC connectivity (validation 
methylation/magnetic resonance imaging, t < -3.81; P for familywise error, <.04; validation magnetic 
resonance imaging, t < -3.54; P for familywise error, <.02), mirroring the lack of functional decoupling 
in schizophrenia. There was no significant association of the interaction between PMS and PRS with 
DLPFC-HC connectivity (P > .19). 
Conclusions and relevance: We identified a reproducible blood DNA-methylation signature specific 
for schizophrenia that was correlated with altered functional DLPFC-HC coupling during working 
memory and mapped to methylation differences found in DLPFC postmortem samples. This indicates 
a possible epigenetic contribution to a schizophrenia intermediate phenotype and suggests that PMS 
could be of interest to be studied in the context of multimodal biomarkers for disease stratification 
and treatment personalization. 
 
2.1.3 Introduction 
Schizophrenia is a severe brain disorder thought to be caused by a complex interplay of genetic 
predisposition and environmental exposure (Weinberger 1987, Cannon 1998, Sullivan, Kendler et al. 
2003, van Os, Rutten et al. 2008, Bergen, O'Dushlaine et al. 2012). In the context of gene-
environment may account for heritability not captured by other current methods, such as polygenic 
interplay and developmental programming (van Os, Kenis et al. 2010, Brown 2011), epigenetic 
mechanisms, such as DNA methylation, have received substantial attention in schizophrenia(Nishioka 
2012, Aberg, McClay et al. 2014) and other neuropsychiatric disorders (Mill, Tang et al. 2008, Cecil, 
Walton et al. 2015, Teroganova, Girshkin et al. 2016, Zhang and Gelernter 2017). As epigenetic 
mechanisms risk scores (PRS), potential interactions between genetic susceptibility and epigenetic 
changes are of particular interest. To date, much of this work has studied single genes. For example, 
methylation at the Single Nucleotide Polymorphism (SNP) rs6265 within the neurodevelopmentally 
important brain-derived neurotrophic factor (BDNF) gene shows a genotype-dependent association 
with WM, hypoxia-related early life events, and a WM-related schizophrenia intermediate phenotype 
(Ursini, Cavalleri et al. 2016). Similarly, methylation differences in dopamine receptor D4 (DRD4) 
predict WM, suggesting that the dopaminergic methylation status could affect cognitive functions in 
a dissociable manner (Lewis, Henderson-Smith et al. 2019). Likewise, membrane-bound catechol-O-
EMPIRICAL STUDIES 
24 
 
methyltransferase (MB-COMT) promoter methylation is associated with DLPFC activity during WM 
(Walton, Liu et al. 2014) and methylation of the COMT Val(158) allele with lifetime stress, WM 
performance and prefrontal activity during WM (Ursini, Bollati et al. 2011).  
While these studies have explored targeted hypotheses, methylation differences in single genes  
(Ursini, Bollati et al. 2011, Ursini, Cavalleri et al. 2016) are only weakly associated with schizophrenia. 
To capture systems-level effects, methylation differences have been explored across the genome in 
whole-blood (Aberg, McClay et al. 2014, Hannon, Dempster et al. 2016) and post-mortem brain 
tissue samples (Pidsley, Viana et al. 2014, Jaffe, Gao et al. 2016). Joint analysis of genome-wide 
methylation and genotyping data provided evidence that the methylation changes found in 
schizophrenia differ from those associated with polygenic risk, but overlap with previously identified 
genetic susceptibility loci (Schizophrenia Working Group of the Psychiatric Genomics 2014, Hannon, 
Dempster et al. 2016, Jaffe, Gao et al. 2016). This supports the notion that the methylation 
differences are indeed associated with schizophrenia and not merely a result of disease-unrelated 
environmental factors (Lim and Song 2012, Zakhari 2013, Voisin 2015). An important question is 
whether, similar to polygenic scores, there is a combined contribution of these methylation 
differences on illness risk. A machine learning study provided evidence for a schizophrenia poly-
methylation signature (PMS) that could be validated in independent data (Chen and Schwarz 2017). 
We do not, however, yet understand whether this PMS is relevant in the brain and how it is 
associated with genomic risk with regard to neural effects.  
Components of the risk architecture of schizophrenia have been successfully interrogated using a 
strategy termed imaging genetics (Meyer-Lindenberg 2010), an approach that has facilitated the 
identification of so called neural ‘intermediate phenotypes’, illness-associated, heritable traits that 
reflect a manifestation of illness liability(Lenzenweger 2013). One of the best established 
intermediate phenotypes of schizophrenia is Dorsolateral-Prefrontal-Cortex–Hippocampus (DLPFC-
HC) connectivity during working memory (Malki, Tosto et al.) performance (Meyer-Lindenberg, Olsen 
et al. 2005, Malki, Tosto et al. , Schneider, Walter et al. 2017). DLPFC-HC connectivity is altered in 
healthy first-degree relatives of patients with schizophrenia and is linked to risk alleles of established 
genome-wide significant schizophrenia gene variants, such as ZNF804A (Rasetti, Sambataro et al. 
2011). WM is impaired in schizophrenia, linked to genetic risk (Schwarz, Tost et al. 2016) and affected 
by environmental factors contributing to illness risk, including childhood trauma and socioeconomic 
status (Evans and Schamberg 2009, Vargas, Lam et al. 2018), strengthening the argument that this 
intermediate phenotype reflects risk-related pathophysiological processes.  
Using this approach, we investigated genome-wide DNA methylation data from 2041 whole-blood 
samples from four independent cohorts comprising 1238 healthy controls (HC) and 803 patients with 
schizophrenia (SCZ). We aimed to identify and validate a PMS differentiating SCZ from HC. 
Subsequently, we assessed whether the PMS reproducibly predicted altered DLPFC-HC connectivity 
in HC and explored potential interactions with a schizophrenia PRS. Finally, we used genome-wide 
DNA methylation data from post mortem DLPFC samples from 136 healthy donors and 108 donors 
with schizophrenia to assess whether the peripheral PMS was mirrored by analogous changes in the 
brain. This investigation aimed at characterizing the systems-level relationship between genetic and 
epigenetic risk for schizophrenia, and to test the effects of these parameters on schizophrenia-
relevant neural functioning.  
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2.1.4 Methods 
Cohorts 
Genome-wide DNA methylation data from 7 cohorts, denoted as discovery methylation, validation 
methylation, validation methylation/magnetic resonance imaging (MRI), validation MRI, validation 
post mortem, specificity methylation, and relatives methylation, were analyzed in this work 
(demographic characteristics are summarized in Table 1 and eTable 1 in the Supplement). All 
participants (or their legal next-of-kin in case of brain tissue donors) gave written or audiotaped 
informed consent and all studies were approved by the local ethics committees (eMethods in 
the Supplement). Discovery methylation and validation methylation consisted of 2 independent 
cohorts 767 patients with schizophrenia [95.5%] and 755 HC [61.0%]). These data sets were used to 
identify and validate a PMS using machine learning. Validation methylation/MRI (36 patients with 
schizophrenia [4.5%] and 331 HC [26.7%]) was used for additional validation of the PMS, while MRI 
data from a subset of the HC (241 [19.5%]; n-back WM functional MRI paradigm (Rasetti, Sambataro 
et al. 2011, Schneider, Walter et al. 2017)) were used to test associations with DLPFC-HC 
connectivity. The MRI data from validation MRI (n = 152 HC) acquired during the Sternberg WM task 
(Geiger, Moessnang et al. 2018) were used to validate the identified DLPFC-HC connectivity 
associations. The functional MRI face-matching task (Cao, Bertolino et al. 2016) was used in 
validation MRI to explore the specificity of findings for WM. Validation post mortem comprised 
genome-wide methylation data from postmortem DLPFC samples 108 schizophrenia [44.3%]; 136 HC 
[55.7%]) and was used to assess the overlap of the PMS with brain methylation changes. Genome-
wide association study (GWAS) data in validation methylation/MRI and validation MRI were used to 
compute a schizophrenia PRS to test associations with the PMS and interactions with PMS on brain 
functional connectivity. For specificity testing, we explored DNA methylation data from a cohort 
(specificity methylation) of patients with bipolar disorder (BD; 39 [1.7%]), major depressive disorder 
(MDD; 35 [1.6%]) and autism (27 [1.2%]). To further characterize the effect of genetic schizophrenia 
risk, a cohort (relatives methylation) of unaffected first-degree relatives of participants with 
schizophrenia (27 [1.2%]), BD (15 [0.7%]), MDD (29 [1.3%]), and autism (17 [0.8%]) were analyzed. 
The machine-learning procedure used here was further applied to GWAS data from GWAS molecular 
genetics of schizophrenia (GWAS MGS) (n = 2718 HC and n = 2296 schizophrenia) to identify risk 
components not captured by the PRS that could potentially explain PMS-associated findings. 
The data, methods, and confounding correction are detailed in the eMethods in the Supplement. 
Most patients were taking medication. Neuroimaging analyses focused on HCs not taking medication 
to demonstrate that PMS associations were not associated with medication. Additionally, we 
explored the association of the PMS and DLPFC-HC connectivity with chlorpromazine equivalents. 
Gene and pathway assignment of genome-wide DNA methylation data 
For each gene, CpGs harbored by the gene with an extended window size of 20 kb downstream and 
upstream were used for analysis. CpG locations and gene annotations used for mapping were 
obtained from the R library IlluminaHumanMethylationEPICanno.ilm10b2.hg19 (R Foundation). 
Genes were binned into biological process categories (denoted as pathways) using the GeneOntology 
database (data freeze in Dec. 2018) (Gene Ontology, Blake et al. 2013). 2846 pathways comprising 
between 10 and 200 genes with at least 10 CpGs per pathway were used for analysis.  
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Machine learning, replication and validation 
An updated biologically informed machine learning (BioMM) approach was used (eMethods in 
the Supplement). (Chen and Schwarz 2017). BioMM is a 2-stage machine-learning approach that first 
builds separate machine learning models for methylation sites mapping to each of the 2846 
pathways, yielding 1 machine-learning model per pathway (first-stage). This procedure compresses 
data from individual methylation sites into a pathway-level feature. Then, a second-stage algorithm 
integrates these pathway-level features into a systems-level classifier. BioMM was trained on 
discovery methylation and the algorithm then applied to all other data sets. In each data set, the 
output of BioMM was a score (PMS) that quantified the likelihood of a given participant being in the 
schizophrenia group. To assess predictive accuracy, we determined the area under the receiver 
operating characteristic curve (AUC) as well as Nagelkerke R2. 
 
Statistical analysis 
Associations between PMS and DLPFC-HC functional connectivity were assessed using a linear 
regression in SPM, version 12, using PMS as covariate of interest and age and sex as covariates of 
noninterest. Statistical significance was set at P < .05. The PMS and DLPFC-HC connectivity 
associations in the imaging space were corrected using a familywise small-volume correction in the 
hippocampus (eFigures 1 and 2 in the Supplement) based on the automated anatomical labeling 
template. Associations between PMS and the schizophrenia PRS, as well as the association of the 
PMS by PRS interaction with DLPFC-HC connectivity, were tested using a multiple linear regression 
that accounted for the effects of sex, age, and (for PRS-associated analyses) 10 genetic principal 
components. For details and analysis of potential confounding, see the eMethods in the Supplement. 
2.1.5 Results 
Determination and validation of a PMS in blood samples 
Genome-wide DNA methylation data from discovery methylation (675 [30.3%]) were used for model 
training. In this data set the model showed a cross-validation accuracy of an AUC of 0.78 
(P = 2.95 × 10−6, corrected for 20 potential confounders; R2 = 21%). The model was then predicted 
into validation methylation (847 [38.0%]), yielding an AUC of 0.69 (P = 1.24 × 10−7; R2 = 10.5%). For 
additional validation, the model was predicted into validation methylation/MRI (367 [16.5%]), 
yielding an AUC of 0.74 (P = .049; R2 = 21.8%). This demonstrates the biological reproducibility of the 
PMS (Table 2 and Figure 1). 
 
Identification of implicated biological pathways  
To identify pathways with methylation changes contributing strongly to the epigenetic signature, 
pathway-level (second-stage) data from BioMM in discovery methylation were used. The 10 
pathways most associated with schizophrenia are shown in Figure 2 (eTable 2 in the Supplement). Of 
the 2846 pathways, 917 (32.2%) were positively associated with diagnosis and 57 (6.2%) of these 
showed significance at P for familywise error <.05. They did not differ significantly from the 
remaining pathways regarding size (determined as the number of CpGs per pathway; 
β = 2.46 × 10−5; P = .61). Individual genes within the 10 pathways harboring methylation differences 
have been previously implicated in schizophrenia (eTables 3 and 4 in the Supplement). 
 
Identifying and validating the association between PMS and functional DLPFC-HC coupling 
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The schizophrenia PMS predicted in data from HCs not taking medication from validation 
methylation/MRI (241 [10.8%]) was negatively associated with DLPFC-HC functional connectivity 
during WM (P for familywise error, <.04; F1,237 = 14.55; t237 = −3.81; bilateral hippocampus-corrected, 
peak voxel at 33, −22, −13) in the right posterior hippocampus (Figure 3; eFigure 3 in 
the Supplement). The negative association between PMS and DLPFC-HC connectivity was replicated 
in validation MRI (n = 152), with the Sternberg WM paradigm within right posterior hippocampus 
(P for familywise error = .02; t148 = −3.54; peak voxel at 33, −37, −7) corrected for right posterior 
hippocampus (Figure 3; eFigure 3 in the Supplement). Post hoc 1-sample t tests revealed negative 
connectivity between DLPFC and HC in the validation methylation/MRI (t240 = −14.09; P < .001) and 
the validationMRI (t151 = −6.94; P < .001) sample. Associations between PMS and DLPFC-HC 
connectivity were specific for the WM tasks compared with the faces tasks and were not confounded 
by brain-structural effects (eResults in the Supplement). Association between PMS and PRS and 
interactions on DLPFC-HC coupling 
The DLPFC-HC connectivity was not associated with the schizophrenia PRS in validation 
methylation/MRI (β = 126.6; P = .79) or validation MRI (β = 401.3; P = .67). Similarly, no significant 
interactions between PMS and PRS on DLPFC-HC connectivity were found in validation 
methylation/MRI (β = −7280; P = .19) or validation MRI (β = −10 540; P = .41). The BioMM model was 
used to identify a risk score from GWAS MGS data using the same pathways assignment as used for 
DNA methylation data. The resulting associations with PMS and DLPFC-HC connectivity are described 
in the eResults and eTable 5 in the Supplement. Analysis of relatives methylation demonstrated that 
none of the groups of relatives showed significant PMS differences compared with HC (eFigure 4 in 
the Supplement). 
 
Prediction of PMS in DLPFC post-mortem brain samples 
Predicted PMS in validation post mortem was significantly higher in schizophrenia compared with HC 
(AUC = 0.63; P = 1.42 × 10−4; R2 = 8.3%). Notably, the reverse prediction (i.e., building a PMS from 
postmortem brain data and testing this score in blood data) did not allow case-control differentiation 
(eTable 6 in the Supplement) and showed no association with DLPFC-HC connectivity (validation 
methylation/MRI: P = .89; validation MRI: P = .92). 
 
Assessment of the robustness, diagnostic specificity and residual confounding  
Permutation of diagnostic labels, as well as the random selection of pathways used by BioMM, 
supported the significance and robustness of the PMS finding (eResults and eTables 7 and 8 in 
the Supplement). Analysis of the specificity methylation cohort further showed that the PMS increase 
was specific for schizophrenia (eTable 9 and eFigure 5 in the Supplement). Because despite the 
confounding correction the PMS was associated with some of all potential variables, additional 
analyses regarding confounding can be found in the eResults and eTables 10 and 11 in 
the Supplement. 
2.1.6 Discussion 
In this article, we identified a blood DNA methylation signature that reproducibly 
differentiated schizophrenia from HC and several other major neuropsychiatric 
disorders. The underlying biological pathways implicated several synaptic processes 
as contributing most to the classification. A more schizophrenia-like epigenetic profile 
was associated with an established intermediate phenotype for the disorder, 
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persistent DLPFC-HC connectivity, in HC during 2 different WM tasks. Notably, the 
epigenetic signature could also differentiate schizophrenia from HC in data from 
DLPFC postmortem samples, supporting the relevance of the identified blood-derived 
epigenetic signature for brain-associated phenotypes associated with schizophrenia 
in vivo and ex vivo. 
The pathways contributing most to the schizophrenia classification comprised synaptic and 
neurodevelopmental processes. This is consistent with previous results showing a co-localization of 
epigenetic changes with genetic susceptibility variants of schizophrenia (Hannon, Dempster et al. 
2016), which are over-represented in synaptic pathways (Network and Pathway Analysis Subgroup of 
Psychiatric Genomics 2015). The important role of synaptic processes in schizophrenia is supported 
by findings from induced pluripotent stem cells (Brennand, Simone et al. 2011, Wen, Nguyen et al. 
2014), and changes in different omics modalities pointing towards a synaptic pathology [e.g.(Osimo, 
Beck et al. 2019)]. Furthermore, schizophrenia-related neurodevelopmental processes show an over-
representation of methylation changes in the schizophrenia prefrontal cortex, and these are enriched 
for sites undergoing epigenetic changes during fetal neocortex brain development (Pidsley, Viana et 
al. 2014). Notably, post-mortem expression and methylation studies support that the neural effects 
of epigenetic and genetic risk factors for schizophrenia already occur during early brain development, 
rather than the typical onset-age of the illness (Birnbaum and Weinberger 2017), highlighting their 
importance for altered neurodevelopment in schizophrenia.  
We show that during two WM tasks, higher, more schizophrenia-like scores of the identified DNA 
methylation signature were associated with stronger negative DLPFC-HC connectivity. DLPFC-HC 
connectivity is altered in the same way in SCZ, unaffected first-degree relatives, as well as HC carrying 
specific risk genetic variants (Meyer-Lindenberg, Olsen et al. 2005, Esslinger, Walter et al. 2009, 
Rasetti, Sambataro et al. 2011, Schneider, Walter et al. 2017), with more negative DLPFC-HC 
connectivity being related to higher risk for schizophrenia. Furthermore, functional and structural 
abnormalities in the hippocampus and prefrontal cortex are at the core of the schizophrenia 
pathophysiology (Weinberger 1987, Bahner, Demanuele et al. 2015) and disease processes of both 
areas are highly interassociated (Lipska and Weinberger 2000, Bahner, Demanuele et al. 2015). For 
example, altered DLPFC-HC microcircuits in post-mortem brains of SCZ influence both excitatory and 
inhibitory cells as well as interneurons (Harrison and Weinberger 2005). Interestingly, while the 
general liability for schizophrenia and specific genetic risk variants do impact this phenotype, 
common polygenic risk for schizophrenia has been repeatedly demonstrated not to (Erk, Mohnke et 
al. 2017, Miller, Scult et al. 2018), suggesting either a restricted set of genes responsible and/or more 
complex gene-environment interactions to shape DLPFC-HC connectivity. We extend these findings 
by demonstrating that an epigenetic risk signature for schizophrenia correlates with DLPFC-HC 
coupling and we did not find sufficient evidence for a direct polygenic and interactive association, 
suggesting that epigenetic analysis provides pathophysiologically relevant information not captured 
by PRS. Also, a BioMM-derived PRS was not associated with PMS or DLPFC-HC and showed no 
interactions with PMS on DLPFC-HC connectivity. This supports that the PMS outperformed classifiers 
identified from genetic association data and the observed PMS effects were not primarily driven by 
underlying genetics. The lack of PMS differences in relatives of patients with schizophrenia, BD, MDD 
and autism supported this finding. Notably, the accuracy a classifier can achieve is limited by the 
clinical and biological heterogeneity of schizophrenia. Applying multimodal subgroup identification 
strategies may aid in deconstructing this heterogeneity and ultimately contribute to an alternative 
disease classification. 
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Epigenetic modifications including DNA methylation are strongly influenced by life-span 
environmental exposures, such as postnatal mother-infant interactions (Fagiolini, Jensen et al. 2009) 
and experiencing of stress-related events (Klengel, Pape et al. 2014), making the poly-epigenetic 
signature a potential proxy on which cumulative environmental risk factors could converge. 
Moreover, studies in animals and humans indicated that several neurobiological processes at 
different stages of development can modify DLPFC-HC connectivity across the life span. This includes 
early neuronal formation (Lee, Dvorak et al. 2012, Phillips, Bartsch et al. 2012) and synaptic plasticity 
related processes (Fagiolini, Jensen et al. 2009, Meadows, Guzman-Karlsson et al. 2015), raising the 
possibility that the neural impact of epigenetic and genetic schizophrenia risk on synaptic processes 
during early development may have a lasting impact on DLPFC-HC connectivity. Such an 
interpretation is also consistent with results from animal studies showing that lesions in the 
hippocampus lead to delayed maturation and dysfunction of the DLPFC (Lipska and Weinberger 
2000, Bahner, Demanuele et al. 2015). Taken together, the present results may suggest that DLPFC-
HC connectivity is influenced by environmental risk accumulation mediated by the association of 
altered DNA methylation with synaptic plasticity (Fagiolini, Jensen et al. 2009, Meadows, Guzman-
Karlsson et al. 2015). 
In this article, the PMS was found to differentiate schizophrenia from HC when predicted in DLPFC 
DNA methylation data, indicating that elements of the signature were represented in the brain and 
may have mediated the observed DLPFC-HC connectivity association. This finding is consistent with 
the previously observed correlation between postmortem brain and blood methylation. (Walton, 
Hass et al. 2016, Edgar, Jones et al. 2017, Braun, Han et al. 2019). Such cross-tissue correlation has 
been hypothesized to result from genetic influences, casting doubt on the added value of peripheral 
epigenome-wide association studies in brain disorders (Hannon, Lunnon et al. 2015). However, the 
association of the PMS with schizophrenia and schizophrenia-relevant neural phenotypes based on 
epigenetic changes in pathophysiologically relevant pathways, as well as the lack of evidence for an 
association with polygenic susceptibility, supports their use for integrative, multimodal approaches 
toward disease stratification and potentially treatment personalization. Notably, a schizophrenia 
PMS derived from DLPFC samples did not predict case-control status in blood samples and was not 
correlated with brain functional connectivity. This may have been due to the larger biological and 
methodologic variability in brain samples (such as cell heterogeneity or postmortem effects) or the 
comparatively smaller sample size. 
The present study has several limitations. First, most investigated patients were taking medication 
and the association of medication with the PMS could not be excluded. However, the association 
between the PMS and DLPFC-HC connectivity in HC not taking medication contradicts the idea that 
the identified methylation signature is a consequence of medication. Second, because of limited 
available data, the associations between DLPFC-HC connectivity and the PMS could not be explored 
in patients. This could have identified a stronger contribution of genetic schizophrenia risk toward 
the PMS associations, which may have been affected by limited statistical power. Third, while the 
PMS replicated in data from postmortem DLPFC samples, the explained variance in the brain data 
was comparatively low. This necessitates further studies to isolate the brain-specific associations of 
methylation differences with brain function. Fourth, despite extensive efforts to correct findings for 
confounding effects, we cannot exclude the potential presence of residual confounding. However, 
the analysis of patients with BD and MDD as well as autism suggested that the PMS increase in 
schizophrenia was not driven by potential confounders with transdiagnostic relevance. These 
findings, and PMS effects in relatives, require validation in larger cohorts. Finally, the machine 
learning approach used was based on the annotation of CpGs to genes and biological pathways, 
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which may be biased and not suitably index biological function and can lead to an overlap of 
annotated genes between pathways. As machine learning isolates the most predictive features 
mapped to a given pathway, this can lead to a loss of biological specificity if the most predictive CpGs 
are shared among different pathways. This necessitates follow-up experiments to more precisely 
characterize the role of the identified pathways for mediating epigenetic risk in schizophrenia.  
2.1.7 Conclusion  
This study shows that a reproducible and specific blood DNA-methylation signature of schizophrenia 
was correlated with functional DLPFC-HC coupling as an intermediate phenotype for schizophrenia, 
mapped to methylation differences found in DLPFC postmortem samples of schizophrenia, and 
indexed biological pathways associated with synaptic function. These results help to characterize the 
systems-level association between genetic, epigenetic, and environmental risk for schizophrenia. 
They further support the use of PMS for multimodal biomarker discovery strategies aimed at disease 
stratification and the development of novel, personalized therapeutic approaches. 
 
Tables  
Table 1. Overview of sample characteristics. The rightmost three columns indicate the sample numbers for 
which the respective data were available (Methylation: DNA-Methylation; Genotypes: whole-genome genetic 
association data; Imaging: functional MRI data [validationMeth/MRI: n-back task; validationMRI: Sternberg task]; 
Case: schizophrenia patients; SubCtl: Subset of healthy controls; AUT: Autism; BP: Bipolar disorder; MDD: 
Major depressive disorder; relSCZ: First-degree relatives of patients with schizophrenia; relAUT: First-degree 
relatives of patients with autism; relBP: First-degree relatives of patients with bipolar disorder; relMDD: First-
degree relatives of patients with major depressive disorder).*40 subjects with missing age information.   
Cohort Tissue Status Sex (m/f) Age Methylation Genotype Imaging 
Discovery 
Methylation 
Whole 
Blood 
Control 142/180 37.7±15.2 322     
 
Case 254/99 43.7±14.7 353     
Validation 
Methylation 
Control 319/114 45.0±12.1 433     
 
Case 283/131 46.6±13.6 414     
Validation 
Methylation/MRI 
Control 168/163 27.8±10.2 331   
SubCtl 126/115 28±10.7 241 241 241 
Case 28/8 33.8±10.4 36   
specificity 
Methylation 
AUT 18/9 33.8±9.6 27   
BP 16/23 36.4±10.5 39   
MDD 11/24 37.2±12.2 35   
Relatives 
Methylation 
relSCZ 8/19 37.2±14.4 27   
relAUT 8/9 44.9±9.1 17   
relBP 8/7 36.9±12.3 15   
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relMDD 11/18 30.3±10.4 29   
validationMRI Control 66/86 26.9±8.8 152 152 152 
validationpostmortem  Brain 
Control 90/46 46.5±16.1 136     
Case 59/49 52.7±14.5 108     
GWASMGS 
Whole 
Blood 
Control 1301/1417 50.6±16.4  2718  
Case 1606/690 43.4±11.7*  2296  
 
Table 2. Prediction performance of BioMM on different cohorts using discoveryMeth as the discovery 
set 
Data sets AUC R
2
 
discoveryMethylation 0.78 0.21 
validationMethylation 0.69 0.105 
validationMethylation/MRI 0.74 0.218 
validationpostmortem 0.63 0.083 
 
 
 
Figures 
 
 
Figure 1. Prediction performance  of Biologically Informed Machine Learning (BioMM) on Different Cohorts 
Using Discovery Methylation as the Training Data 
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Figure 2. Biological pathways contributing most to the PMS and significance of the individual methylation 
sites. GO:0032088: negative regulation of NF-kappaB transcription factor activity; GO:0010977: negative 
regulation of neuron projection development; GO:0030097: hemopoiesis; GO:0000083: regulation of 
transcription involved in G1/S transition of mitotic cell cycle; GO:2000311: regulation of AMPA receptor 
activity; GO:0098962: regulation of postsynaptic neurotransmitter receptor activity; GO:0043154: negative 
regulation of cysteine-type endopeptidase activity involved in apoptotic process; GO:1903427: negative 
regulation of reactive oxygen species biosynthetic process; GO:0031648 protein destabilization; 
GO:1900273: positive regulation of long-term synaptic potentiation; GO:0019395: fatty acid oxidation. The 
immune related pathway is illustrated in yellow, an apoptotic process in purple, synaptic and neural pathways 
in green and the remaining pathways in gray. The dots indicate the significance of individual CpG within these 
pathways. The blue line marks the uncorrected significance level of 0.05. 
 
 
Figure 3. Association between the predicted PMS and DLPFC-HC connectivity in un-medicated, healthy 
controls. A) validationMethylation/MRI (n-back task): uncorrected results (p < 0.05, shown in hippocampus) with 
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peak voxel (F1,237=14.55, T237=-3.81, MNI: [33 -22 -13]) in the right hippocampus significant after bilateral 
hippocampus correction in healthy subjects (n = 241) (PFWE=0.040). B) validationMRI (Sternberg task): 
uncorrected results (p < 0.05, shown in hippocampus) with peak voxel ( T148=-3.54, peak voxel at [33 -37 -7]) in 
the right hippocampus showing a significantly negative association after right posterior hippocampus 
correction in healthy subjects (n = 152) (PFWE=0.016). Age and sex are controlled as covariates of non-interests. 
For presentation purpose, imaging results are shown in p<0.05 uncorrected threshold at similar spatial plane 
(MNI: X=32, Y=-33, Z=-10).  
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eMethods 
 
Genome-wide DNA methylation data 
DNA methylation data from discoveryMeth and validationMeth were downloaded from the GEO 
database (GSE80417 and GSE84727, respectively)(Edgar, Domrachev et al. 2002). All samples were 
analyzed using Illumina Infinium HumanMethylation450 BeadChip (450k) arrays. Detailed 
descriptions of cohorts and data acquisition can be found elsewhere(Hannon, Dempster et al. 2016). 
Subjects part of validationMeth/MRI and validationMRI were recruited at the Central Institute of Mental 
Health, Mannheim, Germany and data from these cohorts has partially been described 
previously(Schneider, Walter et al. 2017). Validationpostmortem was obtained from the GEO database 
under accession GSE74193(Jaffe, Gao et al. 2016). A total of 675 samples were scanned on 534 
unique subjects, but after exclusion (as suggested by the authors of the original study) of a 
problematic processing plate and subjects with an age of less than 16, data from 244 subjects were 
used for analysis. Data processing is described in detail below. 
 
Clinical characteristics of investigated cohorts 
Dicoverymeth 
Dicoverymeth case-control samples were obtained from the UK and consist of unrelated ancestrally 
matched cases and controls as described in the original reference (Datta, McQuillin et al. 2010). 
Briefly, National Health Service (NHS) multicentre and local research ethics approval was obtained 
and all subjects signed an approved consent form. Patients with schizophrenia were selected based 
on the International Classification of Diseases 10 (ICD10) criteria and interviewed with the Schedule 
for Affective Disorders and Schizophrenia-Lifetime Version (SADS-L) schedule(Mannuzza, Fyer et al. 
1986). All cases were further interviewed by a second psychiatrist at the probable level of 
schizophrenia with Research Diagnostic Criteria (RDC). Subjects with brain damage were not 
included. The control subjects were also interviewed with the initial clinical screening questions of 
the SADS-L and selected on the basis of not having a family history of schizophrenia, alcoholism or 
bipolar disorder and for having no past or present personal history of any RDC-defined mental 
disorder. 
 
Validationmeth 
Validationmeth case-control samples were self-identified as born in the British Isles (95% in Scotland) 
as originally described in (Stone, O’Donovan et al. 2008). All cases met the Diagnostic and Statistical 
Manual for Mental Disorders-IV edition (DSM-IV) (Sharp, Mefford et al. 2008) and International 
Classification of Diseases 10th edition (ICD-10) (Janca, Ustun et al. 1993) criteria for schizophrenia. 
Diagnosis was made by Operational Criteria Checklist (OPCRIT) (McGuffin, Farmer et al. 1984).  All 
case participants were outpatients or stable inpatients. Detailed medical and psychiatric histories 
were collected. A clinical interview using the Structured Clinical Interview for DSM-IV (SCID) was also 
performed on schizophrenia cases. Controls were volunteers recruited through general practices in 
Scotland. Practice lists were screened for potentially volunteers matched by age and sex and by 
excluding subjects with major mental illness or use of neuroleptic medication. Volunteers who 
replied to a written invitation were interviewed using a short questionnaire to exclude major mental 
illness in individual themselves and first degree relatives. All cases and controls gave informed 
consent. The study was approved by both local and multiregional academic ethics committees. 
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Validationmeth/MRI 
We included 367 subjects comprising of 331 healthy volunteers and 36 patients with schizophrenia. 
None of the healthy volunteers had a first-degree relative with a history of mental illness. All subjects 
were recruited at the Central Institute of Mental Health in Mannheim, Germany (Cao, Bertolino et al. 
2016, Schneider, Walter et al. 2017). Patients were recruited from inpatient and outpatient 
treatment facilities and psychiatric diagnoses were confirmed based on DSM-IV criteria(Schwarz, 
Moessnang et al. 2019).  The association between PMS and DLPFC-HC connectivity was assessed in 
241 healthy subjects for which n-back fMRI data was acquired. The same 241 subjects were also used 
for genotyping. All participants provided written informed consent that has been approved by the 
ethical committees of the Universities of Heidelberg.   
 
SpecificityMeth 
We have acquired DNA methylation data from patients with bipolar disorder (n=39), major 
depressive disorder (n=35) and autism (n=27). All patients were obtained at the Central Institute of 
Mental Health in Mannheim, Germany (Cao, Bertolino et al. 2016, Schneider, Walter et al. 2017). 
Patients were recruited from inpatient and outpatient treatment facilities and psychiatric diagnoses 
were confirmed based on DSM-IV and ADOS-G26 (for autism) criteria(Schwarz, Moessnang et al. 
2019). All participants provided written informed consent that has been approved by the ethical 
committees of the Universities of Heidelberg.   
 
RelativesMeth 
We included 88 unaffected first-degree relatives of patients with schizophrenia (n=27), bipolar 
disorder (n=15), major depressive disorder (n=29) and autism (n=17). All subjects were recruited at 
the Central Institute of Mental Health in Mannheim, Germany (Cao, Bertolino et al. 2016, Schneider, 
Walter et al. 2017). For the first-degree relatives, diagnostic assessments were based on ICD-10 and 
DSM-IV criteria. All participants provided written informed consent that has been approved by the 
ethical committees of the Universities of Heidelberg.   
 
Validation MRI 
In the Validation MRI sample, we investigated 152 healthy participants. All subjects had no history of 
psychiatric and neurological illness, prior head trauma, or current alcohol or drug abuse. The samples 
were collected at Central Institute of Mental Health in Mannheim, Germany (Geiger, Moessnang et 
al. 2018, Zang, Geiger et al. 2018). All participants provided written informed consent that had been 
approved by ethics committee of the Universitiy of Heidelberg. 
 
Validationpostmortem 
Validationpostmortem postmortem brain samples were donated through the Offices of the Chief Medical 
Examiners of the District of Columbia and of the Commonwealth of Virginia, Northern District to the 
NIMH Brain Tissue Collection at the National Institutes of Health in Bethesda, MD, according to NIH 
Institutional Review Board guidelines (Protocol #90-M-0142), which is originally described in (Jaffe, 
Gao et al. 2016). All postnatal non-psychiatric control donors (N=300) were free from psychiatric 
and/or neurologic diagnoses and substance abuse according to DSM-IV. All control donors had 
toxicology screening for the exclusion of acute drug and alcohol intoxication/use at time of death. 
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GWASMGS 
GWASMGS comprised genome-wide association data from 2718 healthy controls and 2296 patients 
with schizophrenia. All subjects were of European ancestry. The genotype data was obtained from 
Database of Genotypes and Phenotypes (dbGaP) 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=gap)(Mailman, Feolo et al. 2007). The samples that 
included subjects with Caucasian origin were collected from (a) GAIN (Genetic Association 
Information Network) dataset [dbGAP accession number: phs000021.v2.p1] genotyped for 906,600 
SNPs(Shi, Levinson et al. 2009); (b) non-GAIN dataset [dbGAP accession number: phs000167.v1.p1] 
genotyped for 909,622 SNPs(Shi, Levinson et al. 2009). Diagnostic assessments were based on the 
Diagnostic and Statistical Manual of Mental Disorders criteria. Approximately 10% of the cohorts 
consisted of patients with schizoaffective disorder who had schizophrenia-like symptoms for at least 
six months. Detailed information on these cohorts has previously been described in (Shi, Levinson et 
al. 2009). 
 
Preprocessing of genome-wide DNA methylation data 
The Infinium MethylationEPIC BeadChip was used to obtain genome-wide DNA methylation profiles 
for validationMeth/MRI and validationMRI from whole blood samples. Raw signal intensities were 
obtained from IDAT files using the minfi Bioconductor R package (Aryee, Jaffe et al. 2014). Both 
background noise subtraction and dye-bias normalization are performed using the function 
preprocessNoob for each sample individually. Red and green intensities were mapped to the M(Cao, 
Bertolino et al.) and U(nmeth) channels, and the log median intensity in both channels was used to 
check for low quality samples  (the cutoff for low quality samples was defined as 10.5 for both 
channels, one subject was removed). Intensities from the sex chromosomes were used to predict sex, 
and we removed 10 samples that had predicted sex distinct from the phenotypic sex. Probes with a 
detection P-value > 0.05 in at least 1% of samples and annotated with SNPs at the target CpG or 
single base extension (SBE) site with minor allele frequency > 5% were filtered out. DNA methylation 
data from the validationpostmortem set were assessed using the Illumina HumanMethylation450 
microarray. Raw signal intensities from IDAT files were preprocessed and normalized same as above 
using the minfi R package. 
The data of four cohorts from the whole blood samples were corrected to account for the influence 
of potential confounders, which comprised cigarette smoking (de Leon and Diaz 2005), population 
structure (Liu, Hutchison et al. 2010), cellular composition, gender and age at  the time of 
recruitment. Smoking was quantified from DNA methylation levels as described previously (Zeilinger, 
Kuhnel et al. 2013, Elliott, Tillin et al. 2014). Population structure was determined from methylation 
data via Principal Components Analysis. Specifically, the first 10 principal components were 
considered as covariates. Cellular composition was quantified using the Epigenetic Clock tool 
(https://dnamage.genetics.ucla.edu/) (Horvath 2013) and included the seven recommended cell 
types: CD8.naive, CD8pCD28nCD45RAn, PlasmaBlast, CD4T, NK, Mono, Gran. The validationpostmortem 
set was corrected to adjust for gender, age, ethnic background and the first four PCs of the negative 
control probes on the microarrays, as well as brain cell types provided by (Jaffe, Gao et al. 2016). All 
covariates were used in a linear model to residualize each given methylation probe. This was 
performed separately for the each cohort and the resulting residuals were used for downstream 
analysis. For all cohorts, we focused on the overlapping set of autosomal methylation sites to limit 
the potential influence of sex on machine learning due to the phenomenon of X chromosome 
inactivation or the existence of an additional X chromosome in female subjects. In total, 389,228 
CpGs were retained for subsequent analysis. 
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Genotyping QC and imputation 
Infinium PsychArray BeadChip by Illumina (“PsychChip”) was used for genotyping samples from 
ValidationMeth/MRI and ValidationMRI. The initial number of SNPs was 577,832 without considering 
chromosome Y and the mitochondrial DNA. For all given samples, standard quality control (QC) and 
imputation are performed using Gimpute pipeline (Chen, Lippold et al. 2018). The following QC steps 
were applied: 1.) Remove male subjects with more than 10 haploid heterozygous SNPs on 
chromosome X; 2.) Remove SNPs with missing genotyping rate > 5%; 3.) Exclude samples with 
missingness >= 0.02; 4.) Exclude samples with autosomal heterozygosity deviation |Fhet| >= 0.2; 5.) 
Remove SNPs with the proportion of missing genotyping > 2%; 6.) If controls existed in the dataset, 
remove SNPs with difference in SNP missingness between cases and controls >= 0.02;  7.) Remove 
SNPs if the Hardy-Weinberg equilibrium exact test P-value was < 1 x 10-6 in controls. Imputation was 
carried out using IMPUTE2/SHAPEIT (Howie, Donnelly et al. 2009, Howie, Fuchsberger et al. 2012, 
Delaneau, Zagury et al. 2013), which chooses a European reference panel for each study sample in 
each 3 Mb segment of the genome. This imputation reference set is from the full 1000 Genome 
Project dataset (August 2012, 30,069,288 variants, release “v3.macGT1”). The length of buffer region 
is set to be 500 kb on either side of each segment. All other parameters were set to default values 
implemented in IMPUTE2.   
Genome-Wide Human SNP Array 6.0 by Affymetrix was used for GWASMGS genotyping. The same 
genotyping QC and imputation procedure as above was applied for GWASMGS data.  
 
Population structure and relatedness testing  
After imputation, SNPs with high imputation quality (INFO >= 0.6) and successfully imputed in >= 20 
samples were retained. The proportion of alleles shared identity-by-decent estimated using PLINK 
was used to identify relatedness for all pairs of samples (Stevens, Heckenberg et al. 2011). The 
following criteria were used to select a subset of autosomal SNPs for relatedness testing:  1.) SNPs 
from the MHC region were excluded (chr6:28,477,797-33,448,354); 2.) SNPs were pruned based on 
linkage disequilibrium (r2 > 0.02 within 50 variant windows); 3.) SNPs with minor allele frequency 
(MAF) < 0.05 were removed. A threshold of π ̂ > 0.2 was used to identify related pairs of samples and 
exclude one member of each pair at random. Using the same set of autosomal SNPs, we determined 
principal components to be used as covariates during downstream analyses. The final imputed 
dataset comprised of N=7,660,409 autosomal SNPs for ValidationMeth/MRI and ValidationMRI, and N= 
11,798,966 autosomal SNPs for GWASMGS. 
  
Polygenic risk score (PRS) determination on genotype data 
The schizophrenia PRS was computed using Psychiatric Genomics Consortium (PGC) summary 
statistics taken from (Schizophrenia Working Group of the Psychiatric Genomics 2014) following the 
method developed by Purcell and colleagues (International Schizophrenia, Purcell et al. 2009) and 
using the PRSice software (Euesden, Lewis et al. 2015). Briefly, PRSs were calculated by summing 
schizophrenia-associated alleles, weighted by the natural log of the odds ratio. To ensure that SNPs 
were not in high linkage disequilibrium (LD) with one another, clumping was applied on the genotype 
data using an LD r2 threshold of 0.1 and a genomic distance threshold of 250 kb. PRSs were 
constructed based on the P-value threshold 0.05. The PRS score was then transformed into z-scores 
separately for validationMeth/MRI and validationMRI and utilized for subsequent analyses.  
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BioMM framework     
BioMM framework consisted of two major stages which is an updated version of the BioMM (Chen 
and Schwarz 2017) and is publically available as a Bioconductor R package (vs 1.1.11) (Chen and 
Schwarz 2019). Parameters of BioMM were optimized through 100-fold bootstrapping in the training 
data. Feature selection and random forest models with 1000 trees were employed at both stages. At 
the first stage, methylation sites with a case-control difference of P < 0.05, 0.1, 0.5 and 1 (no feature 
selection) using the Wilcoxon test were selected for a given pathway to reduce the impact of non-
predictive features. The best p value threshold was determined by 100 times bootstrapping. When no 
methylation sites passed the significance threshold, the 10% most significant sites determined using 
the Wilcoxon test were selected. At the second stage, the association between pathway-level 
features and diagnosis was tested using Wilcoxon tests and corrected for multiple hypothesis testing 
according to the method of Bonferroni. Then only features that showed a positive association with 
diagnosis were used for building the second-level classifier. This was due to the fact that in random 
data, the machine learning-based compression of methylation sites into pathway-level features can 
yield features that are strongly, but negatively associated with diagnoses (Perlich and Swirszcz 2011). 
The above procedure ensured such features were not used for prediction. Prediction performance 
for the training data was evaluated using 10-fold cross validation. Second-stage analyses were 
repeated 20 times and the predictions were averaged, to reduce the effect of variability intrinsic to 
random forest prediction.  
 
Permutation test procedure 
Two permutation strategies were employed to explore the predictive value of the DNA methylation 
signatures identified by the BioMM procedure: 
1.) Permutation of diagnostic label 
During this procedure, diagnostic labels were permuted prior to application of the BioMM procedure. 
It was expected that BioMM will identify a random DNA methylation ‘signature’ that would lead to 
an AUC of approximately 0.5 when applied in independent test data. Due to the computational 
complexity of the procedure, only 30 permutations were performed. 
2.) Permutation of pathway level features  
This procedure explores the specificity of the DNA methylation signature for the set of pathways 
selected at the second stage of the BioMM procedure. For this, the same number (here 57) of 
pathways were selected randomly and used for building the second stage classifier. It was expected 
that a high biological specificity for the actual pathways would lead to a substantial drop in AUC 
values when applying the classifier that is based on randomly selected pathways to independent 
data. 500 permutations were performed. An empirical P-value was determined as (Good 2013):   
𝑝 =
|{D′ ∈ Ď: e(f, D′)} ≤ 𝑒(𝑓, 𝐷)| + 1
k + 1
 
Where Ď is a set of k permuted versions D’ of the original data D sampled from a given null 
distribution.  
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Analysis of schizophrenia specificity 
To test the specificity of the identified PMS for schizophrenia, predictions were analyzed in other 
related psychiatric conditions including bipolar disorder, major depressive disorder and autism. We 
applied the same BioMM framework on genome-wide DNA methylation data from these conditions. 
Machine learning for case-control prediction based on GWAS data 
We applied the same BioMM framework on GWASMGS but with 50-fold bootstrapping to reduce 
computational running time. Feature selection and random forest models with 1000 trees were 
carried out at both stages. At the first stage, SNPs with a case-control difference of P < 0.05 using the 
Wilcoxon test were picked for each pathway and if no SNPs passed this significance threshold, the 
10% most significant SNPs determined using the Wilcoxon test were selected. At the second stage, 
the association between pathway-level features and diagnosis was tested using Wilcoxon tests and 
corrected for multiple hypothesis testing according to the method of Bonferroni. Only features that 
showed a positive association with diagnosis were used for building the second-level classifier. The 
final prediction performance for the training data was evaluated using 10-fold cross validation. 
 
Working memory and faces matching task - imaging data acquisition and preprocessing 
Whole-brain fMRI was performed on two 3T MR systems (Siemens Trio, Erlangen, Germany) in 
Mannheim, Germany. In the validationMeth/MRI sample, we studied brain function during working 
memory using a well-established n-back fMRI paradigm as previously described (Rasetti, Sambataro 
et al. 2011, Schneider, Walter et al. 2017). In addition, we tested the specificity of the working 
memory imaging phenotype by using the ‘faces matching’ task(Cao, Bertolino et al. 2016). Briefly, for 
the n-back working memory task, subjects were instructed to press the button when a stimulus 
(number 1-4) was presented. For the sensorimotor control condition (0-back), subjects pressed the 
button that was linked to the current number while during the working memory condition (2-back), 
subjects were asked to press the button corresponding to the number presented two stimuli before. 
For the faces matching task, subjects were instructed to respond to the fearful or angry face 
expressions during emotional conditions and simple geometric shapes during the control condition. 
Both the n-back and faces matching tasks were block design and each of the block was 30 seconds. 
Here, all functional data were acquired using echo planar imaging (EPI) sequence with the following 
specifications: 28 axial slices, 4 mm slice thickness, 1 mm gap, TR/TE = 2000/30 ms, 80° flip angle, 192 
mm × 192 mm field of view (FOV), 64 × 64 matrix. In the validationMRI sample, we studied brain 
function during working memory using a well-established Sternberg paradigm as previously 
described(Geiger, Moessnang et al. 2018). Briefly, for the Sternberg task, subjects were trained to 
memorize five letters (e.g. FGMPT) and were asked to press the button if the upcoming presented 
letter belonged to the five trained letters during training condition. For novel conditions, five novel 
letters were presented (e.g. DCKWX) first and subjects were asked to respond to the upcoming 
presented letter if it was shown before. The Sternberg paradigm comprised a sensorimotor control 
condition (where five ‘A’ were presented) and a resting baseline condition (where subjects were 
instructed to only look at the screen). Here, functional images were acquired with an EPI sequence 
with the following specifications: TR = 1790 ms, TE = 28 ms, flip angle = 76°, 34 axial slices, 3 mm slice 
thickness, matrix size: 64 × 64, FOV: 192 × 192 mm. Images were preprocessed using standard 
processing routines in SPM12 (http://www.fil.ion.ucl.ac.uk/spm/). Briefly, preprocessing procedures 
in included realignment to the first image of the time series, then registered to the mean of the 
images, slice time correction. Functional images were then co-registered to 3D T1 weighted 
anatomical images. The 3D T1-weighted anatomical images were segmented into grey matter, white 
matter and cerebrospinal fluid and other non-brain tissues. The computed warps from the 
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segmentation steps then were applied to the functional images for nonlinear normalization to the 
template in Montreal Neurological Institute (MNI) space, resampling to 3 mm isotropic voxels, and 
smoothed with an 8 mm full-width at half-maximum (FWHM) Gaussian Kernel.  
 
First-level DLPFC-HC functional connectivity 
DLPFC ROI definition and calculation of DLPFC-HC functional connectivity were performed consistent 
with our previous study (Schneider, Walter et al. 2017). In short, for each individual, we extracted the 
first eigenvariate of the seed time series from a 6 mm sphere centered on the individual activation 
maximum in the “2-back > 0-back” (n-back task, validationMeth/MRI) or “novel > practice” (Sternberg 
task, validationMRI) contrasts in the right DLPFC (defined by anatomical masks covering Brodmann 
area (BA) 46 and BA 9). Then, individual first-level models were defined with the subject-specific 
DLPFC time series as covariate of interest, and the following covariates of non-interest: (1) 
movement parameters from the realignment step, (2) first eigenvariates derived from cerebral spinal 
fluid and white matter masks, and regressors encoding for the experimental conditions. The model 
estimation step included a high pass filter of 128 seconds and an adjustment for the global brain 
signal. For an illustration of the DLPFC ROI and hippocampus mask used in validationMeth/MRI and 
validationMRI, please see Supplementary Figures 4 and 5, respectively.   
Functional connectivity for the ‘faces matching’ task were computed following the same procedures 
and parameters as the working memory fMRI data. We used individual DLPFC ROIs that were defined 
for the working memory tasks. 
 
Structural MRI data acquisition, preprocessing and influence. 
The high resolution structural MRI data were acquired using the magnetization-prepared rapid 
gradient echo sequence (3D-MPRAGE) and the following parameters: for validationMeth/MRI sample, TR 
1570 ms, TE 2.75 ms, TI 800 ms, 176 slices, 256 mm FOV, and 15° flip angle and 1 mm3 spatial 
resolution (Cao, Bertolino et al. 2016). For validationMRI sample, TR = 2530 ms, TE = 3.8 ms, TI = 1100 
ms, 176 slices, 256 x 256 mm field of view, 7° flip angle, and 1 mm3 spatial resolution (Zang, Geiger et 
al. 2018).  Briefly, the grey matter (GM), white mater (Malki, Tosto et al.) and cerebral spinal fluid 
(CSF) were segmented and spatially normalized linearly and nonlinearly to the standard MNI 
template using the Diffeomorphic Anatomical Registration Through Exponential Lie algebra (DARTEL) 
template and approach. Then the images were modulated with the Jacobian determinants to correct 
for differences in head size. Additionally, gray matter maps were corrected for bias-field 
inhomogeneities and were cleaned up for gray matter partitions. Next, we applied a classical Markov 
random field model and spatial adaptive nonlocal means denoising. We then smoothed the 
preprocessed structural data using a 8mm FWHM Gaussian kernel. 
 
 
Task specificity and structural influences 
To investigate whether the identified association between PMS and DLPFC-HC connectivity, we 
tested the association between PMS and DLPFC-HC connectivity using emotion processing ‘faces 
matching’ task in the sample validationMeth/MRI (Cao, Bertolino et al. 2016). In addition to evaluate the 
structural influences of DLPFC and hippocampus grey matter volume, we extracted mean grey matter 
volume from the individual DLPFC ROIs and the right hippocampus (6 mm sphere ROI MNI [33 -22 -
12] for validationMeth/MRI and MNI [30 -37 -7] for validationMRI). We assessed the task specificity of the 
association between PMS and DLPFC-HC connectivity using post-hoc analyses, treating age and sex as 
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covariates of non-interests. For analyses of evaluating the structural influences on PMS and DLPFC-
HC connectivity association, we further treated grey matter volume of the individual DLPFC ROIs and 
the hippocampus as covariates of non-interests.  
Previous publications have indicated that during working memory processing, the connectivity of 
DLPFC to parietal regions were significantly increased in a population with high genetic risk for 
schizophrenia(Whalley, Simonotto et al. 2005) and interhemispheric DLPFC connectivity was reduced 
in risk gene carriers (ZNF804a rs1344706)(Rasetti, Sambataro et al. 2011). We in addition tested the 
association between PMS and DLPFC-parietal regions (MNI [±42 -48 48], 6mm sphere ROI) and 
interhemispheric DLPFC (left DLPFR ROI at MNI [-48 33 30]) connectivity. 
 
Medication influences on PMS and DLPFC-HC connectivity 
To clarify the potential influence of medication on the  PMS as well as DLPFC-HC connectivity, we 
acquired and calculated chlorpromazine equivalents (for details please refer to our previous 
study(Schwarz, Moessnang et al. 2019)) from 33 out of 36 patients in our validationMeth/MRI. We used 
linear regression model to test the association between chlorpromazine equivalents and PMS as well 
as DLPFC-HC connectivity. 
 
Statistical analysis 
Association between PMS and DLPFC-HC functional connectivity were assessed using linear 
regression in SPM12 (https://www.fil.ion.ucl.ac.uk/spm/software/spm12/), using PMS as covariate of 
interest and age and sex as covariates of non-interest. An F-test was applied for the discovery sample 
(validationMeth/MRI) and a one-tailed T-test for the replication sample (validationMRI). PMS and DLPFC-
HC connectivity associations in the imaging space were corrected using family-wise small-volume 
correction in the hippocampus based on the Automated Anatomical Labeling (AAL) template. Using 
small-volume correction approach based on the hippocampus mask could allow us to detect location 
within the hippocampus that shows strongest association between DLPFC-HC connectivity and PMS. 
For validationMeth/MRI, we used bilateral hippocampus for small-volume correction. For validationMRI, 
we focused on the anterior or posterior section of the hippocampus (see(Erickson, Voss et al. 2011), 
determined by y coordinate in MNI space of the hippocampus center of gravity) that showed the 
highest correlation between PMS and DLPFC-HC connectivity in validationMeth/MRI. Other post-hoc 
statistics were performed in R using mean DLPFC-HC connectivity extracted from a 6mm sphere ROI 
located at the peak voxel identified by SPM group statistics outlined above. Associations between 
PMS and the schizophrenia PRS, as well as the PMS by PRS interaction on DLPFC-HC connectivity 
were tested using multiple linear regression, accounting for the effects of sex and age. All analyses 
involving PRS additionally incorporated 10 genetic principal components as covariates to account for 
the potential confounding effect of genetic population structure. 
2.1.9 Supplementary Results 
Task specificity and structural confounding influences on the identified associations between PMS and 
DLPFC-HC coupling 
In the validationMeth/MRI sample, we found no significant association between the PMS and DLPFC-HC 
connectivity during emotion processing ‘faces matching’ task (P=0.60). In the validationMeth/MRI 
sample, we did not find significant association between PMS and DLPFC-parietal region and 
interhemispheric DLPFC connectivity (PFDR values > 0.14, Hochberg correction). In the validationMRI 
sample, the association between PMS and DLPFC-parietal region and interhemispheric DLPFC 
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connectivity were not significant (PFDR values > 0.42, Hochberg correction). In addition, we found the 
association between PMS and DLPFC-HC connectivity were still significant after controlling for grey 
matter volume of DLPFC and the hippocampus (t = -3.70, P<0.001 in validationMeth/MRI sample; t = -
3.48, P=0.001 in validationMRI sample). 
 
Analysis of residual confounding effects on the PMS and DLPFC-HC connectivity 
Linear regression was used to explore the association between the PMS and potential confounding 
variables in HC across studies (see Supplementary Table 6). We found that despite the employed 
correction procedure for confounding, the predicted PMS were significantly associated with some of 
all available potential confounders. Since this may have downstream impact on classification 
accuracy, we additionally determined AUC-values for case-control differentiation using PMS 
residualized for the effects of all potential variables (see Supplementary Table 7). The residualized 
predictions showed AUC values of approximately 0.60 across cohorts, which supports the 
reproducibility of the PMS-effects despite potentially present residual confounding.  
We additionally performed linear regression analyses on the association of DLPFC-HC connectivity 
and covariates of non-interests including age, sex, cigarette smoking score, 10 principal components 
determined via principle component analyses of the methylation data and seven cell types: 
CD8.naive, CD8pCD28nCD45RAn, PlasmaBlast, CD4T, NK, Mono, Gran. None of the 20 covariates 
were associated with the DLPFC-HC connectivity (PFDR values > 0.32 for validationMeth/MRI sample; PFDR 
values > 0.30 for validationMRI sample). 
 
Associations between PMS, DLPFC-HC connectivity and medication in schizophrenia patients 
We acquired and calculated chlorpromazine equivalents from 33 out of 36 patients in our 
validationMeth/MRI sample and found no correlation between the predicted PMS and chlorpromazine 
equivalents (p = 0.30). Neither did we observed significant correlation between DLPFC-HC 
connectivity and chlorpromazine equivalents (p = 0.28). 
 
Association between BioMM-derived polygenic risk signature, PMS and DLPFC-HC connectivity 
We used the BioMM procedure to identify a polygenic risk score from GWAS data using the same 
pathways assignment as used for DNA methylation data (PRSBioMM). PRSBioMM was significantly 
predictive of schizophrenia in GWASMGS cohort with a p value of 2.88x10
-15 accounting for sex, age 
and 10 PCs (AUC=0.58, R2=0.015). However, DLPFC-HC connectivity was not associated with the 
schizophrenia PRSBioMM in validationMeth/MRI (P=0.299). It was significantly associated in validationMRI 
(P=0.032) but in a wrong direction (t=2.168). Similarly, no significant interactions between PMS and 
PRSBioMM on DLPFC-HC connectivity were found in validationMeth/MRI (P=0.104) or validationMRI 
(P=0.443). Detailed comparative information is shown in Supplementary Table 3. 
 
Permutation test analysis 
Two permutation strategies were employed to characterize the predictive value of the DNA 
methylation signatures identified by the BioMM procedure: I) Permutation of the diagnostic label 
where diagnostic labels were permuted prior to application of the BioMM procedure; II) Permutation 
of pathway level features, where a random set of 57 pathways was selected from stage 2 data to 
build a stage-2 classifier. The results of the permutation tests are shown in Supplementary Tables 4 
and 5. Permutation of the diagnostic label yielded AUC values close to 0.5 for cross-validation in 
discoveryMeth as well as independent prediction in the remaining cohorts. These AUC values were 
significantly lower (empirical P < 0.032, based on 30 permutations due to the high computational 
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demand of the procedure) than those observed in the non-permuted data, with the exception of 
validationpostmortem (P=0.23). The subsequent imaging associations were also significantly weaker 
compared to non-permuted data (P < 0.032).  
For the permutation of pathway level features, the predictions of all datasets but validationpostmortem 
showed an empirical P-value < 0.002 based on 500 permutations, with the exception of 
validationpostmortem (P=0.10), supporting a degree of specificity of the predictive signal for the 57 
originally identified pathways. 
 
2.1.10 Supplementary Tables  
Supplementary Table 1. Differences of subject demographics between patients and controls (P values are 
based on the Wilcoxon signed-rank test (continuous variables) or logistic regression (categorical variables), 
respectively)  
  discoveryMeth* validationMeth# validationMeth/MRI   validationpostmortem 
Covariates whole blood Covariates post-mortem 
Sex 7.44x10
-14
 0.088 3.27x10
-3
 Sex 0.067 
Age 1.50×10
-9
 0.199 1.59×10
-4
 Age 7.63×10
-3
 
PC1 2.82×10
-5
 8.09×10
-13
 0.713 negControl_PC1 0.347 
PC2 9.21×10
-12
 1.85×10
-15
 0.868 negControl_PC2 0.107 
PC3 5.71×10
-2
 0.181 0.613 negControl_PC3 0.969 
PC4 0.357 8.58×10
-4
 0.623 negControl_PC4 0.496 
PC5 2.18×10
-2
 0.615 0.470 race 0.102 
PC6 1.30×10
-2
 2.20×10
-7
 0.031     
PC7 0.701 0.589 0.331     
PC8 6.42×10
-3
 4.29×10
-2
 0.903     
PC9 3.45×10
-2
 1.24×10
-3
 0.574     
PC10 4.65×10
-2
 5.45×10
-2
 0.760     
smokeScore 3.31×10
-42
 1.32×10
-26
 9.750×10
-6
      
  
          Cell types 
CD8.naive 2.86×10
-2
 0.221 0.034 ES 0.286 
CD8pCD28nCD45RAn 0.963 3.80×10
-2
 
0.401 
NPC 0.412 
PlasmaBlast 5.05×10
-3
 9.32×10
-7
 0.964 DA_NEURON 0.359 
CD4T 4.68×10
-3
 3.47×10
-8
 0.410 NeuN_pos 0.190 
NK 2.56×10
-8
 1.57×10
-8
 0.818 NeuN_neg 0.265 
Mono 0.698 2.50×10
-2
 0.956     
Gran 2.34×10
-10
 6.60×10
-20
 0.531     
*age information was missing for 37 subjects and estimated using the Epigenetic Clock tool as described in the 
methods.  
# age information was missing for 182 subjects and estimated using the Epigenetic Clock tool as described in 
the methods.  
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Supplementary Table 2. Overall prediction performance of BioMM on different cohorts and specificity analysis. 
* low statistical power likely due to small sample size in these cohorts. P-value is adjusted for all potential 
confounding variables. 
 
   Cohorts Status Control/Case PMS prediction 
   AUC R2 P value 
DiscoveryMeth SCZ 322/353 0.78 0.21 2.95 x10
-6
 
ValidationMeth SCZ 433/414 0.69 0.10 1.24 x10
-7
 
*ValidationMeth/MRI SCZ 331/36 0.74 0.22 4.95x10
-2
 
*SpecificityMeth 
AUT 331/27 0.526 0.006 0.658 
BP 331/39 0.578 0.015 0.211 
MDD 331/35 0.509 0.004 0.164 
Validationpostmortem  SCZ 136/108 0.63 0.08 4.20x10
-4
 
 
Supplementary Table 3. The association between PMS and DLPFC-HC, PMS and PRS, PMS and PRSBioMM, as well 
as the interaction of these two PRSs and PMS on DLPFC-HC in two different cohorts. ** Significant result was 
observed in the imaging space after family-wise error correction. 
 
Association ValidationMeth/MRI (N=241) ValidationMRI (N=152) 
 
T value P value T value P value 
**PMS vs DLPFC-HC -3.81 0.04 -3.54 0.016 
PRSBioMM vs DLPFC-HC 1.042 0.299 2.168 0.032 
PRS vs DLPFC-HC 0.263 0.793 0.432 0.667 
PRSBioMM vs PMS 0.389 0.698 0.031 0.975 
PRS vs PMS 0.002 0.999 0.252 0.802 
PMSxPRSBioMM vs DLPFC-HC 1.633 0.104 0.769 0.443 
PMSxPRS vs DLPFC-HC -1.312 0.191 -0.835 0.405 
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Supplementary Table 4. Permutation of diagnostic label for both machine learning prediction and the 
subsequent testing of imaging associations. Due to computational complexity, 30 permutations were 
performed. 
Cohorts Prediction/Association Measure Mean/SD P value 
discoveryMeth Cross validation AUC 0.532±0.026 < 0.032 
validationMeth Independent prediction AUC 0.517±0.017 < 0.032 
validationMeth/MRI Independent prediction AUC 0.539±0.03 < 0.032 
validationpostmortem Independent prediction AUC 0.58±0.059 =0.226 
validationMeth/MRI Imaging association T value -0.348±0.852 < 0.032 
validationMRI Imaging association T value -0.243±0.999 < 0.032 
 
 
Supplementary Table 5. Permutation of pathway level features for both machine learning prediction and 
subsequent testing of imaging associations. 500 permutations were performed.  
 
Cohorts Prediction/Association Measure Mean/SD P value 
discoveryMeth Cross validation AUC 0.707±0.017 < 0.002 
validationMeth Independent prediction AUC 0.563±0.041 < 0.002 
validationMeth/MRI Independent prediction AUC 0.572±0.058 < 0.002 
validationpostmortem Independent prediction AUC 0.57±0.045 = 0.1018 
validationMeth/MRI Imaging association T value -1.203±0.982 < 0.002 
validationMRI Imaging association T value -0.486±1.024 < 0.002 
 
Supplementary Table 6. The association between predicted PMS and the confounding variables in controls (P 
values are based on generalized linear regression) 
  discoveryMeth* validationMeth# validationMeth/MRI   validationpostmortem 
Covariates whole blood Covariates post-mortem 
Sex 0.928 0.679 2.81x10
-7
 Sex 0.460 
Age 0.038 0.506 1.11x10
-4
 Age 0.179 
PC1 2.08x10
-13
 0.011 8.26x10
-5
 negControl_PC1 0.052 
PC2 0.134 0.487 3.99x10
-3
 negControl_PC2 0.224 
PC3 0.160 0.340 0.040 negControl_PC3 0.234 
PC4 0.282 0.121 1.99x10
-5
 negControl_PC4 0.006 
PC5 0.068 0.244 1.27x10
-8
 race 0.376 
PC6 0.041 0.243 8.13x10
-4
     
PC7 0.091 0.304 1.83x10
-7
     
PC8 2.81x10
-5
 0.610 0.012     
PC9 0.119 0.981 0.164     
PC10 0.084 0.791 0.691     
smokeScore 4.78x10
-16
 4.89x10
-10
 2.64x10
-7
     
  
          Cell types 
CD8.naive 0.339 0.446 1.98x10
-4
 ES 0.316 
CD8pCD28nCD45RAn 
0.855 0.649 1.53x10
-6
 
NPC 
0.089 
PlasmaBlast 0.804 6.59x10
-3
 0.022 DA_NEURON 0.088 
CD4T 0.361 8.39x10
-3
 1.64x10
-3
 NeuN_pos 0.925 
NK 0.988 0.027 0.086 NeuN_neg 0.964 
Mono 2.54x10
-4
 0.029 0.427     
Gran 0.072 0.014 0.062     
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Supplementary Table 7. Prediction performance of BioMM on different cohorts and specificity analysis 
following residualization of predicted PMS scores against all potential covariates using linear regression. * 
low statistical power likely due to small sample size in these cohorts. P-value is adjusted for all potential 
confounding variables. 
 
Cohorts Status Control/Case PMS prediction 
   AUC P value 
DiscoveryMeth SCZ 322/353 0.60 2.95 x10
-6
 
ValidationMeth SCZ 433/414 0.59 1.24 x10
-7
 
*ValidationMeth/MRI SCZ 331/36 0.62 4.95x10
-2
 
*SpecificityMeth 
AUT 331/27 0.524 0.658 
BP 331/39 0.578 0.211 
MDD 331/35 0.565 0.164 
Validationpostmortem SCZ 136/108 0.62 4.20x10
-4
 
 
 
 
 
Supplementary Table 8. Top 10 schizophrenia-associated pathways in the discovery sample (discoveryMeth). 
(P values are based on the Wilcoxon signed-rank test) 
ID Description 
Z 
score 
Size P value 
GO:0032088 negative regulation of NF-kappaB transcription factor 
activity 
9.188 1623 7.72x10
-23
 
GO:0010977 negative regulation of neuron projection development 8.905 1929 2.41x10
-21
 
GO:0030097 hemopoiesis 8.667 1423 9.01x10
-20
 
GO:0000083 regulation of transcription involved in G1/S transition 
of mitotic cell cycle 
8.557 765 1.01x10
-19
 
GO:2000311 regulation of AMPA receptor activity 7.037 955 1.25 x10
-13
 
GO:0098962 regulation of postsynaptic neurotransmitter receptor 
activity 
6.948 353 3.13x10
-13
 
GO:0043154 negative regulation of cysteine-type endopeptidase 
activity involved in apoptotic process 
7.081 1554 3.33x10
-13
 
GO:0031648 protein destabilization 6.747 986 2.08x10
-12 
GO:1900273 positive regulation of long-term synaptic potentiation 6.637 675 3.94x10
-12
 
GO:0019395 fatty acid oxidation 6.753 372 4.96x10
-12
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Supplementary Table 9. 30 most significant CpGs derived from top 10 pathways. (P values are based on the 
Wilcoxon signed-rank test) 
 
ID CHR pos RefGene island P value Rho 
cg14385231 13 76112274 COMMD6 S_Shore 4.70x10
-11
 -0,023 
cg20227766 1 27998703 IFI6 S_Shelf 3.52x10
-10
 -0,002 
cg22062597 12 1905547 CACNA2D4 Island 4.15x10
-10
 -0,03 
cg21012647 2 201981814 CFLAR N_Shore 3.87x10
-9
 0,008 
cg18316974 1 92947035 GFI1 Island 1.03x10
-8
 0,079 
cg18316974 1 92947035 GFI1 Island 1.03x10
-8
 0,079 
cg18316974 1 92947035 GFI1 Island 1.03x10
-8
 0,079 
cg18316974 1 92947035 GFI1 Island 1.03x10
-8
 0,079 
cg12017057 20 377006 TRIB3 Island 1.27x10
-8
 -0,003 
cg18146737 1 92946700 GFI1 Island 3.84x10
-7
 0,077 
cg18146737 1 92946700 GFI1 Island 3.84x10
-7
 0,077 
cg18146737 1 92946700 GFI1 Island 3.84x10
-7
 0,077 
cg18146737 1 92946700 GFI1 Island 3.84x10
-7
 0,077 
cg25286967 7 75623934 TMEM120A Island 1.60x10
-6
 -0,034 
cg25286967 7 75623934 TMEM120A Island 1.60x10
-6
 -0,034 
cg01415275 7 75624096 TMEM120A Island 4.28x10
-5
 -0,03 
cg01415275 7 75624096 TMEM120A Island 4.28x10
-5
 -0,03 
cg09846458 19 55972646 ISOC2 N_Shore 1.31 x10
-4
 0,02 
cg09846458 19 55972646 ISOC2 N_Shore 1.31 x10
-4
 0,02 
cg09846458 19 55972646 ISOC2 N_Shore 1.31 x10
-4
 0,02 
cg09846458 19 55972646 ISOC2 N_Shore 1.31 x10
-4
 0,02 
cg12195369 19 55972957 ISOC2 Island 1.33 x10
-4
 0,018 
cg12195369 19 55972957 ISOC2 Island 1.33 x10
-4
 0,018 
cg12195369 19 55972957 ISOC2 Island 1.33 x10
-4
 0,018 
cg12195369 19 55972957 ISOC2 Island 1.33 x10
-4
 0,018 
cg06338710 1 92946187 GFI1 Island 1.69 x10
-4
 0,047 
cg06338710 1 92946187 GFI1 Island 1.69 x10
-4
 0,047 
cg06338710 1 92946187 GFI1 Island 1.69 x10
-4
 0,047 
cg06338710 1 92946187 GFI1 Island 1.69 x10
-4
 0,047 
cg02105261 17 1945138 DPH1 Island 1.74 x10
-4
 -0,108 
 
 
  
EMPIRICAL STUDIES 
48 
 
Supplementary Table 10. The existing evidence for the top genes harboring top CpGs from Supplementary 
Table 9.  
Gene names Definition Reference 
COMMD6 COMMD6 belongs to a family of NF-kappa-B (Roussos, Katsel et al. 2013) 
CACNA2D4 
Calcium channel, voltage-dependent, alpha 
2/delta subunit 4 
(Cross-Disorder Group of the 
Psychiatric Genomics 2013, Purcell, 
Moran et al. 2014) 
GFI1 Growth Factor Independent Protein 1  (Hannon, Dempster et al. 2016) 
TRIB3 Tribbles Pseudokinase 3 (Duan, Sanders et al. 2015) 
TMEM120A Transmembrane protein 120A (Glatt 2009) 
 
 
 
 
Supplementary Table 11. Prediction performance of BioMM on different cohorts using validationpostmortem as 
the discovery set. 
Data sets AUC R2 
validationpostmortem 0.738 0.17 
discoveryMeth 0.572 0.006 
validationMeth 0.566 0 
validationMeth/MRI 0.52 0.001 
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2.1.11 Supplementary Figures  
 
 
Figure S1. PMS comparision in validationmeth/MRI and relativesMeth. The control group is compared with the 
relscz: first-degree relatives of schizophrenia patients; relbp: first-degree relatives of patients  with bipolar 
disorder; relmdd: first-degree relatives of patients with major depressive disorder; relaut: first-degree relatives 
of patients  with autism. P-values are denoted between comparison groups based on the t-test. 
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Figure S2. PMS comparision in validationMeth/MRI and specificityMeth. The schizophrenia group is compared with 
the healthy control group; bp: bipolar disorder; md: major depressive disorder; aut: autism. P-values are 
denoted between comparison groups based on the t-test. 
 
 
 
Figure S3. Post-hoc partial regression plots of the association between PMS and DLPFC-HC connectivity in the 
n-back (validationMeth/MRI, panel A) and Sternberg (validationMRI, panel B) working memory fMRI data. The post-
hoc partial regression plot from the identified 6mm sphere ROI centered at the peak voxel (Panel A: T = 3.81, 
pFWE = 0.040, MNI [33 -22 -13], bilateral hippocampus corrected; Panel B: T = 3.54, pFWE = 0.016, MNI [33 -37 -
7], right posterior hippocampus corrected). The partial regression plots were adjusted for age and sex and are 
only shown for illustration purpose. No statistical interference was further made based on these plots. 
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Figure S4 DLPFC ROI and hippocampus mask in the validationMeth/MRI sample. Panel A shows the right BA 9 and 
46 area and an overlap of all subjects’ 6mm DLPFC sphere ROIs. Panel B shows the bilateral hippocampus 
masks from AAL. 
 
 
 
 
 
Figure S5 DLPFC ROI and hippocampus masks in validationMRI sample. Panel A shows the right BA 9 and 46 area 
and an overlap of all subjects’ 6mm DLPFC sphere ROIs. Panel B shows the right posterior hippocampus masks 
(determined by the y MNI coordinates of COG and we choose the posterior overlap mask from the AAL 
template) that we have applied for small volume correction analysis. 
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2.2 Study 2 - Male increase in brain gene expression variability is linked to genetic risk 
for schizophrenia2 
2.2.1 Abstract 
Schizophrenia shows substantial sex differences in age of onset, course and treatment response but 
the biological basis of these effects is incompletely understood. Here we show that during human 
development, males show a regionally specific decrease in brain expression similarity compared to 
females. The genes modulating this effect were significantly co-expressed with schizophrenia risk 
genes during prefrontal cortex brain development in the fetal period as well as during early 
adolescence. This suggests a genetic contribution to a mechanism through which developmental 
abnormalities manifest with psychosis during adolescence. It further supports sex differences in brain 
expression variability as a factor underlying the well-established sex differences in schizophrenia.  
 
2.2.2 Introduction 
Schizophrenia is a severe developmental mental illness with an incidence approximately 1.4 times 
higher in men compared to women(Aleman, Kahn et al. 2003). The disorder is substantially heritable 
and a large number of common and rare variants have been associated with illness risk(International 
Schizophrenia, Purcell et al. 2009, Sullivan, Daly et al. 2012, Ripke, O'Dushlaine et al. 2013, 
Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014). A widely accepted 
neurodevelopmental hypothesis posits that genetically determined alterations in early brain 
development interact with developmental changes during adolescence in the prefrontal cortex to 
lead to the manifestation of psychosis(Weinberger 1987, Birnbaum R 2017). Consistent with this, 
developmentally changing prefrontal cortex expression has been found to be linked to neuronal 
differentiation and maturation, as well as genetic schizophrenia risk(Jaffe, Shin et al. 2015).  
In men, the illness has a more severe course characterized by more pronounced negative symptoms 
as well as cognitive impairment(Leung and Chue 2000, Maric, Krabbendam et al. 2003), although 
evidence has been reported that substance abuse in men may confound such clinical 
differences(Abel, Drake et al. 2010). Males with schizophrenia have also, albeit inconsistently, been 
reported to have a lower age of onset, show more pronounced alterations of brain morphology and 
poorer response to antipsychotic medication(Pinals, Malhotra et al. 1996, Leung and Chue 2000, 
Morgan VA 2008, Abel, Drake et al. 2010). Genetic risk associations, as well as molecular profiles, 
contain sex-dependent factors(Goldstein, Cherkerzian et al. 2013, Ramsey, Schwarz et al. 2013) and 
sex hormones are thought to play an important role for illness course(Leung and Chue 2000, 
Markham 2012), but again little is known about the underlying neurobiological mechanisms.  
We pursued a novel strategy to explore how biological sex differences may impact on the 
manifestation of genetic risk and the clinical sex differences of schizophrenia. Inspired by a recent 
study on the human brain connectome(Kaufmann, Alnaes et al. 2017), we tested whether during 
development human brain gene expression is more variable in males than females. We hypothesized 
that such increased expression variability might contribute to a predisposition of males for heritable 
neurodevelopmental disorders. A similar hypothesis has previously been explored for HIV, where 
gene expression variability has been suggested as a modulator for susceptibility to infection(Li, Liu et 
                                            
2
 Published as: Chen, J., Cao, H., Meyer-Lindenberg, A. and Schwarz, E., 2018. Male increase in brain gene 
expression variability is linked to genetic risk for schizophrenia. Translational psychiatry, 8(1), p.140. 
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al. 2010). Our study is further motivated by previous identification of sexual dimorphisms of brain 
expression(Kang, Kawasawa et al. 2011, Trabzuni, Ramasamy et al. 2013, Werling, Parikshak et al. 
2016), protein abundance(Raser and O'Shea 2005), as well as genetic and epigenetic factors 
modulating gene expression noise(Raser and O'Shea 2004, Alemu, Carl et al. 2014), supporting the 
possibility of links between polygenic risk and expression variance. The longitudinal exploration of 
variability differences is further motivated by previous identification of differential variance of 
transcriptional regulators during human embryonic development(Hasegawa, Taylor et al. 2015). 
Analysis of gene expression variability has also been successfully applied to identify genes and 
pathways implicated in several illnesses and highlighted such variability as an informative biological 
signal(Ho, Stefani et al. 2008, Ran and Daye 2017). 
Expression variability as genetic risk mediator can capture polygenic effects beyond sex differences 
of expression. To investigate this, we identified genes driving brain-region and age specific variability 
differences between sexes and tested whether these were associated with expression of 
schizophrenia risk genes.  
 
2.2.3 Materials and Methods 
Data preprocessing. To characterize brain expression throughout the human lifespan, we used data 
from the BrainSpan: Atlas of the Developing Human Brain (funded by ARRA Awards 1RC2MH089921-
01, 1RC2MH090047-01, and 1RC2MH089929-01 and available from: 
http://developinghumanbrain.org), as well as Braincloud microarray data (GSE30272(Colantuoni, 
Lipska et al. 2011), available from the GEO database(Edgar, Domrachev et al. 2002)).  
The primary analysis was performed on BrainSpan exon microarray data (GSE25219, preprocessed as 
described in(Goyal, Hawrylycz et al. 2014)) due to availability of a larger sample number. BrainSpan 
RNA sequencing (RNAseq) data was used for replication and Braincloud data for validation of 
findings. BrainSpan data comprised transcriptome-wide expression information on subjects between 
the 6th post-conceptional week and 40 years of age (Table 1, supplementary Tables 2, 8 and 9). We 
did not consider older subjects, as sex effects on risk are not likely to manifest beyond the typical age 
of onset that ranges between late adolescence and early adulthood. As performed by Willsey et 
al.(Willsey, Sanders et al. 2013), subjects were grouped in age-bins by a windowing approach that 
joins three consecutive age periods into a single group.  
Preprocessing of all datasets followed a similar sequence of steps (Supplementary Figure 1). 
Procedures performed on all datasets comprised: RNA Integrity Number (RIN) filtering (for BrainSpan 
exon microarray data, all donors were removed that had more than 25% of microarray samples with 
RIN < 7.5, as in (Goyal, Hawrylycz et al. 2014); for BrainSpan RNAseq data and Braicloud data, a more 
stringent filtering was performed by removing all samples with RIN <= 7.5); removal of subjects >40 
years; log2 transformation of data; extraction of autosomal genes (without minimum expression 
filter); quantile normalization; surrogate variable determination; covariate adjustment and outlier 
detection. This data contained the respective median values if multiple replicates per subject were 
present. Following a previously described pipeline(Werling, Parikshak et al. 2016), processing of 
RNAseq data included two additional steps: gene-level reads per kilobase million mapped reads 
(RPKM) were normalized for GC content using conditional quantile normalization based on the R 
library cqn(Hansen, Irizarry et al. 2012) and all genes with less than 1 RPKM in more than 50% of 
male or female samples were removed. Surrogate variable analysis was performed to account for the 
potential effects of unobserved confounders(Leek and Storey 2007). The number of surrogate 
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variables were automatically determined using the num.sv function of the R package sva(Leek and 
Storey 2007), using the approximation method by Leek(Leek and Storey 2007, Leek 2011). The 
underlying full model matrix contained gender, whose effects on expression variability should be 
preserved, as well as age, PMI, RIN and brain pH (as well as an array indicator for Braincloud data). 
The null-model matrix contained all covariates but gender. Age was used as a covariate, to prevent 
artifactual correlations between genes due to their joint association with age. This is particularly 
important for age-bins covering a broader range of ages, where significant correlations between age 
and expression can be expected. The number of surrogate variables determined for BrainSpan exon 
microarray was 0, 2 for BrainSpan RNAseq and 0 for the Braincloud data. Covariate adjustment was 
performed via residualization against all covariates described above (except for gender) using linear 
models. Missing brain pH values were replaced by the mean of non-missing values. 
Outlier detection. After preprocessing, principal component analysis was used to exclude outliers 
(Supplementary Figure 2). For this, we identified separately for males and females observations that 
deviated more than three  standard deviations from the mean of the respective first two principal 
components. This removed 7 samples in the BrainSpan exon microarray data (6 from male donors), 
11 observations in the BrainSpan RNAseq data (6 from male donors), and 1 outlier (from a female 
donor) in the Braincloud data.   
Schizophrenia risk genes. Schizophrenia risk variants, loci, and associated genes were taken from 
(Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014) (Supplementary Table 
3). Previous analyses have pursued different approaches to identify genes linked to genetic 
schizophrenia risk. Among these approaches is the selection of all genes or those within a certain 
distance from a given locus(Schizophrenia Working Group of the Psychiatric Genomics Consortium 
2014), or genes affected by index variant eQTLs(Gamazon, Wheeler et al. 2015). For the present 
study, we aimed to identify a single gene per locus. This was due to the risk of introducing statistical 
bias from including multiple genes per locus, caused by (1) the undue influence of loci harboring a 
larger number of genes and (2) the gene-gene correlation of genes in close chromosomal proximity. 
Therefore, for loci harboring multiple genes, we here used the gene in closest chromosomal 
proximity to the genome-wide significant index variant. If a locus contained more than one index 
variant, we selected the gene in closest chromosomal proximity to the most significant index variant. 
Chromosomal locations were determined from the R library org.Hs.eg.db., vs. 3.1.2 (genome build 
hg19, assembly GRCh37). Genes within the MHC region were not considered due to their significant 
linkage disequilibrium pattern. Two loci mapped to the genes IMMP2L and TCF4, and these were 
considered only once for subsequent analyses. C10orf32, C12orf79 and VPS14C were not annotated 
by the library org.Hs.eg.db. and not considered for further analysis. The final set of schizophrenia risk 
genes contained 100 genes, of which 97 were autosomal. Of these, 87 were part of the BrainSpan 
dataset (see Supplementary Table 3).  
Analysis of expression similarity. First, all samples were identified for a given brain-regional-cluster 
and age-bin. Based on such data subset, we performed a three stage resampling approach separately 
for males and females. The objective of this resampling was to quantify the expression similarity (and 
its confidence interval) between subjects while accounting for the non-independence of multiple 
samples taken from the same donor:    
1. First, we randomly selected a single sample per subject to prevent an impact of sample non-
independence on results.  
2. Second, we took a bootstrap sample of subjects by sampling with replacement and chose the 
unique set of subjects. This was performed to prevent the perfect correlation between 
multiply selected samples.  
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3. Finally, we subsampled the selected subjects, such that the same number of subjects was 
chosen for males and females. This was aimed at preventing an influence of unequal sample 
numbers on results.  
Then separately for males and females, we determined the pairwise Pearson correlation coefficients 
between all subject pairs using expression values from all genes. The mean of these estimates was 
used as an estimate of expression similarity between subjects for a given regional-cluster age-bin 
combination. Only the upper triangular matrix of a given correlation matrix was used for estimation. 
This entire resampling was repeated 100 times and the mean value (for confidence intervals the 
upper and lower 2.5% percentile) of obtained estimates used to quantify expression similarity.  
The difference between males and females was then quantified as the mean difference between the 
point estimates of each regional-cluster age-bin combination. To assess significance, the resampling 
procedure was repeated 1,000 times. During each repetition, gender information was permuted for a 
given regional-cluster age-bin combination, such that different samples of the same subject were 
always assigned the same gender. The frequency of bootstrapping point estimates at least as high as 
the one obtained from non-permuted data was used as empirical P-value and corrected for multiple 
comparisons according to the method of Bonferroni. To perform two-sided tests, absolute values 
were used for this calculation.  
Identification of genes driving expression similarity differences. We anticipated that genes driving 
the difference of expression similarity between males and females would likely show strong 
differences in expression variance between sexes. For each regional-cluster age-bin combination, we 
therefore performed the same resampling strategy as described above. For a given set of subjects 
(males and females separately), we then determined the standard deviation of expression for a given 
gene. These estimates were averaged over 100 resampling repetitions. We then determined the ratio 
of these averages between males and females and used the 100 genes (arbitrary cut-off) with the 
highest ratio as ‘variability genes’. To test whether these gene sets were also ‘variability genes’ in 
replication (BrainSpan RNAseq data) and validation (Braincloud) data, we determined the difference 
of expression similarity estimates (using the resampling strategy described above) between males 
and females. An empirical P-value was then determined by comparing this estimate against those 
derived from random ‘variability genes’ identified as described below (1000-fold resampling, one-
sided test). 
Testing associations with schizophrenia risk genes. To explore associations between variability 
genes and schizophrenia susceptibility genes, the co-expression between the two gene sets was 
determined for a given regional-cluster age-bin combination, by calculating a matrix of all pairwise 
Pearson correlation coefficients using expression values from both gene sets. The median value of 
this correlation matrix was then used as a measure of co-expression. Again, these calculations were 
determined as part of the resampling procedure described above, with the exception of the third 
step (undersampling to obtain equal numbers of male and female subjects), since calculations were 
performed using males only.  
Significance was determined using 1,000 fold resampling. During each repetition and for each 
regional-cluster age-bin combination, the low number of donors prevented meaningful permutation 
of gender information. Therefore, random ‘variability genes’ were selected such that for each real 
variability gene, one gene with a standard deviation of expression within 5% of the original gene was 
randomly chosen. The resulting co-expression values were then used to form null-distributions. 
Empirical P-values were determined as the frequency of co-expression values at least as high as that 
observed from real data (one-sided test). Since a total of 22 sets of variability genes were tested, P-
values were corrected for the Family Wise Error Rate according to the method of Bonferroni.  
EMPIRICAL STUDIES 
56 
 
Analysis of schizophrenia specificity. To test the specificity of the co-expression between variability 
genes and schizophrenia susceptibility genes, five additional analyses were performed, using 
different selections of “susceptibility genes”: (I) random selection of schizophrenia susceptibility 
genes for a given locus (instead of based on physical proximity to the index SNP). (II) Random 
selection of genes from loci with comparable DNA sequence variability compared to the 
schizophrenia loci. For this analysis, the number of common (MAF >=1%) variants recorded in dbSNP 
(GRCh37, available from https://genome.ucsc.edu/) was used as a proxy for DNA sequence 
variability. For each schizophrenia locus, a locus of the same size was selected from the same 
chromosome and retained if the DNA sequence variability was within 10% of the original locus. A 
random gene was then selected from the locus, extended by 20kbp, using the R library 
biomaRt(Durinck, Spellman et al. 2009). (III) Random selection of genes from the same chromosome 
as a given schizophrenia gene, irrespective of DNA sequence variability. (IV) Selection of genes in 
proximity to SNPs associated with major depressive disorder (35 genes; closest gene selected to a 
given index SNP, as described in (Wray, Ripke et al. 2018)). (V) Selection of genes in proximity to SNPs 
associated with a non-psychiatric phenotype (coronary artery disease; 35 genes; random gene 
selected from a given susceptibility locus, as described in (Schunkert, Konig et al. 2011)). 
Exploratory age-windowing. To perform a ‘fine-mapping’ of effects within a set of age-bins, we 
performed separate analyses for subjects within a given age-window (supplementary Table 7). The 
width of the window was determined as four consecutive age-entries among the recorded ages in 
weeks. Differences of expression similarity and co-expression with schizophrenia susceptibility genes 
were determined separately for each age-window as described above. Genes identified as ‘variability 
genes’ of the investigated age-bins were combined and used for this analysis. 
Functional analysis. To explore biological functions of genes contributing to differences of expression 
similarity between sexes, we used the DAVID functional annotation tool using default settings 
(https://david.ncifcrf.gov/home.jsp)(Huang da, Sherman et al. 2009). In this tool, enrichment is 
quantified based on a modified Fisher’s exact test. The 14702 autosomal genes part of the BrainSpan 
exon microarray data were used as background for functional analysis. We retained all functional 
annotation clusters with at least one annotation term passing the False-Discovery-Rate (FDR) 
corrected P-value threshold of 0.05.  
Code availability. Code is available from the corresponding author upon request.  
 
2.2.4 Results 
Expression similarity differences in BrainSpan exon microarray data. The filtered dataset contained 
autosomal, transcriptome-wide expression data on healthy subjects between the 6th post-
conceptional week (PCW) and 40 years of age(Kang, Kawasawa et al. 2011) (42 donors, 23 males, 
14702 autosomal genes; Figure 1). We tested whether gender was confounded by ethnicity, but 
found no association (P = 0.77, Chi-squared test). Subjects were binned into 11 age groups and the 16 
brain areas were aggregated into 4 regional-clusters with similar expression values (Supplementary 
Tables 1 and 2, regional-clustering was taken from(Willsey, Sanders et al. 2013) and based on 
hierarchical clustering of fetal transcriptome profiles; for abbreviations, see Figure 1): (1) the V1C-
STC cluster; (2) the prefrontal and primary motor-somatosensory cortex or PFC-MSC cluster; (3) the 
STR-HIP-AMY cluster; and (4) the MD-CBC cluster.  
Figure 2a shows that despite substantial variability, males had significantly lower expression 
similarity compared to females in three of the four brain regional-clusters (PV1C-STC<0.004, PPFC-
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MSC<0.004, PSTR-HIP-AMY=0.003, PMD-CBC=0.080; FWER corrected). Due to the more pronounced 
differences in the regional clusters V1C-STC and PFC-MSC, subsequent analyses focused on these 
areas. Figure 2a further shows that in females, expression similarity tended to decrease across 
developmental time-points, suggesting that inter-subject similarity was lower in adulthood compared 
to younger age. We aimed to explore whether sex differences in expression similarity were 
associated with genetic schizophrenia risk, to pinpoint a potential biological mechanism for the well-
known sex differences of the disorder.  
Identification of genes driving sex differences in expression similarity. For each age-bin-regional-
cluster combination we identified the 100 ‘variability genes’ with the greatest ratio (male divided by 
female) of standard deviations of expression (see Supplementary Figure 3 and Supplementary 
Dataset for a list of all ‘variability genes’). Figure 2b shows that expression similarity determined 
from these genes differed strongly between sexes. 
Co-expression between variability and schizophrenia susceptibility genes. Next, we investigated 
potential relationships between these variability genes and genes harbored by the 108 well-
established schizophrenia susceptibility loci(Schizophrenia Working Group of the Psychiatric 
Genomics Consortium 2014). This analysis was performed in males, since the lack of variance in 
female expression levels would prevent meaningful association analyses. Across 22 sets of variability 
genes (11 age-bins in the 2 regional-clusters V1C-STC and PFC-MSC), we found that variability genes 
derived from both clusters were significantly co-expressed with schizophrenia susceptibility genes in 
age-bins 8 (4 months – 4 years, rhoV1C-STC=0.05, rhoPFC-MSC=0.05),  9 (10 months – 11 years , rhoV1C-
STC=0.10, rhoPFC-MSC=0.12) and 10 (2 years – 19 years , rhoV1C-STC=0.07, rhoPFC-MSC=0.13; all PFWER<0.022, 
Figures 3a and b). Significant co-expression was additionally observed for the PFC-MSC in age-bin 1 
(6 PCW – 13 PCW, rho=0.11) and 2 (9 PCW – 16 PCW, rho=0.08; all PFWER<0.022). 
Age-bin specificity and pathway analysis. Next, we explored whether differences in expression 
similarity were age-bin specific. Figure 2c shows that PFC-MSC variability genes of age-bin blocks 1-2 
and 8-9-10 were also associated, albeit to a lesser extent, with decreased male expression similarity 
in the respectively other age-bin blocks.  
In this brain-regional-cluster, the 257 genes of age-bins 8-9-10 were significantly linked to synaptic 
processes and (calcium-) ion signaling (Supplementary Table 4). Notably, the 138 variability genes 
from age-bins 1 and 2 in the PFC-MSC cluster were associated with similar ontological categories, 
including ‘post-synaptic membrane’ and ‘synapse’ (Supplementary Table 5). Interestingly, the genes 
from age-bins 1-2 and age-bins 8-9-10 showed only a minimal overlap (8 genes shared). These 
ontological associations showed regional specificity for the PFC-MSC cluster, as the V1C-STC 
variability genes (age-bins 8-9-10) that also showed significant co-expression with susceptibility 
genes, were not associated with similar ontological categories (Supplementary Table 6). 
Furthermore, the ontological overlap between age-bins 1-2 and age-bins 8-9-10 in the PFC-MSC 
cluster is consistent with the correlation of the male expression similarity profiles (Figure 2c). 
Schizophrenia specificity. To explore the specificity of co-expression results for schizophrenia, 
analysis was repeated using (I) schizophrenia susceptibility genes randomly selected for a given locus 
(instead of based on physical proximity to the index SNP), (II) genes randomly selected from loci with 
comparable DNA sequence variability compared to the schizophrenia loci, (III) genes randomly 
selected from the same chromosome as a given schizophrenia gene, irrespective of DNA sequence 
variability, (IV) genes in proximity to SNPs associated with major depressive disorder, (V) genes in 
proximity to SNPs associated with a non-psychiatric phenotype (coronary artery disease). Figure 3c 
shows that random and proximity-based selection of genes from schizophrenia loci yielded similar 
results. Despite a similar co-expression profile across age-bins, schizophrenia gene co-expression 
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showed specificity against DNA sequence variability-stratified gene selection in age-bins 8 and 9 
(P=0.05) and a trend towards specificity in age-bins 2 and 10 (P=0.06). Randomly selected genes 
(procedure III) showed substantially lower mean co-expression, leading to specificity of schizophrenia 
results (age-bins 8-9-10, P<=0.05; age-bin 2, P=0.06). For both random selection procedures, 
schizophrenia specificity could not be observed in age bin 1 (P=0.12 and P=0.11, for procedures II and 
III, respectively). Genes in the proximity of SNPs linked to major depression or grip strength led to 
lower co-expression values in age bins 2 and 8-9-10; in age-bin 1, major depression genes showed 
higher co-expression than the schizophrenia genes.  
Age-windowing. Finally, since age-bins 8-9-10 covered a broad age range (4 months – 19 years), we 
performed an exploratory ‘fine-mapping’ of PFC-MSC effects using an age-windowing approach. 
While based on small sample numbers, this analysis suggested that co-expression had a broad 
plateau from a mean age of 4.8 years to 10.9 years (Figure 3d). Differences in expression similarity 
between sexes were consistent across all age windows (Figure 3d).   
Replication in BrainSpan RNAseq data. Preprocessed BrainSpan RNAseq data comprised expression 
information on 11514 autosomal genes in 400 samples (37 subjects, 20 males). The transcriptome-
wide expression similarity showed similar profiles as observed for exon microarray data 
(Supplementary Figure  4a). Similarly, the variability genes identified from exon microarray data 
were also variability genes in RNAseq data (Supplementary Figure 4b, P<0.001). These genes were 
significantly correlated with schizophrenia susceptibility genes in the PFC-MSC regional-cluster for 
age-bins 2 (rho=0.01, P<0.001), 9 (rho=0.05, P<0.001) and 10 (rho=0.03, P<0.001), validating exon 
microarray observations. For the V1C-STC cluster, we found significant associations for age-bins 3 
(rho=0.03, P<0.001), and a trend towards nominal significance in age-bins 8 (P=0.07), and 10 
(P=0.05). 
Validation in Braincloud data. Filtered Braincloud data contained dorsolateral prefrontal cortex 
(DLPFC) expression information on 14773 autosomal genes from 112 subjects (75 males). In 
covariate-corrected data, expression similarity is dependent on expression variance. Therefore, we 
compared the standard deviation of expression across all genes overlapping with BrainSpan exon 
microarray data. We found these estimates to be strongly correlated across datasets (rho=0.40, 
P<2.2·10-16, Spearman correlation), suggesting that preprocessing resulted in high cross-dataset 
comparability. Since the Braincloud data contained no subjects in age groups 1 and 2 (i.e. age-bin 1 
only consisted of subjects in age group 3), age-bin 1 was not used for further analysis. Assessment of 
expression similarity differences using BrainSpan exon microarray PFC-MSC variability genes 
validated the decreased similarity in males (P<0.001, Supplementary Figure 5), which was less 
pronounced in Braincloud data and driven by genes from age-bins 8 and 9. Consistent with BrainSpan 
results, co-expression with schizophrenia susceptibility genes was significant in age-bin 2 (rho=0.03, 
P<0.001), age-bin 9, (rho=0.07, P<0.001) and age-bin 10 (rho=0.03, P<0.001) and showed a trend 
towards significance in age-bin 8 (rho=0.01, P=0.08).  
 
2.2.5 Discussion 
The present results demonstrate that the similarity of gene expression profiles in males shows a 
brain-region specific decrease compared to females. Some of the genes driving this effect were co-
expressed with schizophrenia susceptibility genes, in a regionally specific and age-dependent 
manner. Importantly, co-expression was found in the brain regional-cluster encompassing the 
prefrontal cortex during fetal brain development, confirming a core prediction of the 
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neurodevelopmental hypothesis of schizophrenia(Weinberger 1987). Additionally, and again as 
predicted by this hypothesis, significant co-expression was further found during adolescence. Similar 
differences of expression similarity were found in RNAseq data acquired on a subset of the same 
samples. In this dataset, we further replicated associations between variability and susceptibility 
genes in data from adolescent donors, but found no associations during the fetal period. Expression 
similarity differences were further validated in the independent Braincloud data and significant co-
expression was found in samples from fetal, as well as adolescent donors.  
Co-expression did not depend on how genes were selected from a given susceptibility locus and 
exceeded that observed for major depression (in age-bin 1 by a small margin) and coronary artery 
disease in the early fetal phase, as well as during adolescence. We observed that genes selected from 
randomly chosen loci stratified for DNA sequence variability showed a broadly similar, although less 
pronounced, co-expression trend compared to schizophrenia genes. In contrast, genes selected 
randomly without consideration of DNA sequence variability were not co-expressed with variability 
genes, on average. This may suggest that sequence variability associated with schizophrenia 
susceptibility loci impacted on diversification of gene expression and the sex-differences observed in 
the present study.  
Genes from the fetal and adolescent periods were involved in synaptic processes, which have been 
implicated in schizophrenia by a range of genetic, histopathological, neuroimaging, pharmacological 
and neurotransmitter studies(McGlashan and Hoffman 2000, Tsai and Coyle 2002, Glausier and Lewis 
2013, Network and Pathway Analysis Subgroup of Psychiatric Genomics 2015, Schwarz, Izmailov et al. 
2016). They are affected by genetic and environmental risk in particular during early life, leading to 
subsequent impairments in synaptic plasticity and connectivity(Lewis and Levitt 2002). The lack of 
overlap between variability genes from the fetal period and adolescence may hint at biologically 
divergent risk processes that converge on the same synaptic pathways.  
The main limitation of the present study is sample size. The primary analysis of the BrainSpan data 
reported that brain-region and age are stronger modulators of gene expression compared to sex or 
inter-individual variation(Kang, Kawasawa et al. 2011). Therefore, the present study focused on 
analyses that are stratified by regional clusters and age-bins, with significant impact on sample 
numbers available for a given analysis. In the BrainSpan dataset, data from multiple brain regions 
was available for most donors. We performed a donor-wise bootstrapping procedure during all 
resampling analyses, to account for the non-independence of the samples. This procedure further 
accounted for potential effects arising from differences in donor numbers between sexes, further 
reducing the effective sample size.  The low donor number per regional-cluster age-bin combination 
prevented meaningful permutation of gender. Therefore, random ‘variability genes’ were created by 
randomly sampling genes, stratified by expression variance. This may have led to bias, due to the 
potential correlation among the actual variability genes that is not captured by the procedure 
employed here. The low sample number in all three investigated datasets also limits the power to 
identify and validate significant associations, including expression similarity differences and co-
expression between variability and susceptibility genes. This may have contributed to the partial non-
replication of findings across datasets. 
Another limitation is that we selected a single susceptibility gene per locus to prevent statistical bias, 
but this selection may not accurately reflect genetic schizophrenia risk. By comparison, other studies 
have previously selected susceptibility genes by extracting all genes within a given 
locus(Schizophrenia Working Group of the Psychiatric Genomics Consortium 2014) or by focusing on 
effectors of index variant eQTLs(Gamazon, Wheeler et al. 2015). Another interesting aspect is that 
the present findings may relate to underlying, variable phenotypes, such as personality traits and 
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comorbid psychiatric conditions. Furthermore, we aimed to account for the effects of known and 
unknown confounders during all analyses, but this may not have comprehensively captured 
experimental artefacts that may have influenced between-subject or gene-gene correlations. Finally, 
we did not use genetic association data to correct for potential subject relatedness or population 
structure, due to data availability and sample size limitations.  
In conclusion, this study indicates sex specific genetic mechanisms operating during fetal brain 
development linked to the variability of prefrontal brain gene expression during adolescence, as 
predicted by the neurodevelopmental hypothesis of schizophrenia. These effects may contribute to 
the well-established clinical sex differences of schizophrenia and underlying gene sets may be 
valuable for biologically stratified exploration of the illness’s etiology.  
 
Tables 
Table 1. BrainSpan exon microarray sample numbers for males and females across 11 age bins and 4 
brain regional clusters after data preprocessing (1: V1C-STC, 2: PFC-MSC, 3: STR-HIP-AMY, 4: MD-
CBC, see Supplementary Table 1 for details). Subject numbers are shown in brackets. 
  Males Females 
Age bin 
Regional 
cluster 1 2 3 4 1 2 3 4 
1  12 (3) 21 (4) 11 (4) 1 (1) 20 (4) 24 (4) 12 (4) 7 (4) 
2  23 (5) 31 (6) 16 (6) 5 (4) 20 (4) 24 (4) 12 (4) 7 (4) 
3  23 (5) 27 (5) 14 (5) 5 (4) 33 (7) 39 (7) 20 (7) 13 (7) 
4  23 (5) 27 (5) 14 (5) 8 (5) 27 (6) 31 (6) 16 (6) 12 (6) 
5  15 (3) 18 (3) 9 (3) 6 (3) 27 (6) 31 (6) 16 (6) 12 (6) 
6  30 (6) 36 (6) 18 (6) 12 (6) 14 (3) 16 (3) 8 (3) 6 (3) 
7  24 (5) 29 (5) 12 (4) 10 (5) 5 (1) 6 (1) 3 (1) 2 (1) 
8  24 (5) 28 (5) 12 (4) 10 (5) 10 (2) 9 (2) 6 (2) 4 (2) 
9  19 (4) 20 (4) 8 (3) 7 (4) 15 (3) 15 (3) 8 (3) 5 (3) 
10  20 (4) 21 (4) 10 (4) 7 (4) 20 (4) 21 (4) 11 (4) 7 (4) 
11  36 (8) 42 (8) 19 (7) 14 (8) 33 (7) 39 (7) 19 (7) 12 (7) 
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Figures 
 
Figure 1. Analysis workflow. Transcriptome-wide expression data were extracted from the BrainSpan 
Atlas of the Developing Human Brain for each age-bin – brain regional-cluster combination. Age-bins 
and regional-clusters were taken from (Willsey, Sanders et al. 2013). Using a resampling procedure, 
expression variability was then quantified in males and females as the mean of the pairwise 
correlations of transcriptome-wide expression between samples from the respective subjects. PCW, 
post conceptional week; V1C, primary visual cortex; ITC, inferior temporal cortex; IPC, posterior 
inferior parietal cortex; A1C, primary auditory cortex; STC, superior temporal cortex; M1C, primary 
motor cortex; S1C, primary somatosensory cortex; VFC, ventral prefrontal cortex; MFC, medial 
prefrontal cortex; DFC, dorsal prefrontal cortex; OFC, orbital prefrontal cortex; STR, striatum; HIP, 
hippocampal anlage/ hippocampus; AMY, amygdala; MD, mediodorsal nucleus of the thalamus; CBC, 
cerebellar cortex. 
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Figure 2. Sex differences in expression similarity in BrainSpan exon microarray data. a) Expression 
similarity for four brain regional-clusters: V1C-STC, PFC-MSC, STR-HIP-AMY, and MD-CBC for males 
(blue) and females (orange). The panels display mean estimates (solid lines) and 95% confidence 
intervals (shaded areas). The panels show no values for regional-cluster age-bin combinations 
containing data from only one donor. b) Expression variability for ‘variability genes’, identified 
separately for each given age-bin. In age-bin 7, data from only one donor was available for females. 
c) Expression variability profiles for variability genes derived from age-bins 9 [10 months – 11 years] 
and 10 [2 years – 19 years] in the PFC-MSC cluster. This panel shows variability profiles for male 
subjects only.  
 
Figure 3. Co-expression between variability genes and schizophrenia susceptibility genes. a) 
Significance of median co-expression for variability genes determined for each age-bin in the 
regional-clusters V1C-STC, PFC-MSC and STR-HIP-AMY of male subjects. b) Co-expression in PFC-MSC 
cluster, age-bin 10, for males and females, respectively. Rows and columns were ordered separately 
based on median co-expression. c) Comparison of co-expression between variability genes and 
schizophrenia susceptibility genes chosen based on physical proximity to index SNPs (red), random 
selection within a given susceptibility locus (orange), randomly selected loci with comparable DNA 
sequence variability compared to schizophrenia loci (blue), random genes selected from the same 
chromosomes as schizophrenia susceptibility genes (purple), major depression susceptibility genes 
(green) and genes linked to a non-psychiatric phenotype (coronary artery disease, grey). d) 
Windowing of age-bins 8, 9 and 10 in the PFC-MSC cluster. The panel shows variability difference and 
co-expression for variability genes determined for age-bins 8 to 10. Co-expression was determined 
for males only. 
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2.2.6 Supplementary Tables 
Supplementary Table 1: Brain regions and regional clusters used in the present study.  
Cluster Region Description 
1 V1C primary visual cortex 
1 ITC inferior temporal cortex 
1 IPC posterior inferior parietal cortex 
1 A1C primary auditory cortex 
1 STC superior temporal cortex 
   
2 M1C primary motor cortex 
2 S1C primary somatosensory cortex 
2 VFC ventral prefrontal cortex 
2 MFC medial prefrontal cortex 
2 DFC dorsal prefrontal cortex 
2 OFC orbital prefrontal cortex 
   
3 STR striatum 
3 HIP hippocampal anlage (periods 1–2), hippocampus (periods 3–13) 
3 AMY amygdala 
   
4 MD mediodorsal nucleus of the thalamus 
4 CBC cerebellar cortex 
 
 
Supplementary Table 2: Grouping of subjects into age bins as performed by Willsey et al (Willsey, 
Sanders et al. 2013). Periods of human brain development were taken from Kang et al (Kang, 
Kawasawa et al. 2011).  
Age 
bin 
Period Ages Description 
1 1,2,3 6 PCW – 13 PCW embryonic to early fetal 
2 2,3,4 9 PCW – 16 PCW early fetal to early mid-fetal 
3 3,4,5 12 PCW – 19 PCW early fetal to early mid-fetal 
4 4,5,6 16 PCW – 22 PCW early mid-fetal to late mid-fetal 
5 5,6,7 17 PCW – 37 PCW early mid-fetal to late fetal 
6 6,7,8 21 PCW – 6 months late mid-fetal to neonatal & early infancy 
7 7,8,9 25 PCW – 1 year Late fetal to late infancy 
8 8,9,10 4 months – 4 years neonatal & early infancy to early childhood 
9 9,10,11 10 months – 11 years late infancy to middle and late childhood 
10 10,11,12 2 years – 19 years early childhood to adolescence 
11 11,12,13 11 years – 40 years Adolescence to young adulthood 
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Supplementary Table 3: Schizophrenia susceptibility genes used in the present study. Susceptibility 
loci were taken from a study by the Schizophrenia Working group of the Psychiatric Genomics 
Consortium (Schizophrenia Working Group of the Psychiatric Genomics 2014). Rank: rank of 
significance of case-control difference described in (Schizophrenia Working Group of the Psychiatric 
Genomics 2014). Chr and position: chromosomal position of index SNP. Gene: gene in closest 
chromosomal position to the index SNP of a given locus. If a given locus contained multiple index 
SNPs (annealed locus), the gene in closest proximity to the most significant index SNP was chosen. 
Genes marked with # were not annotated by the R library org.Hs.eg.db. Genes marked with an 
asterisk were not part of the BrainSpan data. 
Rank Index SNP Chr Position Gene 
1 rs115329265 MHC locus position 
2 rs1702294 1 98501984 MIR137* 
3 rs11191419 10 104612335 C10orf32# 
4 rs2007044 12 2344960 CACNA1C 
5 rs4129585 8 143312933 TSNARE1 
6 rs35518360 4 103146890 SLC39A8 
7 chr7_2025096_I 7 2025096 MAD1L1 
8 rs4391122 5 60598543 ZSWIM6* 
9 rs2851447 12 123665113 MPHOSPH9 
10 chr2_200825237_I 2 200825237 C2orf47 
11 rs4702 15 91426560 FURIN 
12 rs75968099 3 36858583 TRANK1* 
13 chr10_104957618_I Annealed with rs11191419 
14 rs12887734 14 104046834 APOPT1* 
15 rs8042374 15 78908032 CHRNA3 
16 rs13240464 7 110898915 IMMP2L 
17 rs10791097 11 130718630 SNX19 
18 rs11693094 2 185601420 ZNF804A 
19 rs1378559 X 21380266 CNKSR2 
20 rs7893279 10 18745105 CACNB2 
21 rs12826178 12 57622371 SHMT2 
22 rs12129573 1 73768366 LRRIQ3 
23 rs6704768 2 233592501 GIGYF2 
24 rs55661361 11 124613957 NRGN 
25 rs9636107 18 53200117 TCF4 
26 chr11_46350213_D 11 46350213 DGKZ 
27 rs7907645 Annealed with rs11191419 
28 chr3_180594593_I 3 180594593 FXR1 
29 rs6065094 20 37453194 PPP1R16B 
30 rs11682175 2 57987593 VRK2 
31 rs950169 15 84706461 ADAMTSL3 
32 rs72934570 18 53533189 TCF4 
33 rs6434928 2 198304577 SF3B1 
34 rs9607782 22 41587556 EP300 
35 rs36068923 8 111485761 KCNV1 
36 rs17194490 3 2547786 CNTN4 
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37 rs2514218 11 113392994 DRD2 
38 rs75059851 11 133822569 IGSF9B 
39 rs2535627 3 52845105 ITIH4 
40 rs12691307 16 29939877 KCTD13 
41 chr22_39987017_D 22 39987017 CACNA1I 
42 rs7432375 3 136288405 STAG1 
43 chr18_52749216_D Annealed with rs9636107 
44 rs111294930 5 152177121 GRIA1 
45 rs2973155 Annealed with rs111294930 
46 rs5937157 X 68377126 PJA1 
47 rs4523957 17 2208899 SRR 
48 rs12704290 7 86427626 GRM3 
49 rs12903146 15 61854663 VPS14C# 
50 rs11210892 1 44100084 PTPRF 
51 rs2905426 19 19478022 MAU2* 
52 rs140505938 1 150031490 VPS45 
53 chr6_84280274_D 6 84280274 SNAP91 
54 rs4648845 1 2387101 PLCH2 
55 rs7405404 16 13749859 ERCC4 
56 rs6466055 7 104929064 SRPK2 
57 chr1_8424984_D 1 8424984 RERE 
58 rs4766428 12 110723245 ATP2A2 
59 rs10520163 4 170626552 CLCN3 
60 rs117074560 6 96459651 FUT9 
61 rs6002655 22 42603814 TCF20 
62 chr2_146436222_I No gene in proximity  
63 rs9420 11 57510294 C11orf31 
64 rs11027857 11 24403620 LUZP2 
65 rs1498232 No gene in proximity  
66 rs3735025 7 137074844 DGKI 
67 rs11139497 9 84739941 TLE1 
68 rs77149735 1 243555105 SDCCAG8 
69 rs56205728 15 40567237 PAK6 
70 rs2053079 19 30987423 ZNF536 
71 rs16867576 5 88746331 MEF2C 
72 rs4330281 3 17859366 TBC1D5 
73 rs3849046 5 137851192 ETF1 
74 rs2693698 14 99719219 BCL11B 
75 rs2332700 14 72417326 RGS6 
76 rs1501357 5 45364875 HCN1 
77 rs6984242 8 60700469 CA8 
78 chr1_243881945_I Annealed with rs77149735  
79 rs79212538 Annealed with rs111294930 
80 rs3768644 2 72361505 CYP26B1 
81 rs77502336 11 123394636 GRAMD1B 
82 rs6704641 2 200164252 SATB2 
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83 rs59979824 2 193848340 PCGEM1* 
84 rs1106568 4 176861301 GPM6A 
85 rs10503253 8 4180844 CSMD1 
86 rs10043984 Annealed with rs3849046 
87 rs11685299 2 225391296 CUL3 
88 rs7819570 8 89588626 MMP16 
89 rs715170 Annealed with rs72934570 
90 rs9922678 16 9946319 GRIN2A 
91 rs78322266 Annealed with rs9636107 
92 rs2068012 14 30190316 PRKD1 
93 rs832187 3 63833050 C3orf49 
94 rs8044995 16 68189340 NFATC3 
95 chr2_149429178_D 2 149429178 EPC2 
96 rs8082590 17 17958402 GID4* 
97 rs12148337 15 70589272 TLE3 
98 rs12325245 16 58681393 CNOT1 
99 rs2239063 Annealed with rs2007044 
100 rs12522290 Annealed with rs111294930 
101 rs10803138 Annealed with rs77149735  
102 rs73229090 8 27442127 CLU 
103 rs324017 Annealed with rs12826178  
104 rs12845396 X 6029533 NLGN4X 
105 rs55833108 Annealed with rs11191419 
106 rs9841616 Annealed with chr3_180594593_I 
107 rs76869799 Annealed with rs1702294  
108 rs1339227 6 73155701 RIMS1 
109 chr7_24747494_D 7 24747494 DFNA5 
110 rs4388249 5 109036066 MAN2A1 
111 rs215411 4 23423603 MIR548AJ2* 
112 rs11740474 5 153680747 GALNT10 
113 rs1023500 Annealed with rs6002655  
114 rs12421382 11 109378071 C11orf87 
115 rs211829 7 110048893 IMMP2L 
116 rs679087 12 29917265 TMTC1 
117 rs75575209 Annealed with rs11682175  
118 rs7801375 7 131567263 PODXL 
119 rs14403 Annealed with rs77149735  
120 rs6670165 1 177280121 BRINP2* 
121 rs7523273 1 207977083 CD46 
122 rs7267348 20 48131036 PTGIS 
123 rs4240748 12 92246786 C12orf79# 
124 rs2909457 2 162845855 DPP4 
125 rs56873913 19 50091199 PRRG2 
126 rs190065944 Annealed with rs8042374  
127 rs10860964 12 103596455 C12orf42 
128 chr5_140143664_I 5 140143664 PCDHA1* 
EMPIRICAL STUDIES 
67 
 
Supplementary Table 4: Ontological terms associated with heterogeneity genes of age bins 8, 9 and 
10 in the PFC-MSC cluster, as determined using the DAVID tool (Huang da, Sherman et al. 2009). P-
values were corrected for the False Discovery Rate (FDR) according to the method of Benjamini and 
Hochberg.  
Category P(FDR) 
calcium ion binding 2.60E-04 
Synapse 3.50E-03 
Epilepsy 3.80E-03 
Phosphoprotein 4.00E-03 
Ion channel 4.20E-03 
Parkinson disease 5.10E-03 
Membrane 5.90E-03 
Alternative splicing 1.10E-02 
Glycoprotein 2.50E-02 
Ion transport 2.80E-02 
Parkinsonism 3.20E-02 
Cell membrane 3.40E-02 
Cell adhesion 3.40E-02 
Cell junction 4.10E-02 
plasma membrane 4.90E-02 
 
Supplementary Table 5: Ontological terms associated with heterogeneity genes of age bins 1 and 2 
in the PFC-MSC cluster, as determined using the DAVID tool (Huang da, Sherman et al. 2009). P-
values were corrected for the False Discovery Rate (FDR) according to the method of Benjamini and 
Hochberg. 
Category P(FDR) 
Synapse 3.30E-03 
Postsynaptic cell membrane 5.50E-03 
dendrite 1.90E-02 
cell junction 2.20E-02 
Cell membrane 2.60E-02 
postsynaptic membrane 3.50E-02 
Membrane 4.50E-02 
chemical synaptic transmission 4.60E-02 
 
Supplementary Table 6: Ontological terms associated with heterogeneity genes of age bins 1 and 2 
in the PFC-MSC cluster, as determined using the DAVID tool (Huang da, Sherman et al. 2009). P-
values were corrected for the False Discovery Rate (FDR) according to the method of Benjamini and 
Hochberg. 
Category P(FDR) 
Phosphoprotein 1.60E-07 
CARM1 and Regulation of the Estrogen Receptor 7.70E-03 
Cell division and chromosome partitioning 4.40E-02 
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Supplementary Table 7: Age and sex distribution for donors part of the age-windowing analysis. Age 
is shown as mean ± sd. 
Age-window age sex (m/f) 
1 1.9 ± 1.3 28/9 
2 4.8 ± 3.1 20/9 
3 6.8 ± 3.7 15/15 
4 9.2 ± 3.5 15/15 
5 10.9 ± 3.7 21/12 
6 13.3 ± 3.9 16/18 
 
 
Supplementary Table 8: BrainSpan RNAseq sample numbers for males and females across 11 age 
bins and 4 brain regional clusters after data preprocessing (1: V1C-STC, 2: PFC-MSC, 3: STR-HIP-AMY, 
4: MD-CBC, see Supplementary Table 1 for details). Subject numbers are shown in brackets. 
  Males Females 
Age bin 
Regional 
cluster 1 2 3 4 1 2 3 4 
1  10 (3) 21 (4) 10 (4) 0 (0) 19 (4) 23 (4) 12 (4) 2 (2) 
2  23 (5) 29 (6) 15 (6) 4 (3) 19 (4) 23 (4) 12 (4) 2 (2) 
3  23 (5) 25 (5) 13 (5) 4 (3) 27 (6) 32 (6) 17 (6) 5 (4) 
4  18 (4) 19 (4) 10 (4) 5 (4) 9 (3) 9 (2) 5 (2) 4 (3) 
5  4 (1) 6 (1) 3 (1) 1 (1) 12 (5) 10 (3) 5 (2) 4 (3) 
6  12 (3) 13 (3) 9 (3) 5 (3) 4 (2) 1 (1) 0 (0) 1 (1) 
7  12 (3) 11 (3) 6 (2) 5 (3) 3 (1) 1 (1) 0 (0) 0 (0) 
8  13 (4) 15 (5) 8 (3) 6 (4) 5 (2) 2 (1) 1 (1) 2 (2) 
9  15 (4) 17 (5) 6 (3) 4 (4) 10 (3) 8 (2) 3 (2) 3 (3) 
10  19 (5) 17 (5) 8 (5) 4 (4) 20 (5) 20 (4) 9 (4) 6 (5) 
11  28 (7) 30 (6) 13 (7) 8 (6) 30 (6) 35 (6) 16 (6) 8 (6) 
 
 
Supplementary Table 9: BrainCloud subject numbers for each age-bin after data preprocessing. 
Age bin  Males Females 
1  2 2 
2  8 5 
3  19 19 
4  17 17 
5  11 14 
6  6 1 
7  6 1 
8  10 4 
9  4 4 
10  30 14 
11  46 14 
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2.2.7 Supplementary Figures  
 
Supplementary Figure 1. Schematic overview of the preprocessing steps performed for the 
microarray and RNAseq data used in the present study. 
 
 
Supplementary Figure 2. PCA scores plots of BrainSpan exon microarray (left panel), BrainSpan 
RNAseq (middle panel) and Braincloud (right panel) data. Excluded outliers are shown in red. 
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Supplementary Figure 2. Examples of variability genes in the PFC-MSC cluster, age bin 9. The three 
panels on the left show the three genes with the most significant expression difference between 
males and females. The three panels on the right the genes with the least significant sex-difference in 
expression. Significance was determined using Wilcoxon rank-sum tests, which do, however, not 
account for the non-independence between the multiple samples from a given donor.  
 
Supplementary Figure 3. Sex differences in expression similarity in BrainSpan RNAseq data.  a) 
Expression similarity for four brain regional clusters: V1C-STC, PFC-MSC, STR-HIP-AMY, and MD-CBC 
for males (blue) and females (orange). The panels display mean estimates (solid lines) and 95% 
confidence intervals (shaded areas). b) Differences of expression similarity (male coexpression – 
female coexpression) for BrainSpan exon microarray ‘variability genes’, assessed separately for each 
given age bin in BrainSpan RNAseq data. 
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Supplementary Figure 4. Differences of expression similarity (male coexpression – female 
coexpression) for BrainSpan exon microarray ‘variability genes’, assessed separately for each given 
age bin in Braincloud data. 
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3 DISCUSSION 
Technological advances in the omics and neuroimaging fields and fast-paced progress in the field of 
data science, combined with the establishment of large-scale international research consortia and 
the resulting increase in data availability have led to a substantial improvement of our understanding 
of the biological etiology of schizophrenia. Despite this progress, however, advances made have not 
yet been translated into the improved clinical management of this severe illness. The overarching 
objective of the work described in this thesis was to use contemporary data science methodologies 
to provide a more in-depth characterization of the (epi-)genetic landscape of schizophrenia and its 
relation to neural functioning relevant for the illness. An important basis for this work provided the 
development of a biologically-informed machine learning tool termed BioMM, which we have made 
publicly available in the form of a library for the statistical programming environment R. In 
preliminary previous work we have shown that BioMM outperforms conventional machine learning 
approaches when applied to high-dimensional omics data, providing an ideal foundation for the work 
presented in this thesis. Using this technology, we set out to identify an epigenetic signature 
associated with schizophrenia, characterize the relationship between this epigenetic signature and 
GWAS derived polygenic risk, and explore the impact of the epigenetic signature on schizophrenia-
relevant brain function (Study 1). The possibility to incorporate systems-biological information into 
machine learning approaches and thereby improve the predictive value for complex conditions such 
as schizophrenia also provides the opportunity for an improved understanding of the spatiotemporal 
components underlying illness susceptibility as well as the potential to use this knowledge towards 
future, more personalized therapeutic approaches. Towards this, and based on the well-established 
sex-dimorphisms in onset-age and clinical course, we set out to characterize sex-specific differences 
in brain-region specific gene expression trajectories during human development and characterize 
their relationship with genetic risk for schizophrenia (Study 2). Using advanced, multimodal data 
science methodology, the studies described in this thesis aim to elucidate brain functionally-relevant 
components of the schizophrenia etiology and improve our understanding of how genetic risk 
translates into altered function in a spatiotemporally specific manner.  
3.1 Epigenetic modulation of risk 
In Study 1, we applied the BioMM procedure to identify a peripheral epigenetic risk signature (PMS). 
The signature identified was significantly predictive of schizophrenia case-control status and 
explained 10.5% to 21.8% of the variance across two independent peripheral samples, as well as 
8.3% of the variance in the post-mortem DLPFC samples. These findings demonstrate the presence of 
a reproducible poly-epi-genetic signature associated with schizophrenia that can be detected in 
peripheral samples of patients with schizophrenia, and which is partly mirrored in epigenetic changes 
present in the DLPFC of patients. The presence of such an epigenetic signature is consistent with the 
strong impact of environmental risk factors on illness susceptibility and the notion that epigenetic 
effects may explain part of the missing heritability phenomenon (Harrison 2015). Notably, the 
overlap of the epigenetic differences that led to the significant cross-tissue prediction of 
schizophrenia is in agreement with the previously observed correlation of DNA methylation between 
blood and the brain (Walton, Hass et al. 2016, Edgar, Jones et al. 2017, Braun, Han et al. 2019). An 
important result of Study 1 was that the identified PMS was reproducibly associated with DLPFC-HC 
functional connectivity during two working memory tasks, suggesting a schizophrenia-related brain-
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functional effect of the identified epigenetic differences. These results further support the illness-
relevance of the hippocampal-dorsolateral prefrontal interaction in the pathophysiology of 
schizophrenia (Weinberger 1987, Bahner, Demanuele et al. 2015) and highlight its likely susceptibility 
to environmental risk effects.   
Remarkably, the epigenetic signature did not correlate with a GWAS derived polygenic risk score, and 
no association was found for the interaction of PMS and polygenic risk score on DLPFC-HC 
connectivity. Furthermore, a significant relationship was detected between the polygenic risk score 
and DLPFC-HC connectivity. These findings suggest that I) the identified PMS carried illness- and 
brain-functionally-relevant information that was largely independent of genetic schizophrenia risk, II) 
that the identified epigenetic differences were not secondary to genetic susceptibility and III) that 
epigenetic effects did not amplify genetic schizophrenia risk in terms of its impact on DLPFC-HC 
connectivity. These results were further substantiated by analysis of unaffected first-degree relatives 
of schizophrenia, which also indicated the absence of a strong genetic effect. Notably, it has been 
argued that some patients may be affected by a stronger genetic load leading to psychosis 
irrespective of epigenetic modifications or environmental insult while others may be more affected 
by environmental exposure (Vitale, Matigian et al. 2017). Therefore an interesting focus of future 
studies is the application of multimodal data science approaches to disentangle this biological 
heterogeneity and identify patient subgroups where illness risk is mainly driven by genetic or 
environmental effects.  It is important to consider that environmental risk exposure likely occurs far 
in advance of illness onset, with previously described risk factors including famine, prenatal stress 
and maternal depression, as well as toxicological exposures (Kundakovic and Jaric 2017). Therefore, 
the biological manifestation of environmental risk effects may have spatiotemporal specificity and 
compound genetic risk in brain areas and developmental periods of particular relevance for 
schizophrenia, such as adolescence. Disentangling such effects, including the downstream impact of 
epigenetic effects on gene expression will form an important part of future studies aimed a providing 
a more in-depth characterization of gene-environment interactions in schizophrenia.  
3.2 Spatiotemporal characterization of risk 
The spatiotemporal analysis in Study 2 led to the identification of a set of genes significantly co-
expressed with schizophrenia genetic susceptibility genes particularly in brain regions involving the 
prefrontal cortex during the fetal period and adolescence, two critical periods of vulnerability for 
schizophrenia (Selemon and Zecevic 2015). The genes were identified based on sex-dimorphisms of 
their expression variance, and the risk-associated genes showed a more prominent variation in males 
compared to females. These findings provide deeper insight into the biological basis of sex 
differences in schizophrenia and may underlie the frequently observed clinical differences in onset-
age, clinical course and treatment response. The results are further consistent with previous 
genomics and transcriptomic studies that support the role of molecular perturbations related to early 
brain development for schizophrenia vulnerability (Gilman, Chang et al. 2012, Xu, Ionita-Laza et al. 
2012, Birnbaum, Jaffe et al. 2014, Birnbaum, Jaffe et al. 2015, Jaffe, Straub et al. 2018, Clifton, 
Hannon et al. 2019). It is noteworthy that DNA methylation data from post-mortem cortical tissue 
across the lifespan has also supported this finding (Jaffe, Gao et al. 2016) and has aided in expanding 
knowledge of the biological basis underlying the neurodevelopmental component of schizophrenia.  
Remarkably, the identified genes in Study 2 were strongly associated with synaptic processes in line 
with the pathway finding in Study 1, which is in accordance with the prominent and repeatedly 
described role of synaptic dysfunction in schizophrenia that is supported by numerous postmortem, 
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brain imaging, epidemiological and clinical studies (McGlashan and Hoffman 2000, Stephan, 
Baldeweg et al. 2006, Yin, Chen et al. 2012, Fromer, Roussos et al. 2016, Jaffe, Straub et al. 2018).  
Exposure to most environmental stressors linked to schizophrenia occurs long before the occurrence 
of clinical symptoms, supporting an early, brain functionally-relevant manifestation of biological risk 
that increases illness vulnerability during later life. In the context of synaptic disturbance, two 
possible mechanisms were proposed by (Faludi and Mirnics 2011): less synapse production or over-
pruning. (I) The number of synapses is suppressed in early life such as during the fetal or postnatal 
periods at the time of insult, while the function of these synapses is still maintained during the ‘pre-
pruning’ phase. However, during the late developmental pruning that occurs during late adolescence 
or early adulthood, the symptoms of schizophrenia appear due to an insufficient number of 
functioning synapses. (II) Alternatively, over-pruning that increases susceptibility for schizophrenia 
during late adolescence or early adulthood may have occurred during early life possibly due to the 
abnormal synapse functioning. We observed that the risk-associated gene sets with sex-dimorphisms 
in expression variability identified in Study 2 did not overlap between the fetal and adolescent 
periods but converged at a functional level to synaptic processes. This suggests that the biological 
basis of schizophrenia risk may be better understood and explored on a systems biology basis 
integrating spatiotemporally-specific effects.  
We show that the identified genes co-expressed with schizophrenia susceptibility genes were 
enriched in the prefrontal cortical region, which is a well-studied area of particular relevance for the 
early developmental pathology of schizophrenia (Weinberger 1987, Selemon and Zecevic 2015, 
Birnbaum and Weinberger 2017). Several gene expression studies focussing on the prefrontal cortex 
have reported that schizophrenia-linked genes involved in transcriptional regulation during fetal life 
are significantly co-expressed with susceptibility genes or over-represented among schizophrenia 
susceptibility loci (Birnbaum, Jaffe et al. 2015, Jaffe, Straub et al. 2018). Similarly, schizophrenia-
associated differential CpG sites identified in the prefrontal cortex have been found to be enriched at 
genetic risk loci (Pidsley, Viana et al. 2014, Jaffe, Gao et al. 2016).  
 
3.3 Synaptic and immune pathways 
The application of the BioMM procedure in Study 1 has allowed the identification of pathways that 
contribute most to the epigenetic schizophrenia classification which comprised four pathways 
related to neural and synaptic functions. Pathway and gene set enrichment analyses based on GWAS 
data from more than 60,000 subjects have previously identified multiple immune, neuronal signaling, 
and synaptic pathways as being most enriched for variants linked to schizophrenia (Network, 
O'Dushlaine et al. 2015). Another similar large-scale GWAS summary statistics-based study also 
pointed to pathways linked to synaptic dysregulation reported by (Schijven, Kofink et al. 2018). 
Furthermore, large-scale de novo mutation and copy number variation (CNV) studies have shown the 
enrichment of a synapse-related gene network (Fromer, Pocklington et al. 2014). These studies are in 
good agreement with the synaptic pathways identified here using machine learning models based on 
epigenetic data. 
Notably, the top pathway from Study 1 was “negative regulation of NF-kappaB transcription factor 
activity”, which is of critical relevance to the immune system. The regulation of nuclear factor kappaB 
(NF-kappaB) involves a family of transcription factors that are important for inflammation, immunity, 
and memory, as well as the nervous system (Oeckinghaus and Ghosh 2009, Dresselhaus and Meffert 
2019). This finding may further support the assumed role of the immune system for schizophrenia 
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(Muller and J Schwarz 2010). The identification of immune-related pathways linked to epigenetic 
schizophrenia risk is further consistent with the most extensive common variant genetic study by the 
PGC that highlighted the enrichment of  identified risk loci genes expressed in tissues with vital 
immune functions (Schizophrenia Working Group of the Psychiatric Genomics 2014), as well as with 
the pathway analysis from large GWAS data that pointed to schizophrenia-relevant immune 
processes (Network, O'Dushlaine et al. 2015). Moreover, the role of immunologic dysfunction is also 
supported by a variety of omics studies (van Mierlo, Schot et al. 2019) including transcriptomics 
(Fillman, Cloonan et al. 2013, Gardiner, Cairns et al. 2013, Mistry, Gillis et al. 2013, Sanders, Goring et 
al. 2013, Bergon, Belzeaux et al. 2015, Hess, Tylee et al. 2016, Sanders, Drigalenko et al. 2017, Duan, 
Goring et al. 2018, Kos, Duan et al. 2018, Leirer, Iyegbe et al. 2019),  and proteomics (Schwarz, Guest 
et al. 2012, Schwarz, van Beveren et al. 2013), as well as epigenomics (Liu, Chen et al. 2013, Aberg, 
McClay et al. 2014, Hannon, Dempster et al. 2016).  In line with this, a recent study has investigated 
the bidirectional relationship between schizophrenia and 19 immune-related diseases and identified 
extensively shared genetic risk factors (Pouget, Consortium et al. 2019). Interestingly, NF-kappaB is 
also known to be involved in synaptic plasticity, memory, and navigation (Snow, Stoesz et al. 2014), 
which may be linked to the abnormal working memory observed in schizophrenia (Forbes, Carrick et 
al. 2009).   
Furthermore, the analysis of randomly selected pathway sets performed in the present work further 
supported the robustness and specificity of the identified, top-ranked pathways, suggesting that 
epigenetic changes in schizophrenia converge on a specific set of synaptic and immune-related 
processes.   
 
3.4 Explainable machine learning models 
Machine learning applied to omics data is receiving increasing attention in psychiatric research, 
partially fueled by the growing amount of available omics data. An important aspect of such models 
is their biological interpretability, which may be challenging when models are trained on high-
dimensional data. In this thesis, the critical features of our devised machine learning framework 
BioMM are discussed here.  
First, generalizability is one of the key components of successful machine learning approaches as the 
trained parameters must be applicable to samples outside of the training data. BioMM has a built-in 
resampling procedure (cross-validation) to estimate and select model parameters at the initial model 
training stage. In Study 1, nested cross-validation of BioMM provided a prediction accuracy of 0.78 in 
AUC, which indicates a reasonably high predictive value given the clinical heterogeneity of 
schizophrenia. More importantly, our model was independently validated in two other datasets. 
BioMM performance was additionally compared with an empirical null obtained using permutation 
testing and the result demonstrated that no random models outperformed the real one, 
strengthening the robustness of our model.  
Second, most machine learning applications on epigenetic data for the classification of health status 
generally do not provide a clear understanding of which factors drive these classifications or 
predictions. For example, Capper and colleagues were able to yield high prediction accuracy using 
the random forest algorithm based on thousands of CpGs for tumor classification (Capper, Jones et 
al. 2018) but the most predictive underlying features were not identified. The advantages of applying 
explainable machine learning approaches to genome-wide data instead of the conventional analysis 
of single genes are demonstrated in study 1. A central idea of the BioMM model is that the 
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incorporation of pathway information into model construction improves the predictive value of the 
combined epigenetic changes. Due to the hierarchical procedure that first builds pathway-specific 
models and then integrates these using a meta-learner, BioMM also provides an intrinsic ranking of 
pathway features. Individual pathway features can further be analyzed using univariate statistics and 
used for other, biologically-informed downstream analyses.- Of particular interest in the context of 
work described here is unsupervised learning, where pathways-level features are used to identify 
subgroups of patients that show similar, systems-level alterations. For example, patients may be 
subtyped by either synaptic or immune-related pathways based on multiple omics data. 
 
3.5 Limitations 
The work described here highlights the utility of multivariate, multimodal approaches to explore 
biological determinants of schizophrenia using large-scale omics data. However, there are several 
limitations of the presented studies that are further detailed below. 
 
One potential limitation of our work is the sample size. In Study 1, we did not directly investigate the 
relationship between PMS and DLPFC-HC coupling by including patient samples because only about 
30 schizophrenia cases were available. This prevented meaningful analysis of epigenetic effects and 
the potentially stronger interactions with genetic risk in patients. In Study 2, since we adopted 
stratified analysis by brain regions and age windows, the samples falling into the respective strata are 
limited. However, the result of the donor-wide bootstrapping based resampling strategy supported 
the confidence in our findings.  
The second limitation is the potential presence of residual confounding despite the stringent data 
preprocessing and quality control steps performed in both studies.  One of the most relevant 
potential confounders in Study 1 is antipsychotic treatment, which could not be accounted for in the 
analysis. As a consequence, it cannot be excluded that PMS itself was partially influenced by 
medication effects. However, the fact that the association between the epigenetic signature and 
DLPFCH-HC connectivity was identified in unmedicated healthy controls supports the findings are 
relevant to schizophrenia. In Study 1, we corrected for available and relevant potential confounders 
(20 covariates in the blood sample, and 12 in post-mortem brain sample) to construct the PMS but 
found residual confounding of the PMS by the smoking score, as well as some cellular component 
variables. These effects were a likely consequence of the fact that the random forest machine 
learning model integrated non-linear confounding effects that could not be removed from the data 
using the employed linear adjustment procedure. However, the post-hoc association results were 
still significant after adjusting the PMS for all confounding variables, further supporting the illness- 
relevance of the identified epigenetic changes.   
The third limitation is the likely influence of post-mortem effects as both studies relied on post-
mortem brain data (either gene expression or DNA methylation). The biological and 
environmental processes induced by death, and other factors such as the post-mortem interval 
(PMI), the post-sampling handling are known to be possible confounders (Birdsill, Walker et al. 2011, 
Ferreira, Muñoz-Aguirre et al. 2018, Sjöholm, Ransome et al. 2018), and information on these was 
not always available for adjustment in our present work. In Study 1, we performed a cross-tissue 
prediction of the identified epigenetic signature, showing that the PMS identified from peripheral 
samples could also differentiate schizophrenia patients in data from post-mortem DLPFC samples. 
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This suggests that the PMS captured schizophrenia-relevant epigenetic differences present in the 
brain and circumvented the risk for the PMS to be confounded by post-mortem artifacts.  
Fourth, the choice of targeted CpGs or genes for downstream analysis may need to be improved. In 
Study 2, we concentrated on schizophrenia risk loci mapping to single genes. Although this kind of 
selection may help prevent the statistical bias, it reduced the granted amount of genetic variability 
and it may not be representative of the schizophrenia risk architecture. Therefore, further studies 
with multiple susceptibility genes per locus are needed to account for possible residual bias. In Study 
1, we selected genes harboring CpGs with an extended window of -20 kb upstream and +20 kb 
downstream to cover possible DNA-regulatory elements such as promoters and enhancers. The 
choice of this proposed window size was somewhat arbitrary but, currently no strategy can capture 
all variations within this window. Alternative parameters may be tested to further extend or shorten 
the gene boundary and CpGs falling into non-coding regions can also be informative.  
Lastly, our proposed biologically informed machine learning approach is computationally intensive 
due to the repeated bootstrapping procedure or the need for optimal parameter selection, which 
may become a downside when it is routinely applied to large datasets. In addition to the use of 
clusters with higher performance, more efficient programming languages or environments (such as 
GPU programming with C++) will be of help to substantially reduce the runtime.   
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3.6 Future work 
The merit of systems biology is to cover all the facets of biological processes from molecules to cells, 
circuits, and organs. The integration of multiple types of omics techniques, so-called multi-omics, has 
become increasingly appealing in the recent years (Hasin, Seldin et al. 2017) and may play an 
essential role in systematically studying biological systems involved in psychiatric illness. On the one 
hand, the multi-omics strategy can be more reflective of the complex biological mechanism of 
schizophrenia as it encompasses independent signals from multiple levels. It should be noted that 
each omics type has its own unique conceptualization. Various advantages and disadvantages of 
omics technologies including genomics, transcriptomics and proteomics, as well as metabolomics are 
elaborately summarized by (Karahalil 2016). Identified biomarkers would represent biological 
changes distributed across a variety of data modalities. On the other hand, the identified biomarkers 
in one data type are perhaps the consequence of alterations found in another correlated data type, 
and therefore not be the causative factors underlying schizophrenia. 
Wang and colleagues (Wang, Chen et al. 2019) recently proposed a Bayesian framework named iRIGS 
(integrative Risk Gene Selector), which is able to infer schizophrenia risk genes driving GWAS signals 
by integrating relevant information from multi-omics data (i.e. epigenomics and transcriptomic data) 
and a gene-gene interaction network. Such a framework could estimate a set of risk genes that are 
primarily expressed in brain tissue, explain a significantly higher portion of heritability, and may 
pinpoint novel targets for already approved drugs. The adaptation of such integrative computational 
approaches to schizophrenia research will allow researchers to benefit more and more from the 
increasing availability of multi-omics data in schizophrenia (Ayalew, Le-Niculescu et al. 2012, Wang, 
Shi et al. 2019).   
However, thus far only few studies have explored multi-omics data acquired on the same subject 
cohort, and even less utilizing machine learning. Machine learning is able to perform automated 
learning from pooled multi-omics data for personalized risk prediction as reviewed by (Li, Wu et al. 
2016, Huang, Chaudhary et al. 2017, Lin and Lane 2017, Mirza, Wang et al. 2019). For example, an 
unsupervised machine learning framework entitled multi-omics factor analysis, or MOFA, was 
developed to detect biomarkers based on multi-omics data modalities from 200 chronic lymphocytic 
leukaemia patients (Argelaguet, Velten et al. 2018). The omics data consisting of four different 
modalities: DNA mutations, RNA expression, DNA methylation and ex vivo drug response were used 
as input and the latent factors derived from MOFA were able to capture variation in the data that 
was significantly associated with diagnosis. Besides advances in multimodal factor analysis, deep 
learning models (Angermueller, Pärnamaa et al. 2016) have been applied on a diversity of multi-
omics data albeit not in schizophrenia (Chaudhary, Poirion et al. 2018, Zhang, Lv et al. 2018, Chung, 
Mirza et al. 2019, Huang, Zhan et al. 2019, Sharifi-Noghabi, Zolotareva et al. 2019). Increasing 
predictive accuracy through deep learning usually requires large sample numbers, which is 
challenging particularly in the multi-omics scenario. Therefore it can be expected that deep learning 
approaches for analysis of multi-omics data will particularly profit from the increased availability of 
large sample size, facilitated by the ever increasing degree of international collaboration and data 
sharing.   
Another promising avenue for future work on biologically informed machine learning in 
schizophrenia is for the advanced analysis of time-dependent data. On the one hand, gene 
expression and epigenetic data is more dynamic than DNA sequence information and may capture 
more accurately the intricate and state-dependent etiological factors of the illness. A notable 
example is the well-described disturbance of biological rhythm in patients with schizophrenia. A 
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recent study (Seney, Cahill et al. 2019) reported that patients with schizophrenia show expression of 
a vastly different set of diurnally rhythmic genes using RNA sequencing data in the DLPFC compared 
to control subjects. These genes were enriched for mitochondrial functions and showed maximum 
expression during the day, which subsequently decreased during the night. This finding supported 
that time-dependent data analysis can provide a more precise characterization of molecular changes 
in schizophrenia. Consequently, data capturing biological information at potentially interesting time 
points, such as time-of-death, time-of-birth, or time of sleeping or wake-up, or even time of day 
when symptoms occurs may be integrated into machine learning modeling. The inclusion of such 
omics-based data from a longitudinal perspective is expected to increase the power of identifying 
risk mechanisms and also help the patient subtype identification. Furthermore, it may aid in 
characterizing the transdiagnostic specificity or pleiotropic effects when utilizing developmental 
trajectories in conjunction with data on psychiatric or somatic comorbidities. 
On the other hand, the missing heritability present in genomic data may partially be addressed by 
non-omics data, such as that capturing environmental risk factors or imaging data. Integrating omics 
and non-omics data into machine learning pipelines may therefore yield substantial gains in 
predictive accuracies. Notably, digital data obtained from wearable devices (Tost, Reichert et al. 
2019) that capture illness-relevant, environmental components along with neuroimaging readouts 
may reveal dynamic variations linked to susceptibility and pinpoint protective and modifiable factors. 
The acquisition of large-scale longitudinal samples needed for characterization of developmental 
trajectories using machine learning can be aided by advances in mobile technology, such as the 5G 
technology. 5G technology holds promise for unprecedented speed, coverage and low latency and its 
adaptation may revolutionize the depth of data acquired  from smartphones or other wearables. It 
should further facilitate the real-time, quantitative feedback of susceptibility or treatment-related 
outcomes to doctors, patients or at-risk subjects through cloud computing assisted prediction, 
moving the psychiatric field closer towards personalized medicine and digital health solutions.  
Therefore, the integration of multiple data modalities, combined with adaptation of advanced data 
science and technological developments may not only aid in better characterizing the complex 
biology underlying schizophrenia, but also facilitate the long-needed clinical translation of biological 
insight to improve patient outcomes and, hopefully, reduce incidence.  
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4 SUMMARY  
Extensive efforts in characterizing the biological architecture of schizophrenia have moved 
psychiatric research closer towards clinical application. As our understanding of psychiatric illness is 
slowly shifting towards a conceptualization as dimensional constructs that cut across traditional 
diagnostic boundaries, opportunities for personalized medicine applications that are afforded by the 
application of advanced data science methods on the increasingly available, large-scale and 
multimodal data repositories are starting to be more broadly recognized. A particularly intriguing 
phenomenon is the discrepancy between the high heritability of schizophrenia and the difficulty in 
identifying predictive genetic signatures, for which polygenic risk scores of common variants that 
explain approximately 18% of illness-associated variance remain the gold standard. A substantial 
body of research points towards two lines of investigation that may lead to a significant advance, 
resolve at least in part the ‘missing heritability’ phenomenon, and potentially provide the basis for 
more predictive, personalized clinical tools.  
 
First, it is paramount to better understand the impact of environmental factors on illness risk and 
elucidate the biology underlying their impact on altered brain function in schizophrenia. This thesis 
aims to close a major gap in our understanding of the multivariate, epigenetic landscape associated 
with schizophrenia, its interaction with polygenic risk and its association with DLPFC-HC connectivity, 
a well-established and robust neural intermediate phenotype of schizophrenia. As a basis for this, we 
have developed a novel biologically-informed machine learning framework by incorporating systems-
level biological domain knowledge, i.e., gene ontological pathways, entitled ‘BioMM’ using genome-
wide DNA methylation data obtained from whole blood samples. An epigenetic poly-methylation 
score termed ‘PMS’ was estimated at the individual level using BioMM, trained and validated using a 
total of 2230 whole-blood samples and 244 post-mortem brain samples. The pathways contributing 
most to this PMS were strongly associated with synaptic, neural and immune system-related 
functions. The identified PMS could be successfully validated in two independent cohorts, 
demonstrating the robust generalizability of the identified model. Furthermore, the PMS could 
significantly differentiate patients with schizophrenia from healthy controls when predicted in DLPFC 
post-mortem brain samples, suggesting that the epigenetic landscape of schizophrenia is to a certain 
extent shared between the central and peripheral tissues. Importantly, the peripheral PMS was 
associated with an intermediate neuroimaging phenotype (i.e., DLPFC-HC functional connectivity) in 
two independent imaging samples under the working memory paradigm. However, we did not find 
sufficient evidence for a combined genetic and epigenetic effect on brain function by integrating PRS 
derived from GWAS data, which suggested that DLPFC-HC coupling was predominantly impacted by 
environmental risk components, rather than polygenic risk of common variants. The epigenetic 
signature was further not associated with GWAS-derived risk scores implying the observed epigenetic 
effect did likely not depend on the underlying genetics, and this was further substantiated by 
investigation of data from unaffected first-degree relatives of patients with SCZ, BD, MDD and 
autism. In summary, the characterization of PMS through the systems-level integration of 
multimodal data elucidates the multivariate impact of epigenetic effects on schizophrenia-relevant 
brain function and its interdependence with genetic illness risk.  
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Second, the limited predictive value of polygenic risk scores and the difficulty in identifying 
associations with heritable neural differences found in schizophrenia may be due to the possibility 
that the manifestation of the functional consequences of genetic risk is modulated by spatio-
temporal as well as sex-specific effects. To address this, this thesis identifies sex-differences in the 
spatio-temporal expression trajectories during human development of genes that showed significant 
prefrontal co-expression with schizophrenia risk genes during the fetal phase and adolescence, 
consistent with a core developmental hypothesis of schizophrenia. More specifically, it was found 
that during these two time-periods, prefrontal expression was significantly more variable in males 
compared to females, a finding that could be validated in an independent data source and that was 
specific for schizophrenia compared to other psychiatric as well as somatic illnesses. Similar to the 
epigenetic differences described above, the genes underlying the risk-associated gene expression 
differences were significantly linked to synaptic function. Notably, individual genes with male-specific 
variability increases were distinct between the fetal phase and adolescence, potentially suggesting 
different risk associated mechanisms that converge on the shared synaptic involvement of these 
genes. These results provide substantial support to the hypothesis that the functional consequences 
of genetic risk show spatiotemporal specificity. Importantly, the temporal specificity was linked to 
the fetal phase and adolescence, time-periods that are thought to be of predominant importance for 
the brain-functional consequences of environmental risk exposure. Therefore, the presented results 
provide the basis for future studies exploring the polygenic risk architecture and its interaction with 
environmental effects in a multivariate and spatiotemporally stratified manner. 
 
In summary, the work presented in this thesis describes multivariate, multimodal approaches to 
characterize the (epi-)genetic basis of schizophrenia, explores its association with a well-established 
neural intermediate phenotype of the illness and investigates the spatio-temporal specificity of 
schizophrenia-relevant gene expression effects. This work expands our knowledge of the complex 
biology underlying schizophrenia and provides the basis for the future development of more 
predictive biological algorithms that may aid in advancing personalized medicine in psychiatry.  
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